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ABSTRACT 
The acute respiratory distress syndrome (ARDS) remains a major cause of 
morbidity and mortality in the critically ill patient. There are no effective 
strategies for identifying those most at risk or therapeutic interventions 
proven to prevent its occurrence. Vitamin D deficiency is common and has 
important functions besides calcium homeostasis with profound effects on 
human immunity. Preliminary data suggests in the high-risk sepsis and 
oesophagectomy groups that vitamin D deficiency may be a pre-existing risk 
factor and mechanistic driver of ARDS. 
 
This thesis investigated in an animal model and in-vitro studies whether 
vitamin D influences the innate immune response to sepsis and resolution of 
neutrophilic injury. In addition, it reports a proof of concept phase II study to 
determine if vitamin D therapy in patients undergoing oesophagectomy is 
anti-inflammatory and protective of markers of lung injury 
 
Vitamin D deficiency significantly increased the bacterial load, bacteraemia 
and translocation to the lung in a murine model of peritonitis. This was 
associated with a rise in tissue permeability locally and within the lung, 
reduced antimicrobial peptide and defective peritoneal macrophage 
phagocytosis. These data support pre-existing vitamin D deficiency as a 
determinant of the severity of bacteraemic sepsis. 
 
In-vivo high dose vitamin D supplementation was a safe, well-tolerated pre-
operative intervention with reduced biomarkers of alveolar oedema, 
capillary leak and macrophage efferocytosis. In-vitro culture with vitamin D 
increased macrophage efferocytosis and promoted monocyte differentiation 
to a pro-resolution phenotype. This suggests a potential mechanism for 
vitamin D on protecting barrier integrity and resolution of neutrophilic 
inflammation, a hallmark of ARDS.  
 
This body of work demonstrates that vitamin D deficiency is a potential 
modifiable risk factor and should be identified and treated in patients at risk 
of sepsis and ARDS. Larger trials powered to evaluate the effect of vitamin D 
on preventing and improving clinical outcomes in sepsis and ARDS are 
warranted.   
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 ACUTE RESPIRATORY DISTRESS SYNDOME 
 
Acute lung injury (ALI) and the more severe acute respiratory distress 
syndrome (ARDS) are devastating clinical syndromes characterised by 
pulmonary inflammation, increased alveolar-capillary permeability and 
pulmonary oedema that typically causes acute respiratory failure refractory 
to oxygen therapy in the critically ill person.1 Patients with ARDS usually 
require mechanical ventilation during the course of their illness and 
mortality remains high. Survivors of ARDS experience a significant reduction 
in health-related quality of life (HRQOL) and debilitating long-term sequelae 
including pulmonary, psychological and neuromuscular impairment.2,3  
Due to the wide presenting phenotype and heterogeneity of the syndrome, 
diagnosis remains challenging and developing therapies to treat and prevent 
it remain elusive despite promising positive pre-clinical studies. The advent 
of lung protective ventilation has resulted in reduced mortality in patients 
with ALI.4 However there are no current readily available tests that can 
clearly identify those who are at high risk of ALI, and no therapeutic 
interventions proven to prevent its occurrence. 
 
 Evolution of the definition 
In 1967 Ashbaugh et al. published the first description of 12 patients with 
similar clinical physiology, radiography and pathology that was later 
described as the acute respiratory distress syndrome (ARDS).5 The 12 
patients involved had acute respiratory distress requiring positive pressure 
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mechanical ventilation with the addition of positive end expiratory pressure 
(PEEP), cyanosis refractory to oxygen therapy, decreased lung compliance 
and diffuse pulmonary infiltrates on chest radiograph (CXR). The majority of 
patients were previously fit and well but mortality was high and post mortem 
examination of the 7 that died demonstrated widespread atelectasis, vascular 
congestion, intra-alveolar haemorrhage, severe pulmonary oedema and 
hyaline membrane formation. It is clear however, that patients with ARDS 
have been described before particularly in the context of battlefield trauma. 
Thus post-traumatic lung injury has been described as “wet lung” in World 
War 2, “shock lung” or “Da-Nang lung” after a particularly bloody battle 
during the Vietnam War.6 
 
Numerous attempts have been made to quantify the degree of lung injury 
severity including a 4 point scoring system by Murray et al in 1988.7 
Nevertheless, specific criteria for ARDS to identify patients were only 
established in 1994 by the American European Consensus Conference 
Committee (AECC).8 They include acute onset of hypoxemia, and bilateral 
infiltrates on chest radiograph in the absence of clinical evidence of left atrial 
hypertension. The severity of hypoxemia differentiates between ALI and 
ARDS (Table 1.1). 
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Table 1.1: American European consensus committee (AECC) 1994 
diagnostic criteria for Acute Respiratory Distress Syndrome and Acute 
Lung Injury.8 
 Acute onset 
 
 Bilateral pulmonary infiltrates on chest radiograph 
 
 Pulmonary Capillary Wedge Pressure <18 mmHg (2.4kPa) or the absence 
of clinical left atrial hypertension  
 
 Acute Lung Injury: PaO2/FiO2 ratio < 300mmHg (40kPa) 
 
 Acute Respiratory Distress Syndrome: PaO2/FiO2 ratio < 200mmHg 
(26.7kPa)  
FIO2, fraction of inspired oxygen; PaO2, partial pressure of arterial oxygen 
AECC diagnostic criteria are a crude screening tool but for many years were 
established as the most widely accepted method of identifying these patients 
both clinically and for research trials.  They have provided a tool to diagnose, 
investigate potential treatment options and understand the epidemiology 
and disease process.  However AECC criteria have been challenged over the 
years due to its limitations relating to specificity and reproducibility9 as well 
as the omission of the standardisation of ventilatory support in its 
assessment of hypoxaemia.10  
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Table 1.2: Berlin definition of Acute Respiratory Distress Syndrome.11 
Timing        
 
 
 
Chest imaging 
 
 
Origin of 
edema  
 
 
 
Oxygenation 
 
Mild  
 
 
Moderate 
 
Severe 
Within 1 week of a known clinical insult or new or 
worsening respiratory symptoms 
 
 
Bilateral opacities—not fully explained by effusions, 
lobar/lung collapse, or nodules 
 
Respiratory failure not fully explained by cardiac failure 
or fluid overload. Need objective assessment (e.g. 
echocardiography) to exclude hydrostatic oedema if no 
risk factor present 
 
 
 
200 mm Hg < PaO2/FIO2 < 300 mm Hg with PEEP or  
CPAP > 5 cm H2O (may be non-invasive ventilation) 
 
100 mm Hg < PaO2/FIO2 < 200 mm Hg with PEEP > 5 cm 
H2O 
 
PaO2/FIO2 < 100 mm Hg with PEEP > 5 cm H2O 
 
CPAP, continuous positive airway pressure; FIO2, fraction of inspired oxygen; 
PaO2, partial pressure of arterial oxygen; PEEP, positive end-expiratory 
pressure. 
 
More recently, a new consensus definition, the Berlin definition for ARDS has 
been described and is currently the recommended definition of the 
condition.11 The new definition maintains the 1994 AECC criteria of timing, 
chest imaging, hypoxaemia and origin of oedema. It attempts to improve 
diagnosis and prognostication by recommending the use of 3 categories of 
ARDS based on level of hypoxaemia (mild, moderate, severe and removing 
the term ALI, together with a minimum level of positive end-expiratory 
pressure (PEEP) (Table 1.2) . It also attempts to address some of the other 
limitations of the AECC criteria by: defining ‘acute’ as a period of onset of 
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ARDS within 7 days of known clinical insult; clarifying chest radiograph 
(CXR) criteria and removing pulmonary artery occlusion pressure as a 
measure of cardiogenic pulmonary oedema as this has been difficult to 
measure and shown to be poor at differentiating between cardiogenic and 
non-cardiogenic pulmonary oedema.12,13 The revised definition appears to 
have marginally improved predictive validity for mortality using a receiver-
operator curve with an area under the curve from 0.53 to 0.57.11 The severity 
and duration of ARDS have also been correlated to histological findings.14,15 
 
In view of the change in the definition of the condition during the period of 
the work presented in this thesis an attempt has been made to use the term 
ARDS. However on occasion when the term ALI is used it refers to the old 
AECC criteria definition (which does not require the use of PEEP or CPAP) 
and ARDS refers to the new Berlin definition.   
 
 Epidemiology and Outcome 
The overall incidence of ARDS remains unclear due to limitations in the 
diagnostic criteria and heterogeneity of the populations and underlying 
causes, but the most recent studies in the USA utilising AECC criteria have 
suggested rates of 13-59 cases per 100,000 population per year for ARDS and 
18-79 per 100,000 population per year for ALI.16,17  Studies in Europe have 
consistently reported lower rates between 4.9-13.5 cases per 100,000 
person-years.18-21 Sigurdsson et al have recently reported a large 
retrospective study spanning 23 years in Iceland in which incidence of ARDS 
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doubled, but hospital mortality decreased.21 The same incidence of 7 cases 
per 100,000 population per year was seen in another recent large 
prospective study in Spain, however despite the use of lung-protective 
ventilation, overall intensive care unit (ICU) and hospital mortality was still 
reported as 43% and 48% respectively.20  
 
Overall, reported mortality rates vary between 36-44%22 but more recent 
clinical trials and reviews in ARDS suggest that this may be lower at 19-
23%.23-26 This may be attributed to lung protective ventilation4,27,28, 
conservative fluid strategies29 and improvements in advanced supportive 
care, as well as avoiding potentially aggravating factors such as ventilator 
associated pneumonia, multiple blood transfusions and gastric aspiration.15,30 
The majority of patients die of the underlying pathology rather than 
respiratory failure itself.31 Several factors have been associated with an 
increased risk of mortality in ARDS including: severity of arterial 
hypoxaemia11 and increase in pulmonary dead space fraction32 as well as 
immune-incompetence, shock, sepsis, liver dysfunction, acute kidney injury 
and age over 60 years.19,31,33-35  
 
Although lung function parameters recover well in ARDS patients who 
survive there is significant residual physical limitations and poorer quality of 
life, with 46% reported to be unable to return to work within 12 months.2,3 
Depression, post-traumatic stress and neurocognitive impairment is not 
uncommon leading to a significant impact on the individual, carers and 
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society as a whole.2,36 In a prospective 5 year follow-up study of 109 
survivors of ARDS, Herridge et al found that although pulmonary function 
(spirometry, lung volumes and gas transfer) were near normal, decrements 
in quality of life and exercise capacity persisted at 5 years.2 The authors 
suggest that this may be due to persistent ICU acquired weakness and 
neuropsychological impairment. A further recent prospective study of over 
200 survivors has also shown substantial physical morbidity after ICU 
discharge, including impairments in muscle strength, physical function, and 
HRQOL.37 Recovery of muscle strength generally occurred within 12 months 
after ALI, but muscle weakness contributed to significant impairments in 
physical function (measured by 6 minute walk test) and HRQOL that 
persisted to 24 months post-ALI.37   
 
 Aetiology 
Certain known risk factors such as sepsis, surgery or trauma lead to the 
development of ALI and ARDS. The mode of injury can be either direct or 
remote to the lung (Table 1.3) with pneumonia and sepsis being the most 
common causes of ALI/ARDS.6,20,21 Only a relatively small proportion of 
patients develop ALI, with research suggesting that genetic38, demographic 
(age)19,31, social (smoking39, alcohol abuse40) and other factors play a role in 
determining who develops ALI.16,17 Due to this broad range of precipitating 
conditions patients can present to any emergency, medical or surgical 
specialty with early recognition being the vital step in providing appropriate 
care.  Considering the underlying aetiology is important, as the initiating 
25 
 
cascade of pathophysiological changes and prognosis may be different 
depending on the underlying cause of injury.6 This is extremely relevant if we 
are to be successful in developing strategies to identify patients at risk of 
developing ARDS. Furthermore this may represent a reason as to why a 
blanket approach to potential drug treatments has resulted in negative trials 
to date. 
 
Table 1.3 Conditions associated with the development of Acute 
Respiratory Distress Syndrome.6 
Indirect 
Sepsis 
Multiple trauma 
Cardiothoracic bypass 
Post-oesophagectomy 
Massive blood transfusion 
Acute pancreatitis 
Direct 
Pneumonia 
Aspiration 
Near drowning 
Smoke inhalation 
Pulmonary contusion 
Post lung transplantation 
 
 
 Early identification of ARDS 
Epidemiologic investigations and clinical trials in ALI and ARDS have 
predominantly focused on mechanically ventilated patients in ICUs, but 
recent data suggests ~9% of patients in respiratory isolation wards meet the 
criteria for ALI at some point during their admission, and 2% met criteria for 
the diagnosis of ARDS.41 Furthermore, Levitt et al have shown that ALI can be 
diagnosed in the spontaneously breathing patient in the emergency 
department42 and subsequently Gajic and colleagues have prospectively 
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derived the Lung Injury Prediction Score (LIPS).43 In this large multi-centre 
study of 5,584 patients admitted with one known risk factor for ALI the 
authors were able to identify patients who went on to develop ALI with an 
area under the receiver operator curve of 0.80 (95% confidence interval, 
0.78–0.82). Consequently it is possible to identify a significant number of 
patients prior to established ALI and prior to the requirement of invasive 
ventilation. Indeed, the LIPS is currently being utilised in ongoing lung injury 
prevention studies of aspirin (LIPS-A)44 and inhaled budesonide/formoterol 
(LIPS-B NCT01783821). Therefore identifying possible modifiable risk 
factors for ARDS may be invaluable in early identification and prevention of 
lung injury.    
 
 Treatment 
1.1.5.1 Pharmacological Interventions 
Despite almost 25 years of research many interventions to treat ARDS have 
failed in clinical trials despite promise in early phase studies. Given their 
established anti-inflammatory properties corticosteroids have unsurprisingly 
been the most studied drugs for the prevention and treatment for ARDS.  
Overall current evidence to support moderate-high dose steroids for treating 
early or late ARDS is limited45 with concern of increased neuro-myopathic 
events.46 However, one study that used prolonged low dose corticosteroids in 
early ARDS reported significant improvement in hypoxaemia and lung injury 
scores by day 7 of treatment.47 However, there remains conflicting evidence 
27 
 
and uncertainty and adequately powered randomised trials are ongoing 
(NCT01731795 and NCT01284452).48      
 
Alveolar fluid clearance is a critical process in the resolution of ARDS.  
Experimental data suggest that adrenergic agonists could augment 
alveolar fluid clearance as well as improve alveolar/capillary barrier function 
and pulmonary mechanics.49 Based on this evidence, the single-centre -
Agonist Lung Injury Trial (BALTI)50 randomised 40 patients and showed a 
reduction in extravascular lung water (EVLW) in the IV salbutamol arm 
compared to placebo. This subsequently led to 2 large multi-centre 
randomised placebo-controlled trials. Both studies were terminated early. 
The ALTA Study (Albuterol Treatment for ALI)23 failed to show a difference 
in ventilator free days between nebulised albuterol and placebo whilst the 
BALTI-2 trial found an excess in mortality in the group receiving IV 
salbutamol.24 On the basis of these larger trials, -agonists should be avoided 
in patients with ARDS due to their postulated harmful cardiac effects, 
inducing tachy-arrhythmias and lactic acidosis. Furthermore, more recently 
the BALTI-prevention trial has reported that although perioperative 
treatment with inhaled salmeterol was well tolerated it did not prevent ALI 
in patients undergoing oesophagectomy.51  
 
Ketoconazole has the ability to block the synthesis of pro-inflammatory 
mediators such as thromboxane A2 and leukotrienes as well as suppress 
alveolar macrophage procoagulant activity52, however again early positive 
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small studies did not translate to a larger study by the ARDSnet group which 
was stopped early due to lack of efficacy.53 
 
Neutrophils are believed to play a key role in the progression of ARDS54 and 
excessive neutrophil elastase, a degranulation protease enzyme has the 
ability to degrade the lung extracellular matrix and has therefore been 
implicated in the pathogenesis of ARDS.48,55 However, a large multi-centre 
trial of the neutrophil elastase inhibitor, silvestat was stopped prematurely 
due to a negative trend in 180-day all-cause mortality,56 which has 
subsequently been supported by a more recent meta-analysis.57 
 
Lisofylline, a synthetic methylxanthine decreases circulating free fatty acids, 
including linoleic acid and was thought to be a potential therapeutic strategy 
to mitigate against lipid-based oxidant injury.58 However the LARMA59 study 
was stopped early due to lack of efficacy and no difference in 28-day 
mortality and ventilator free days.  
 
Statins (HMG CoA-reductase inhibitors) are well established in primary and 
secondary prevention of cardiovascular disease. In-vivo and in- vitro evidence 
suggests that they have pleiotropic anti-inflammatory actions including 
reducing cytokine levels, adhesion molecule expression, neutrophil 
proliferation and nitric oxide production.60 A phase II clinical trial in patients 
with ARDS suggested potential benefit with reduced EVLW and 
improvements in secondary outcomes.61 Nevertheless, two large trials of 
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simvastatin in HARP-262 and rosuvastatin in SAILS63 did not show an 
improvement in clinical outcomes and in the latter may have contributed to 
hepatic and renal organ dysfunction.  
 
Activated platelets play an important role in disease progression in ARDS. 
They sequestrate in the lung, releasing pro-inflammatory cytokines, surface 
adhesion factors and lipid mediators.64 However, observational studies have 
been conflicting and the largest cohort found no protective effect of pre-
hospital anti-platelet use and subsequent ARDS incidence.65,66 Studies are 
ongoing to investigate both the effect of aspirin on reducing inflammation in 
a human model of ARDS (ARENA, NCT01659307) and in the prevention of 
ARDS.44  
 
Neuromuscular blocking agents have recently been re-evaluated with 
favorable results. A recent trial has shown that cisatracurium given for 48 
hours early in the course of severe ARDS (PaO2/FiO2 <150) with low tidal 
volume (VT) ventilation may improve outcomes without significantly 
increasing the incidence of muscle weakness.67 Other potential therapies 
being evaluated include keratinocyte growth factor,68 mesenchymal stem 
cells69 and IFN 70 
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1.1.5.2 Ventilation 
Since there are no current therapeutic treatments for ARDS, critical care 
support and mechanical ventilation is usually required. The ARDSnet ARMA 
study of 20004 was instrumental in turning the tide on conventional high VT  
ventilation for ARDS. This multi-centre, randomised, controlled trial 
compared high VT therapy (12 mL/kg) to low VT therapy (6 mL/kg) in 
mechanically ventilated patients with ALI/ARDS for 28 days. The trial was 
terminated early when the data demonstrated that lower VT ventilator 
settings in ALI/ARDS patients led to a significant decrease in mortality by a 
relative 22%.  Low VT ventilation also led to an increase in ventilator-free 
days and a decrease in the number of days with systemic organ failure.  
Patients assigned to lower VT ventilator settings initially required a higher 
PEEP to maintain arterial oxygenation and were more likely to develop 
respiratory acidosis, although the difference disappeared by day 7, 
suggesting that although lower tidal volumes require a higher respiratory 
rate to maintain adequate ventilation, its benefits on mortality outweigh 
transient acid/base and oxygenation imbalances.  
 
These beneficial results seemed to hold across a wide spectrum of patients, 
including septic and non-septic patients, and also those with different 
degrees of lung dysfunction as assessed by respiratory system compliances. A 
lung protective ventilation strategy should therefore be initiated for all cases 
of ARDS. However, in critically ill patients without ARDS, or those undergoing 
surgery, there is less evidence regarding the benefits of lower VT partly 
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because of a lack of randomised controlled trials. Observational studies 
suggest that the use of higher VT in patients without ARDS at the initiation of 
mechanical ventilation increases morbidity and mortality.71-73 A recent meta-
analysis has suggested that among patients without lung injury, protective 
ventilation with the use of lower tidal volumes at onset of mechanical 
ventilation may be associated with decreased risk for developing ARDS.74 
Furthermore, this was associated with lower mortality, fewer pulmonary 
infections and less atelectasis. Recently, Lellouche et al also found that a VT of 
more than 10mL/kg was risk a factor for organ failure and prolonged 
intensive care unit stay after cardiac surgery.75 Interestingly, another group 
has shown higher VT for even a few hours intra-operatively to be associated 
with postoperative respiratory failure.76  
 
The IMPROVE Study,77 a double blind parallel group trial randomised 400 
adults at intermediate or high risk of pulmonary complications undergoing 
elective abdominal surgery at 7 French academic centres to receive either: 
low VT mechanical ventilation — 6-8 mL/kg ideal body weight; PEEP 6-8 cm 
H2O; recruitment manoeuvres every 30 minutes or non-protective 
mechanical ventilation — VT 10-12 mL/kg; PEEP and recruitment 
manoeuvres were not protocolled but could be provided at the anaesthetists 
discretion for clinical need. The primary outcome, a composite of major 
pulmonary (pneumonia, invasive or non-invasive ventilation for respiratory 
failure) and extra pulmonary complications (sepsis, severe sepsis, shock or 
death) in the first 7 days after surgery, occurred in 10.5% of patients 
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receiving lung-protective ventilation and in 27.5% of patients receiving non-
protective ventilation. Non-invasive ventilation or intubation for acute 
respiratory failure occurred within 7 postoperative days in 5 vs 17% who 
received lung-protective ventilation. 
 
1.1.5.3 Extracorporeal membrane oxygenation 
Extracorporeal membrane oxygenation (ECMO) has been studied in a UK trial 
(CESAR) of 180 patients with refractory hypoxaemia. Patients were 
randomised to transfer to a tertiary care centre where 77% received ECMO 
versus control patients remaining at the referring centre who were treated 
with non-protocolised ventilator strategies. Compared with the control 
group, transferring adult patients with severe but potentially reversible 
respiratory failure to a single centre specialising in the treatment of severe 
respiratory failure for consideration of ECMO significantly increased survival 
without severe disability.78 Considerable debate is ongoing as to whether this 
trial proves the benefit of ECMO per se or the benefits of managing severe 
respiratory failure in specialist centres of excellence.  
 
1.1.5.4 Open lung strategies 
The open lung strategy of ventilation involves the use of recruitment 
manoeuvres followed by increasing PEEP in combination with lung 
protective ventilation to prevent atelectrauma secondary to recurrent 
opening, overdistension and shearing of the alveoli secondary to atelectasis. 
Two trials have shown a benefit on ventilator free days, improved 
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oxygenation and the need for rescue interventions such as ECMO however no 
mortality benefit. However, a meta-analysis from 2010 of 2299 patients 
showed that higher levels of PEEP were associated with improved survival 
among ARDS but not ALI patients (i.e. if PF ratios <200mmHg) with a 
mortality benefit of 34% vs. 39% (adjusted relative risk  0.90; 95% CI, 0.81-
1.00; p= 0.049).79 An open lung approach is therefore safe and may be of 
benefit is moderate to severe ARDS.  
 
High Frequency Oscillation Ventilation (HFOV) showed some initial promise 
with a meta-analysis in 2010 suggesting that it improves oxygenation, risk of 
treatment failure and 30-day mortality compared with conventional 
ventilation.80 Subsequently, two large clinical trials81,82 have shown no 
benefit of HFOV and it may increase hospital mortality.81 In contrast, early 
prolonged prone position ventilation has recently been shown to improve 
oxygenation and outcomes in severe hypoxaemic ARDS (PaO2/FiO2 <150).83  
 
1.1.5.5 Fluids 
Another advance in supportive therapy reported by the National Heart Lung 
and Blood Institute ARDS Network are the results of a prospective, 
randomised clinical trial evaluating the use of a liberal versus conservative 
fluid strategy in patients with ALI. The latter resulted in a significant increase 
in ventilator-free days.29 The conservative fluid management strategy used 
diuretics to target a central venous pressure less than 4 mmHg or a 
pulmonary artery occlusion pressure below 8 mmHg.84 
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 PATHOPHYSIOLOGY OF ARDS 
Despite the varied precipitating events for ARDS the histological changes are 
identical and represent a final common pathway of response. ARDS is 
characterised in the acute phase by an overwhelming inflammatory process 
leading to diffuse alveolar epithelial and endothelial injury with alveolar 
flooding with protein rich exudates due to increased vascular permeability. It 
is this breakdown in the alveolar epithelial and endothelial barrier, 
inappropriate influx of inflammatory cells and platelets, uncontrolled 
inflammation and activation of the coagulation pathways that are the key 
pathophysiological elements of ARDS1,85, illustrated in Figure 1.1.  
 
Alveolar epithelial cell apoptosis and necrosis of Type I cells contribute to the 
pulmonary oedema86 and exposes the basement membrane to further insult. 
Injury to Type II alveolar cells leads to impaired surfactant synthesis 
resulting in alveolar collapse and decreased lung compliance. An increase in 
extra-vascular lung water (EVLW) is also seen during this phase, as 
pulmonary capillary permeability increases.85,87,88 Endothelial and epithelial 
injury is accompanied by an influx of neutrophils into the interstitium and 
alveolar space. This neutrophil recruitment causes both alveolar and 
systemic release of chemokines (e.g. CXCL-8, ENA-78), pro-inflammatory 
cytokines (e.g. IL-1, IL-6, TNF), acute phase reactants (e.g. CRP, lipocalin), 
proteases, reactive oxygen species (ROS) and matrix remodeling enzymes 
(e.g. MMP-9) leading to further tissue damage.1,6,54,85  
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Figure 1.1: The Pathophysiology of ARDS. 
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There may then be further inflammatory cascade due to persistent primary 
stimulus such as pneumonia or due to systemic inflammation being amplified 
by the lung injury or potential secondary insults such as ventilation and 
blood transfusion. The subsequent course of ARDS is variable.6,85 In some 
patients there is reabsorption of alveolar oedema fluid and repair of the 
injured region of the alveolar epithelium, followed by clinical recovery from 
respiratory failure. However, in other patients alveolar oedema persists 
followed by organisation of hyaline membranes, collagen deposition and 
gradual appearance of intra-alveolar fibrosis and scarring.1,85,86  
 
1.2.1 The macrophage and lung injury 
Alveolar macrophages are derived from peripheral blood monocytes and the 
bone marrow and on migration to the lung attain site-specific functions. They 
are normally recruited to the lung forming the first line of defense towards 
pathogen and particulate exposure acting to induce and perpetuate innate 
and adaptive immune responses. Evidence suggests that the diverse activity 
of macrophages is mediated by two distinct subsets playing critical roles in 
both initiation and recovery of inflammation.89 Classically activated M1 
macrophages are activated by cytokines (e.g. IFN TNF) or by pathogen-
associated molecular patterns or PAMPs, e.g. lipopolysaccharide (LPS) or 
danger-associated molecular patterns or DAMPs (e.g. heat shock proteins or 
high mobility box group protein 1, HMGB1) via toll-like receptors (TLRs), 
NOD-like receptors (NLRs) and other pattern recognition receptors leading 
to release of early response cytokines (TNF, IL-6, IL-1) in an NF-
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dependent way, as well as ROS and antimicrobial peptides.89 This pro-
inflammatory activity is counterbalanced by the alternatively activated M2 
macrophage that is involved in down regulating inflammation and promoting 
wound repair by the release of anti-inflammatory cytokines (e.g. IL-10, IL-4). 
M2 macrophages are also involved in the phagocytosis of apoptotic 
neutrophils, supporting an anti-inflammatory, resolving and tissue 
remodelling phenotype by the release of TGF, IL-10 and vascular 
endothelial growth factor (VEGF).90,91 Furthermore the mediators released by 
M2 macrophages have been shown to abrogate alveolar neutrophil 
recruitment and mediate the effects of regulatory T-cells (Treg).92 
Macrophages within the inflamed lung are in a state of dynamic flux and 
different phenotypes are activated by specific signals during inflammation, 
resolution and repair. This microenvironment therefore determines the 
macrophage response to lung injury.   
 
The alveolar macrophage is therefore well placed for the detection of 
injurious pulmonary stimuli and initiation of the inflammatory cascade in 
ARDS. As they activate the host defense response they have an important role 
in the initiation of acute lung injury, and in early ARDS NF- activation 
promotes the transcription of pro-inflammatory genes within alveolar 
macrophages.93,94 However, a key function of alveolar macrophages in ARDS 
is in the resolution of lung injury (Figure 1.2). The resolution of ARDS is 
dependent on the action of macrophages to ingest apoptotic neutrophils, a 
process termed efferocytosis, and prevent the release of their pro-
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inflammatory intra-cellular contents during secondary necrosis.95 In contrast 
to the uptake of other extracellular material providing a pro-inflammatory 
stimulus, the uptake of apoptotic cells is part of an anti-inflammatory 
process96 and there is evidence that a defect in the process of efferocytosis is 
a cause of on-going inflammation in ARDS.97-99 
 
 
 
 
Figure 1.2: Macrophages resolve alveolar inflammation after Acute 
Respiratory Distress Syndrome.  
(adapted from Herold et al)90 
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 MODELS OF ACUTE LUNG INJURY 
1.3.1 Murine Models of ARDS 
Rodent models have been invaluable in the study and understanding of acute 
lung injury.  These have involved direct injury models in the form of intra-
tracheal LPS to model pneumonia, intra-tracheal acid to model aspiration 
pneumonitis and high volume ventilation to reproduce ventilation induced 
lung injury and hyperoxic lung injury. Indirect lung injury models include 
caecal ligation and puncture, intravenous bacteria or LPS to simulate sepsis. 
Although each model can reproduce components of the pathological changes 
seen in ARDS none have been shown to create all the changes of neutrophil 
alveolitis, capillary endothelial and alveolar epithelial damage and hyaline 
membrane formation.100 Despite these models having limitations they remain 
of considerable value in the study of ARDS as they allow genetic 
manipulation, investigation and testing of new therapies in a complex 
biological system. Adopting these models carefully to ensure they are 
pertinent to answering specific hypotheses ensures their scientific validity.101 
 
1.3.2 Human Model of ARDS – One Lung Ventilation  
To allow access to the oesophagus during surgery (using the transthoracic 
technique), one of the lungs is deflated and the subject is ventilated through 
the other lung.  This is known as one-lung ventilation (OLV). There is a high 
postoperative incidence of ALI/ARDS102-106 following OLV and unlike most 
insults leading to lung injury the delivery of OLV is predictably timed, thereby 
allowing serial studies to be carried out throughout the period of stimulus 
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and development of the condition. Preoperative risk factors including age, 
respiratory function and cigarette smoking have been found to be related to 
the incidence of postoperative pulmonary complications.102,105,107-109 It is 
unclear at present why only a percentage of patients undergoing OLV 
develop lung injury or why the lung injury typically occurs 24-48 hours after 
the cessation of OLV.51 Our local data show that the development of lung 
injury is however associated with a doubling of in-hospital stay and elevated 
mortality. 
 
Our group has extensively characterised the local and systemic inflammatory 
response to transthoracic oesophagectomy in patients undergoing OLV.51 
After OLV, patients have a neutrophilic alveolitis, with a significant alveolar 
and systemic inflammatory response.110,111 This is associated with the release 
of markers of both endothelial and alveolar epithelial dysfunction, and an 
increase in the permeability of the alveolar barrier.112,113 This manifests 
clinically as increased extravascular lung water, and a fall in 
oxygenation.51,114 
 
Alveolar levels of surfactant protein D and bronchoalveolar lavage fluid 
(BALF) protein permeability index are highest in those who develop ARDS 
within 72 hours of OLV suggesting that perioperative alveolar epithelial 
damage is a risk factor for the subsequent development of ARDS. Immediate 
post-operative plasma markers of neutrophilic activation [myeloperoxidase, 
and matrix metalloproteinase-9 (MMP-9)] as well as the Receptor for 
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Advanced Glycation End-products (RAGE, a type I epithelial cell marker) are 
similarly raised in those who develop ARDS within 72 hours of OLV.51 
Proposed causative mechanisms for this injury include the 
ischaemia/reperfusion insult suffered by the collapsed lung, as well as 
oxidative stress and barotrauma causing epithelial injury to the ventilated 
lung.115,116 These mechanisms are important in the pathogenesis of ARDS 
making OLV a valid model for studying the pathogenesis of ARDS in humans 
and exploring therapeutic strategies for preventing lung injury in a 
predefined subject population.1,117 
 
1.4 RATIONALE FOR VITAMIN D IN ARDS 
1.4.1 Vitamin D biology 
Vitamin D3, or cholecalciferol, is mainly formed in the skin after exposure to 
sunlight (UVB). Synthesised or dietary vitamin D is hydroxylated in the liver 
by CYP27A1 to 25-hydroxyvitamin D3 (25(OH)D3) the major circulating form 
of vitamin D and widely accepted measure of vitamin D status.118 In the 
classical model (Figure 1.3) of vitamin D metabolism, 25(OH)D3 undergoes 
further hydroxylation in the kidney to the biologically active 1,25-
dihydroxyvitamin D3 [1,25(OH)2D3] by the mitochondrial enzyme 25(OH)D-
1-alpha (CYP27B1).118 When 25(OH)D3 is sufficiently available, 24,25-
dihydroxyvitamin D3 (24,25(OH)2D3) is formed in the kidney which is further 
catabolised.85 Vitamin D metabolites are bound in the circulation to vitamin D 
binding protein (DBP) which has a high affinity for 25(OH)D3, 24,25(OH)2D3 
and 1,25(OH)2D3 and therefore regulates free circulating concentrations of 
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vitamin D metabolites.119 Vitamin D is inactivated by a ubiquitous enzyme, 
24-hydroxylase (CYP24A). The active metabolite, 1,25(OH)2D3 acts on the 
kidney, gut and bone to maintain calcium homeostasis. The effects of vitamin 
D are mediated through the vitamin D receptor (VDR) which is a ligand 
dependant transcription factor. VDR binds to its ligand 1,25(OH)2D3, 
dimerises with the retinoid X receptor (RXR) and attaches to specific genomic 
sequences termed vitamin D response elements (VDRE).85 The transcription 
of VDR target genes also results in cell growth inhibition, induces apoptosis, 
controls proliferation and differentiation. 85,118,120,121  
 
 
Figure 1.3: Schematic diagram of vitamin D biology.85  
(Adapted from Chishimba et al)122 
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In recent years interest has shifted from the calcium homeostasis role to the 
non-classical actions of vitamin D since the biologically active metabolite 
1,25(OH)2D3 can also be generated locally within tissues due to induction of 
extra-renal CYP27B1.85 An increasing number of tissues have been found to 
express CYP27B1, including lung epithelial cells123 and cells of the immune 
system including macrophages124, lymphocytes125 and dendritic cells.126 DBP 
is a serum protein which too has immunomodulatory functions relevant in 
the lung, predominantly relating to macrophage activation and neutrophil 
chemotaxis.122  It has been suggested that local production of 1,25(OH)2D3 
along with the presence of the VDR is evidence of a local paracrine/autocrine 
action in various tissues.120,127  
 
1.4.2 Vitamin D deficiency 
Worldwide prevalence of vitamin D deficiency is on the increase.118,128 In a 
study of middle-aged adults in the United Kingdom, 40% had serum 25(OH)D 
concentrations above 30ng/L in the summer months but this fell to less than 
17% in the winter 129 According to several other studies, 40-100% of U.S and 
European elderly adults are deficient in vitamin D.118,129 Epidemiological 
studies have suggested a role for low vitamin D status in the risk of 
developing both viral and bacterial infection.130,131 A recent study has further 
demonstrated the anti-inflammatory effects of vitamin D in patients with 
pulmonary tuberculosis.132 In addition, asthma, chronic obstructive airways 
disease (COPD), interstitial lung disease and cystic fibrosis show correlations 
between severity and level of vitamin D deficiency.133 Published data suggest 
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that vitamin D deficiency is also common in critically ill patients134 and 
recent prospective studies suggest an association with increased morbidity 
and mortality.135-137  
 
1.4.3 Potential effects on ARDS pathophysiology 
Vitamin D has been linked to many pathophysiological processes within the 
lung. These potential pathological concepts linking vitamin D to ARDS are 
discussed in detail in this section and summarised in Table 1.4.  
 
1.4.3.1 Barrier integrity 
Barrier integrity of the alveolar epithelium is essential not only to prevent 
pulmonary oedema but also to facilitate removal of fluid from the air space. 
The epithelial cell-cell functional complex is formed by gap, tight and 
adherens junctions. 1,25(OH)2D3 has been shown to upregulate transcription 
of proteins required for the formation of connexion 43,  claudin-1, -2 and E-
cadherin in epithelial cells of the skin and intestine.138-141 Although this has 
yet to be confirmed in the lung it suggests that vitamin D mediated action 
may play a role in stabilising the epithelial junction complex. 1,25(OH)2D3 at 
physiological sufficient levels can reduce the activation of lung microvascular 
endothelial cells, reducing adhesion molecule expression (ICAM-1 and ELAM-
1), reducing iNOS expression and NO release, and attenuating platelet 
activating factor (PAF) induced neutrophil adhesion to pulmonary 
microvascular endothelial cells suggesting that sufficient vitamin D levels 
may attenuate/prevent an important initiating event of acute lung injury 142 
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1.4.3.2 Innate immunity 
Vitamin D is a potent stimulator of antimicrobial peptides in innate immunity 
143 and the production of LL-37 (cathelicidin) and some defensins (human -
defensin-2) is dependent on sufficient circulating 25(OH)D3.144 1,25(OH)2D3 
has the ability to induce the release of LL-37 within the lung and LL-37 is 
stored at high concentrations in specific granules of neutrophils, and can also 
be produced by macrophages and epithelial cells. It can be detected in airway 
secretions and is upregulated in response to infection and inflammation.145 In 
addition to direct antimicrobial capability, in vitro and in vivo studies suggest 
a broad range of activities that could modify innate inflammatory processes 
and adaptive immune responses. LL-37 can bind to and neutralize 
lipopolysaccharide (LPS), and functions as a chemoattractant for neutrophils, 
monocytes and T cells through a formyl peptide receptor.145 Furthermore, 
respiratory epithelial cells can convert 25(OH)D3 to 1,25(OH)2D3 and activate 
VDR responsive genes increasing the production of TLR co-receptor CD14 
and hCAP18 from which LL-37 is cleaved within 24 hours.146 In the context of 
ARDS, LL-37 is elevated significantly in the BAL fluid of these patients in 
comparison with normal controls.147 In terms of the pathophysiology of ARDS 
this could be important as LL-37 may drive epithelial repair responses as 
well as being an anti-microbial peptide.148 Elevating local LL-37 may also be 
important as a downstream immunomodulator of vitamin D since it has 
recently been shown to reduce TLR agonist-mediated neutrophil-derived 
increases in IL-1β, IL-6, IL-8 and TNF-α in addition to stimulating bacterial 
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phagocytosis.149 Further studies are needed to determine if LL-37 is 
causative of inflammation or a response to injury in ARDS. 
 
Vitamin D has been shown to stimulate the differentiation of precursor 
monocytes to mature phagocytic macrophages.150 Localised synthesis of 
1,25(OH)2D3 by normal human macrophages on stimulation with interferon 
gamma (IFN) is suggestive of an intracrine system for the action of vitamin 
D.143,151 Hydrogen peroxide secretion in human monocytes is also activated 
by 1,25(OH)2D3 resulting in increased oxidative burst potential.152 NF- 
signalling and suppression of macrophage TLR expression by 1,25(OH)2D3 
suggests that it may also be a regulator of macrophage inflammatory 
responses.153,154 Furthermore, 1,25(OH)2D3 has also been shown to reduce 
the production of inflammatory cytokines and chemokines (IL-8 and CXCL-
10) from stimulated epithelial cells by modulating the NF-kb signalling.155,156 
Any or all of these actions are likely to be relevant in the lung and ARDS. 
Neutrophils also express the VDR157 however, little is known about vitamin D 
regulation of neutrophil function. 
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Process/Cell 
Type 
Role of vitamin D Potential effect in 
ARDS 
Relevant 
references 
Antimicrobial 
peptide 
production  
Increased LL-37 
release by  
macrophages and 
epithelial cells 
Promote epithelial 
repair  
responses and 
reduce 
downstream  
pro-inflammatory 
signals 
Shaykhiev et al148 
Alalwani et al149 
Monocyte 
differentiation 
Stimulates 
differentiation to  
mature phagocytic 
macrophages 
Anti-inflammatory 
actions and  
prevention of 
secondary necrosis 
of apoptotic 
neutrophils and  
persistence of 
inflammation 
Kreutz et al150 
NF- signaling Reduces NF- 
signaling and TLR  
expression 
  
Dampen 
inflammatory 
response 
Sadeghi et al154 
Hansdottir et al156 
Regulatory T-
cells 
Stimulates 
differentiation 
towards  
regulatory T-cell 
and away from  
Th17 cells 
Promote 
resolution of ALI 
D’Alessio et al92 
MMP driven 
tissue remodeling 
Reduces MMP Prevent initial 
destruction of  
basement 
membrane but  
potentially impair 
resolution 
O’Kane et al158 
Albaiceta et al159 
Yamashita et al160 
Song et al161 
Neutrophil 
adhesion to 
endothelium 
Reduces adhesion 
molecule  
expression on the 
endothelium,  
PAF and NO 
release 
Prevent neutrophil 
migration and  
initiation of lung 
injury 
Chen SF et al142 
Vitamin D 
Binding Protein 
(DBP) 
Actin scavenging 
and macrophage  
Activation 
Prevent vascular 
occlusion, tissue  
damage and organ 
dysfunction 
Dahl et al162 
Autophagy Promotes 
autophagy 
Not known Wu et al163 
Barrier integrity  Upregulate gap, 
adherens and tight  
Junctions 
Prevent alveolar 
fluid influx and  
facilitate removal 
Palmer et al140 
Kong et al141 
 
Table 1.4: Pathological concepts linking vitamin D and ARDS
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1.4.3.3 Adaptive immunity 
Recent data have implicated vitamin D in adaptive immunity because of its 
influence upon the differentiation of T cells between the regulatory T cell 
(Treg) and the pro-inflammatory T helper 17 (Th17) subsets.164-166 Th17 cells 
are known to stimulate tissue inflammation and neutrophil chemotaxis, both 
of which are seen in ARDS, predominantly by IL-17 production. It also 
appears that expression of markers of Treg cells (Foxp3) or Th17 cells (IL-17) 
by T cells may not be stable and that there is a greater degree of plasticity in 
their differentiation than previously appreciated.165 Recent evidence has 
further suggested Treg cells are important in resolution of experimental 
ARDS.92 This suggests that local lung regulation of the balance between Treg 
and Th17 cells may be a determinant of resolution/persistence of 
neutrophilic inflammation, which is known to be associated with a poor 
prognosis in human ARDS. 
 
1.4.3.4 Autophagy 
Vitamin D also promotes autophagy, a cellular process that ensures the 
synthesis, degradation and recycling of intracellular macromolecules and 
inclusions in mononuclear cells.163,167 It represents an inducible response to 
stress in lung cells. Agents that trigger autophagy that are particularly 
relevant to lung cell biology include hypoxia, particle and cigarette smoke 
exposure, proinflammatory states, and conditions that promote ER stress or 
oxidative stress.168 Autophagy has been shown to be both protective and 
injurious in a variety of different models, suggesting that its role in human 
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diseases is complex. Relatively few studies have been done in the lung and 
the functional importance of autophagy in ARDS is yet to be explored.  
 
1.4.3.5 Metalloproteinases 
Matrix metalloproteinases (MMPs) are upregulated in activated cells and can 
facilitate tissue remodelling and repair.158 They can also control cytokine and 
chemokine processing, apoptosis and antimicrobial peptide cleavage and 
activation.169 They are however a complex family of enzymes with MMP-2, 
MMP-7 and MMP-9 shown to be involved in alveolar epithelial repair in 
experimental models of lung injury158,170 and increased levels of lung injury 
in MMP-9 deficient mice exposed to ventilator induced lung injury.159 In 
contrast MMP-3 deficient mice were protected against bleomycin induced 
lung injury160 and MMP-8 has shown opposing effects depending on the 
model of lung injury employed. 1,25-(OH)2D3 has been reported to down-
regulate the expression of protein for MMP-9 in airway smooth muscle cells 
from asthma patients161 and inhibit the expression and activity of a number 
of MMP during in vitro mycobacterium tuberculosis (MTB) infection.171 This 
limited data support a role for vitamin D in suppressing MMP. Although 
blockade of specific MMPs during the early stages of ARDS may be beneficial 
to prevent initial destruction of the basement membrane this may be 
detrimental to the resolution process.172 Thus, further investigation of the 
possible effect and mechanisms of vitamin D on MMP function is needed in 
appropriate ARDS models.  
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1.4.3.6 Vitamin D binding protein 
Apart from its specific role in being the carrier protein for 25(OH)D3, DBP 
exerts several other important biological functions, from actin scavenging to 
fatty acid transport and macrophage activation173. Tissue injury and cell 
death release actin into the circulation. In the extracellular compartment, G-
actin polymerizes into F-actin filaments. This may cause vascular obstruction 
and organ dysfunction. Severe cell or tissue loss lowers the DBP-serum level. 
The degree of reduction correlates with the development of organ 
dysfunction, respiratory failure, hematologic failure and sepsis162 and low 
concentrations of DBP have been reported in ARDS173,174, further suggesting a 
role for the vitamin D axis in ARDS.6 
 
1.4.4 Animal studies 
The few animal studies to date investigating the role of vitamin D deficiency 
and its supplementation in ARDS have conflicting results. 1,25(OH)2D3 
inhibited neutrophil but not monocyte recruitment by 40% in a hamster 
model of ALI, thought to be in part due to its inhibitory effects on IL-8.175 It 
also ameliorated lung damage secondary to ischaemia reperfusion injury 
after femoral artery ligation in rats.176 A further study has shown reduced 
interstitial inflammation and collagen deposition post radiotherapy in rats 
administered vitamin D.177 More recently, 1,25(OH)2D3 has been shown to 
attenuate hyperoxia-induced lung injury in neonatal rats with 1,25(OH)2D3 
significantly down-regulating the expression of TLR4, NF-, and the 
inflammatory cytokines TNF-α, IL-1β, and IL-6.178 Aspiration with seawater 
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has been shown to upregulate VDR expression in rat lungs and A459 cells. 
Pre-treatment with 1,25(OH)2D3 significantly inhibited the activation of NF-
 and RhoA/Rho kinase pathways, improved lung histopathologic changes, 
reduced inflammation, lung oedema and vascular leakage.179 Conversely, a 
study of LPS induced lung injury in vitamin D deficient mice found no 
difference in the degree of lung injury.180 Issues centred on differing 
aetiologies of lung injury as well as methodology of when lung injury is 
measured or defined may go some way to explaining this apparent 
contradiction.  
 
1.4.5 Clinical evidence 
Primary studies and meta-analyses have identified significant associations 
between lower serum 25(OH)D3 levels and impaired lung function181, 
decreased survival from lung cancer182,183, increased rates of severe asthma 
exacerbations184, tuberculosis (TB)185, acute respiratory tract infections186 
and chronic obstructive airways disease187. A recent study has shown that 
high vitamin D levels are associated with better lung function, less airway 
hyper responsiveness and improved glucocorticoid response in asthma188 
and others have shown an interesting potential application of vitamin D to 
overcome the poor glucocorticoid responsiveness in severe asthmatics by 
upregulation of IL-10 production from regulatory T-cells.189 Clinical trials of 
steroids in ARDS have to date revealed conflicting results despite their 
potential overwhelming anti-inflammatory effect and could represent an 
element of glucocorticoid resistance as seen in other inflammatory 
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conditions.190 Therefore low levels of vitamin D could be a contributory 
factor in steroid resistance seen in some patients with ARDS.   
 
Exposure to sunlight has been known to help with the treatment of TB for 
more than 100 years, although it is only recently been found that 
macrophage release of cathelicidin, required for efficient macrophage killing 
of mycobacterium tuberculosis, requires co-activation of the VDR and TLR 191. 
The TLR activation of macrophages and the epithelium by PAMPs to 
stimulate local vitamin D expression could theoretically be performed by 
DAMPs and non-pathogen injurious stimuli in a similar fashion, both having 
potential relevance in the multiple aetiologies involved in ARDS.   
 
There are few human studies of vitamin D replacement in critically care 
patients. Cecchi et al reported vitamin D levels to be lower in sepsis patients 
than in trauma and age related controls but this was not related to 
outcome.192 In a recent case-control study reported by Barnett et al serum 
25(OH)D3 measured early after admission to intensive care was not 
associated with the development of acute lung injury, hospital or one-year 
mortality in critically ill patients with sepsis although lower levels were 
associated with higher one-year mortality in patients with severe trauma. In 
contrast in a large cohort of critically ill patients, it has been demonstrated 
that deficiency 25(OH)D3 of at the time of critical care initiation is a 
significant predictor of all-cause patient mortality.136 Findings that are also 
true in surgical patients admitted to critical care.193  
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Sepsis has direct relevance to ARDS and the pathophysiological changes 
leading to multi-organ failure may be similar and therefore highly relevant. A 
study looking at vitamin D levels in patients with severe sepsis showed that 
these patients have a lower serum vitamin D level than intensive care control 
patients which was associated with lower plasma levels of LL-37, suggesting 
that this deficiency is of functional importance in vivo.194 Conversely in a 
small randomized placebo controlled trial of calcitriol (1,25(OH)2D3) 
replacement in patients with severe sepsis or shock reported by Leaf et al did 
not show alterations in plasma LL-37 concentrations but did increase whole 
blood leucocyte LL-37 and anti-inflammatory IL-10 mRNA expression at 24 
hours.195 No differences in other cytokine or clinical outcomes were noted, 
however this was a study with small numbers and there is a debate as to 
whether the intracrine conversion of 25(OH)D3 to 1,25(OH)2D3 is an active 
process required for the cellular responses to vitamin D.196  
 
A large retrospective study of over 1900 patients to critical care has recently 
reported that compared to patients with 25(OH)D3 ≥30ng/mL, patients with 
lower 25(OH)D3 levels had significantly higher cumulative adjusted odds of 
acute respiratory failure (≤10 ng/mL, OR=1.84 (95% CI 1.22 to 2.77); 11–
19.9 ng/mL, OR=1.60 (95% CI 1.19 to 2.15); 20–29.9 ng/mL, OR=1.37 (95% 
CI 1.01 to 1.86)).197 This excluded patients with congestive cardiac failure 
and utilised the Berlin definition of ARDS. Our group has recently shown that 
patients undergoing oesophagectomy are also deficient in vitamin D and the 
severity of deficiency (<20nmolL) is a risk factor for the development of post-
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operative lung injury (37.5% vs 15%).198  Amrein et al have recently reported 
a large randomised placebo controlled clinical trial of single high-dose 
enteral 540,000IU of cholecalciferol in ICU patients that did not reduce 
hospital length of stay, hospital mortality, or 6-month mortality. However, 
higher hospital mortality was observed in the pre-defined severe vitamin D 
deficiency subgroup (<12ng/mL).199 Suggesting that it is patients with severe 
deficiency that are likely to benefit from the hypothesised effects of vitamin 
D. It also confirmed safety and demonstrated successful increase in levels of 
25(OH)D3 and 1,25(OH)2D3 over 7 days. There are currently no registered 
clinical trials of vitamin D replacement in patients with established ARDS, 
although a few trials of high dose cholecalciferol administration in critical 
care are in progress (NCT01372995 and NCT01896544).    
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1.5 SUMMARY 
Despite many years of research, pharmacological therapies for ARDS remain 
elusive with numerous negative clinical trials.  Apart from lung protective 
ventilation and judicious fluid therapy, management remains supportive. 
Although these strategies have improved the outcomes from ARDS, it still 
remains a significant burden and important cause of respiratory failure, 
morbidity and mortality in the critically ill. Improving strategies to identify 
patients at risk of ARDS has been highlighted as an important area of 
research to try and prevent the initiating insult and control the inflammatory 
cascade that ensues. The macrophage plays a pivotal role in initiating this 
cascade and promoting resolution.  
 
The evidence presented supports a profound role of vitamin D in modulating 
immune responses, especially on macrophage differentiation and function. 
Vitamin D deficiency is widespread in critically ill patients and has been 
associated with increased risk of sepsis, respiratory failure and ARDS post 
oesophagectomy.  However whether this is cause or effect is yet to be 
ascertained. Mechanistically vitamin D deficiency could lead to an impaired 
innate immune response to injury to the lung proceeded by an excessive 
adaptive immune response to the injury with increased production of 
inflammatory cytokines, exaggerated inflammation as well as impaired 
resolution and repair of damage. However, many questions remain 
unanswered and more in-vitro, in-vivo and human studies are required to 
ascertain the potential mechanisms of vitamin D deficiency in driving ARDS.
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CHAPTER 2                                                                         
AIMS 
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2.1 HYPOTHESIS 
It was hypothesised that vitamin D deficiency is a mechanistic driver of ARDS 
and that replacement therapy could prevent its occurrence.  
 
2.2 THESIS AIMS 
This thesis is a report of a series of investigations studying the effect of 
vitamin D deficiency and its replacement on ARDS. The specific aims of this 
thesis are to: 
1] To establish in a murine model of sepsis induced lung injury if vitamin D 
deficiency exaggerates innate immune response to sepsis. 
2] Determine if vitamin D replacement therapy can reduce biomarkers of 
local and systemic inflammation in a human model of ARDS – in a phase II 
proof of concept study: vitamin D to prevent acute lung injury following 
oesophagectomy trial.  
3] Study the effect of in-vitro and in-vivo vitamin D on macrophage 
efferocytosis and differentiation. 
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Parts of this chapter have been published: 
Parekh D, Dancer RC, Lax S, et al. 
Vitamin D to prevent acute lung injury following oesophagectomy (VINDALOO): 
study protocol for a randomised placebo controlled trial. 
Trials 2013;14:100. 
 
CHAPTER 3                                                                
GENERAL METHODS  
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 CLINICAL STUDIES 
 Ethical approvals 
National research ethics for the vitamin D to prevent acute lung injury post 
oesophagectomy trial (VINDALOO) reported in this thesis was approved by 
the South Birmingham Research and Ethics Committee (REC 12/WM/0092). 
The trial is registered on the International Standard Randomised Controlled 
Trial Registry (ISRCTN27673620) and European Union database of 
randomised Controlled Trials (2012-000332-25). All participants provided 
written informed consent. Full trial protocol116 has been published and can 
be viewed in the Appendix. 
 
 Patient Recruitment 
Patients for the oesophagectomy study (VINDALOO) were recruited from 3 
large tertiary centres (Queen Elizabeth Hospital, Birmingham, Birmingham 
Heartlands Hospital and University Hospital of Coventry and Warwickshire). 
All 3 centres are regional specialist centres for the management of upper 
gastro-intestinal malignancies. Patients were identified from the upper 
gastrointestinal cancer multidisciplinary team meetings and subsequently 
recruited from a preoperative assessment outpatient clinic after a face to face 
meeting and obtaining informed written consent.  
 
 Midlands Lung Tissue Collaborative (MLTC) 
The MLTC is an ongoing regional collaborative between the University of 
Birmingham, Glenfield Hospital, Leicester and Birmingham Heartlands 
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Hospital that utilises tissue from lung resections to investigate the molecular 
and functional mechanisms of human lung disease. National Research Ethics 
approval was provided by the North West Research Ethics Committee (REC 
07/MRE08/42; UKCRN ID 6664). Eligible patients were those undergoing 
thoracic surgery for lobectomy or pneumonectomy. The surgery was 
conducted at Birmingham Heartlands Hospital Thoracic Unit as part of 
routine treatment for lung cancer. Patients provided informed consent for 
any tissue removed as a part of their surgery not required for diagnostic or 
clinical purposes to be used for research. Baseline demographics including 
age, sex, tumour staging, smoking history and lung function were collected as 
part of the study. 
 
 SURGICAL AND ANAESTHETIC MANAGEMENT 
Patients underwent a 2 stage transthoracic oesophagectomy which included 
a laparoscopic abdominal stage followed by an open thoracotomy or 
minimally invasive technique with thoracoscopy. All approaches required 
one-lung ventilation to facilitate surgical access to the oesophagus in the 
chest.  This was done by collapsing the right lung and ventilating the left lung.  
 
Induction of anaesthesia for surgery was performed intravenously and 
dependent on the anaesthetists preferred practice, however, predominantly 
involved the use of propofol and an opiate. Maintenance of anaesthesia was 
with gaseous isoflurane, sevoflurane or desflurane. Following endotracheal 
intubation a right internal jugular central venous catheter was placed by the 
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anaesthetist as part of routine care. A modified 5 French 20cm arterial 
PiCCO® thermodilution catheter (PULSION Medical Systems, Munich, 
Germany) was placed in the right femoral artery using a seldinger technique 
by the research fellow.  
 
A thoracic epidural was placed when possible to facilitate postoperative 
analgesia. Intraoperative analgesia was provided with intravenous opiates. A 
conservative fluid management approach was adopted perioperatively. 
During the thoracic phase of surgery one-lung ventilation was achieved by 
the use of a double lumen endotracheal tube or bronchial blocker. The 
fraction of inspired oxygen delivered was titrated to maintain oxygen 
saturations above 95%. Patients were ventilated with either pressure or 
volume control ventilation with the application of positive end expiratory 
pressure (PEEP) as per anaesthetic preference. Postoperatively patients were 
either extubated in theatre recovery or after a short period of stabilisation on 
the intensive care unit according to local practice. Patients participating in 
the optional bronchoscopy study underwent bronchoalveolar lavage in 
theatre at the end of surgery. The research team did not interfere with the 
routine anaesthetic and surgical local practice at any point. 
 
 LUNG BIOMARKER PARAMETERS 
Invasive cardiovascular and transpulmonary measurements were performed 
using the Pulse Contour Cardiac Output PiCCO2® system (PULSION Medical 
Systems, Munich, Germany). The PiCCO2® monitor was connected to the 
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femoral arterial catheter with the thermo-transducer at its tip sitting in the 
descending aorta. An injectable sensor was connected to the distal port of the 
right internal jugular central venous catheter that was inserted as routine 
care and to the PiCCO2® monitor.  
 
The PiCCO2® monitor calculates cardiac output (CO), extravascular lung 
water (EVLW) and volumetric parameters by automated analysis of the 
thermodilution curve created by measuring the downstream temperature 
change by the arterial thermistor following injection of 15mls of ice-cold 
0.9% saline (thermal indicator) into the injectable sensor on the central 
venous catheter. These readings were obtained by triplicate injections per 
study and the measures recorded from the monitor represented the mean of 
the 3 readings. Baseline studies were performed in theatre immediately prior 
to surgery, then immediately postoperative within 1 hour and at 9am on day 
1 post-surgery.    
 
The single transpulmonary thermodilution curve allows accurate 
measurement of the CO using the modified Stewart-Hamilton algorithm 
utilising the area under the curve (Figure 3.1).200 Further analysis of the 
curve using the Newman ‘slope-volume’ method201 enables volume 
determination from point of injection (superior vena cava) to point of 
detection (descending aorta).  
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Figure 3.1: Diagram of a temperature-time curve of a thermodilution 
measurement.  
MTt: mean transit time; DSt: downslope time of the curve 
 
 
The volume of distribution of the thermal indicator represents the 
intrathoracic thermal volume (ITTV):  
 
ITTV (ml) = CO × mean transit time of the thermal indicator (MTt) 
 
ITTV reflects both total intravascular and extravascular fluid volume within 
the chest (heart and lungs). The MTt reflects the transit time of the thermal 
indicator through the entire volume. However the largest volume of fluid and 
mixing chamber is the lungs (intra and extravascular) and reflected by the 
pulmonary thermal volume (PTV):  
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PTV (ml) = CO × exponential downslope time of thermodilution curve (DSt) 
 
Thus the difference between ITTV and PTV represents the volume of the non-
pulmonary compartment consisting primarily of the heart and since this is 
greatest at end-diastole is called the global end-diastolic volume (GEDV)201: 
 
GEDV (ml) = ITTV – PTV 
 
Intrathoracic blood volume (ITBV) is the volume of blood within the heart 
and the lungs and is a function of the GEDV and determined by the equation: 
 
ITBV (ml) = 1.25 x GEDV – 28.4ml 
 
The relationship between GEDV and ITBV has been validated and shown to 
have a fixed linear correlation.202,203 EVLW is a measure of the fluid contained 
within the lung but outside the vasculature (interstitial, intracellular, alveolar 
and lymphatic)204 and is calculated as the difference between the thermal 
indicator distribution in the chest (ITTV) and the blood volume of the chest 
(ITBV): 
EVLW (ml) = ITTV – ITBV 
 
This thermodilution volumes are depicted in Figure 3.2. 
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Figure 3.2: Diagrammatic representation of volume of distribution of 
the cold injector when measuring EVLW 
ITTV: intrathoracic thermal volume; PTV: pulmonary thermal volume; GEDV: 
global end diastolic volume; ITBV: intrathoracic blood volume; EVLW: 
extravascular lung water. (adapted from Isakow et al)201 
 
The extravascular lung water index (EVLWI ml/kg) was calculated by 
dividing the EVLW by predicted body weight. EVLW indexed to predicted 
rather than actual body weight has been shown to have a greater correlation 
with mortality in the intensive care unit.87 A recent study has shown that 
height was the only biometric parameter associated with EVLW.205 
Throughout this thesis results are represented as EVLWI.  Extravascular lung 
water measurements have been shown to correlate with gravimetric lung 
water at post mortem206,207 and been shown to be a predictor of adverse 
outcomes in the critically ill.87,208 Increases in EVLW are related to the 
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pathophysiological changes of pulmonary oedema and ARDS209 and an early 
reduction in EVLWI is a prognostic indicator of survival.210  
 
Transpulmonary thermodilution also allows for the measurement of 
pulmonary vascular permeability index (PVPI), which is thought to estimate 
the permeability of the alveolar capillary barrier. PVPI is the ratio between 
EVLWI and pulmonary blood volume (PBV), where PBV is the difference 
between ITBV and GEDV. PVPI has been validated in some animal206 and 
human studies which show it to be higher in patients with ARDS than 
hydrostatic pulmonary oedema.209,211 The thermodilution procedure has 
been utilised by our group for many years, however to test reproducibility, 
studies were performed six times in a single patient at 3 different time points 
to determine the coefficient of variation (CV). The CV was determined by 
dividing the standard deviation of the 6 measurements by their mean. The CV 
of CO, EVLW and PVPI at the 3 different time points is shown in Table 3.1.  
 
Measurement  Preoperative Postoperative Day 1 Mean CV 
(%) 
CO (L/min) 6.5 6.9 7.2 6.8 
EVLW (mls) 5.1 6.3 3.8 5.1 
PVPI  7.7 3.9 6.6 6.1 
Table 3.1: Coefficient of variation for PiCCO measurements.  
CO; cardiac output: EVLW; extravascular lung water; PVPI; pulmonary 
permeability index.  
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 SAMPLE COLLECTION  
 Blood collection 
Blood was taken from patients by peripheral venepuncture or via existing 
arterial or venous lines using a vacutainer® system (Becton Dickinson Ltd, 
Oxford, UK) into 4 Lithium heparin and 2 EDTA bottles (Total 36mls) at 
recruitment pre-drug administration, immediately pre-operatively, post-
operatively, 9am on day 1 and day 3/4. Samples were then immediately 
transported on ice to the laboratory for processing.  
 
Blood was taken from healthy volunteers by peripheral venepuncture into 5 
Lithium heparin vacutainer® bottles (Becton Dickinson) at the University of 
Birmingham Research Laboratories after taking consent as per University 
guidelines and immediately processed in the laboratory. 
 
 Bronchoscopy and bronchoalveolar lavage 
Bronchoscopy was performed immediately following oesophagectomy after 
completion of one-lung ventilation and prior to the patient being woken up 
and extubated. An Olympus LF-TP fibrescope (Olympus Keymed Medical, 
Southend-on-Sea, UK) was inserted into the endotracheal tube into the lung 
that had been deflated during one-lung ventilation, which was the right lung 
in all patients in this study. The scope is 5.2mm in diameter and has a 
sufficient sized suction channel. Bronchoalveolar lavage was performed using 
a standardised protocol that has previously been described.212 The tip of the 
bronchoscope was wedged into a sub-segmental branch of the middle lobe 
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and three 50 millilitre aliquots of sterile 0.9% saline at room temperature 
were instilled down the bronchoscope and the bronchoalveolar lavage fluid 
(BALF) aspirated back into a 100 millilitre collection chamber attached to the 
suction port. The sample was placed immediately on ice and shipped to the 
laboratory for processing and analysis.  
 
 Lung resection tissue 
Lung resections samples collected as part of the MLTC were immediately 
examined in theatre by an experienced member of the surgical team. A 
section of the sample of at least 10grams in weight and distant from the 
tumour, without evidence of macroscopic malignancy that was not required 
for diagnostic or clinical purposes was immediately placed in a sterile sealed 
container with 0.9% saline and handed to the research team.  Samples were 
transported on ice to the laboratory for processing and analysis.   
 
 ARDS bronchoalveolar lavage fluid 
Stored ARDS BALF samples were obtained from 4 patients from the BALTI 
trial of salbutamol to treat ARDS114. This was a randomised study of patients 
with confirmed ALI/ARDS as per AECC criteria that were treated with 
placebo or IV salbutamol. Patients underwent a sub-study bronchoscopy and 
lavage on the day of recruitment as part of the study and unused BALF was 
stored as per ethical approval for use in future ARDS studies. Samples were 
pooled and mixed with 1:1 RPMI 1640 media and 10% FBS (Sigma-Aldrich) 
for further macrophage stimulation as described in section 6.2.1.1. 
69 
 
 SAMPLE PROCESSING 
 Blood processing 
Upon arrival in the laboratory samples were spun at 560g for 10 minutes in a 
centrifuge pre-chilled to 40C (Rotina 46R centrifuge, Hettich AG, Bach, 
Switzerland). The supernatant (plasma) was then aspirated and aliquoted 
into 0.5ml cryovials and stored at -800C until further analysis was performed. 
The blood cell pellet was then mixed in a ratio of 1:1 with phosphate buffered 
saline (PBS; Gibco Invitrogen, Paisley, UK) in a 50ml sterile FalconTM tube 
(Becton Dickinson Ltd) in preparation for monocyte isolation.  
 
 Monocyte Isolation 
The blood cell pellet and PBS (Gibco Invitrogen) mixed solution was gently 
overlay onto LymphoprepTM (Axis-Shield, Oslo, Norway) in a ratio of 3:2 
blood to LymphoprepTM in a 50ml sterile FalconTM tube (Becton Dickinson 
Ltd) and centrifuged (Universal 32 centrifuge, Hettich AG, Bach, Switzerland) 
at 800g with minimal acceleration and zero brake for 30 minutes at 200C. 
Lymphoprep™ is a density gradient medium for the isolation of mononuclear 
cells from peripheral blood as granulocytes and red blood cells have a higher 
density than mononuclear cells and sediment through the Lymphoprep™ 
layer during centrifugation. The interphase created which contains 
mononuclear cells was then gently aspirated using a 2.5 ml Pasteur pipette 
(Alphalabs, Eastleigh, UK) and transferred  into a clean FalconTM tube (Becton 
Dickinson Ltd) and washed by the addition of 30mls of sterile PBS (Gibco 
Invitrogen) with 10% foetal bovine serum (FBS, Sigma-Aldrich, Poole, UK) 
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and centrifuged at 250g for 10mins (Universal 32 centrifuge, Hettich AG, 
Bach, Switzerland). This process enables removal of most of the platelet 
population.  The supernatant was then discarded and cells re-suspended with 
culture medium [RPMI 1640 media; 10% FBS; penicillin 100U/mL; 
streptomycin 100ug/mL (Sigma-Aldrich)].  
 
Total cell count, viability and differential cell count were performed as 
described in 3.5.6 and 3.5.7.  Cells were then re-suspended in culture media 
dependent on monocyte cell percentage and total cell count to a volume such 
that the concentration was 1 x 106 monocytes/mL and plated at 0.5 x 106 per 
well in a 24 well flat bottom cell culture plate (Costar®,Corning®, Wiesbaden, 
Germany) and incubated at 370C in a 5% CO2 atmosphere in preparation for 
cellular experiments. 
 
 Bronchoalveolar fluid  
The lavage fluid was initially filtered through sterile surgical gauze to remove 
mucous and particulate matter in a sterile 50ml FalconTM tube (Becton 
Dickinson Ltd) and the total volume of lavage documented. A total cell count 
was performed using trypan blue and the haemocytometer and a differential 
cell count performed using Quick-diff (Gentaur Europe, Kampenhout, 
Belgium) as described in 3.5.6 and 3.5.7.  The BALF was then centrifuged in a 
pre-chilled centrifuge (Rotina 46R centrifuge, Hettich AG) 40C at 560g for 10 
mins. BALF supernatant was aspirated and stored in aliquots of 0.5ml at -
800C for future analysis. The cell pellet was then re-suspended in 10mls of 
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RPMI 1640 media supplemented with 10% FBS (Sigma-Aldrich) for further 
processing.  
 
 Lung resection samples 
Upon arrival in the laboratory lung resection samples were immediately 
washed through with 2000mLs of sterile 0.9% sodium chloride (Baxter, 
Newbury, UK) using a 14 gauge needle (Vasofix®, Braun, Melsungen, 
Germany). The needle was moved through the lung sample whilst continuous 
fluid was connected using an intravenous giving set and allowed to run 
freely. The washed through fluid or lavage was collected and decanted into 
50ml FalconTM tubes (Becton Dickinson Ltd) and centrifuged in a pre-chilled 
centrifuge (Rotina 46R centrifuge, Hettich AG) 40C at 560g for 10 mins. The 
supernatants were discarded and the cell pellets pooled and re-suspended in 
10mls of RPMI 1640 media supplemented with 10% FBS (Sigma-Aldrich) for 
further processing. 
 
 Alveolar macrophage isolation 
Re-suspended cell pellets from BALF and lung resection washings were 
treated identically from this point onwards.  The re-suspended cell pellets 
were overlay onto 10mls of  LymphoprepTM (Axis-Shield) and centrifuged at 
800g for 30minutes at 200C with minimal acceleration and no brake 
(Universal 32 centrifuge, Hettich AG). The interphase or buffy layer of 
mononuclear cells was aspirated carefully with a 2.5 ml Pasteur pipette 
(Alphalabs) into a fresh sterile 50mL FalconTM tube (Becton Dickinson Ltd) 
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and washed with PBS (Gibco Invitrogen) supplemented with 10% FBS 
(Sigma-Aldrich) at 300g for 10 mins (Universal 32 centrifuge, Hettich AG) to 
facilitate removal of platelets. A further cell count and viability was 
performed on all samples as described in 3.5.6 and 3.5.7 (purity >95%) and 
cells re-suspended in culture medium [RPMI 1640 media; 10% FBS; penicillin 
100U/mL; streptomycin 100ug/mL (Sigma-Aldrich)] to a concentration of 1 x 
106 cells/mL.  Cells were then plated into a 24 well flat bottom culture plate 
(Costar®,Corning®) at 0.5 x 106 cells/mL and cultured in an incubator at 370C 
in a 5% CO2 atmosphere in preparation for cellular studies. For the in-vitro 
studies, cells were treated with experimental conditions at this point.  
 
 Cell count and viability 
Fifty microlitres of cell solution was mixed with equal volume of 0.4% (w/v) 
trypan blue solution and left to incubate for 5 minutes. Cell count and 
viability was performed by adding 10ul of the solution to a haemocytometer 
with improved Neubar markings and cells counted in each chamber.  Non-
viable cells take up the dye and appear blue whilst viable cells exclude the 
dye. Total viable cell count was performed multiplying the number of viable 
cells on the haemocytometer grid by 2 (to account for trypan blue solution 
dilution) and then multiplying by 104 (number of cells per millilitre from 
haemocytometer).  
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 Differential cell count 
A differential cell count was performed using a cytospin preparation. Fifty 
microlitres of re-suspended cells were placed in the cytospin apparatus ad 
spun at 300 r.p.m (rotations per minute) for 5 minutes in a Shandon Mk II 
cyto-centrifuge (Thermo electron corporation, Basingstoke, UK). Slides were 
air dried and stained with Quick-Diff (Gentaur Europe, Kampenhout, 
Belgium). The differential cell count was then determined by counting 100 
cells under 40 x magnification and noting the number of individual cell types.  
 
 EFFEROCYTOSIS ASSAY 
An efferocytosis assay was undertaken to assess the phagocytic capacity of 
apoptotic neutrophils by alveolar macrophages and cultured peripheral 
blood monocytes.  This assay has previously been validated by our group. 
 
 Isolation and preparation of neutrophils 
Neutrophils were isolated from whole blood using a Percoll® (pH 8.5-9.5; 
Sigma-Aldrich) discontinuous density gradient as previously described.213 
Blood was drawn from healthy volunteers by peripheral venepuncture into 
lithium heparin vacutainer® bottles (Becton Dickinson Ltd) and transferred 
into a 50ml sterile FalconTM tube (Becton Dickinson Ltd). One millilitre of 2% 
dextran (Sigma-Aldrich) was added for every 6mls of blood and gently mixed 
prior to incubation for 30minutes at room temperature to facilitate 
sedimentation of the red blood cells.  
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A working 90% isotonic stock solution of Percoll® was made by mixing 45 ml 
of Percoll® (Sigma-Aldrich) with 5 ml of sterile 9% (w/v) sodium chloride 
(Sigma-Aldrich). The 80% Percoll® was prepared by diluting 40 ml of the 
isotonic Percoll® stock with 10 ml 0.9% (w/v) sodium chloride (Baxter, 
Newbury, UK) whilst 56% Percoll® comprised of 28 ml of the working 
isotonic Percoll® stock and 22 ml of 0.9% (v/v) sodium chloride (Baxter). 
Gradients were then prepared by carefully under- layering 2.5ml 80% 
Percoll® with a 3ml Pasteur pipette (Alphalabs) under 5 ml of 56% Percoll® 
in a 15ml sterile FalconTM tube (Becton Dickinson, Ltd). 
 
The white cell rich plasma top layer created by the dextran step above was 
then aspirated with a 3ml Pasteur pipette (Alpha labs) and carefully layered 
onto the Percoll® density gradient. The tubes were then centrifuged at 220g 
and 200C for 20 minutes with minimal acceleration and no brake (Universal 
32 centrifuge, Hettich AG). This process separates blood into distinct layers, 
with the uppermost being diluted plasma, followed by an interphase of 
mononuclear cells, a layer of 56% Percoll®, then a neutrophil cellular 
interphase followed by the 80% Percoll® layer and red cell pellet at the base. 
Neutrophils were carefully aspirated from the 80% and 56% gradient 
interface using a fine bore Pasteur pipette (Alphalabs)  and re-suspended and 
washed twice in phosphate buffered saline (PBS; Gibco Invitrogen) at 440G 
for 10 minutes at room temperature. Post-centrifugation the supernatant 
was discarded and the cells re-suspended in RPMI 1640 (Sigma-Aldrich). 
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Cells were counted with trypan blue on a haemocytometer and a differential 
cell count was also performed as described above to ensure purity of >95%.  
Cells were then re-suspended in a 1 micromolar (uM) solution of 
CelltrackerTM Green 5-chloromethylfluorescein diacetate (CMFDA) (Life 
Technologies Ltd, Paisley, UK) in warmed, serum free RPMI 1640 (Sigma-
Aldrich) at a concentration of 2 x 106 cells/mL and incubated for 30minutes 
at 370C in a 5% CO2 atmosphere to allow uptake of the marker. This 
fluorescent stain passes through cell membranes; however, once inside the 
cell is transformed by intra-cellular esterase enzymes into cell-impermeable 
fluorescent cytoplasmic reaction products with a green excitation/emission 
spectra (492/517 nm maxima). This product has both good fluorescent 
retention of over 72 hours and low cytotoxicity. This was followed by 2 
washes with warm serum free RPMI 1640 (Sigma-Aldrich) by centrifuging 
for 5minutes at 1500g at room temperature (Universal 32 centrifuge, Hettich 
AG). Finally the cells were re-suspended at a final concentration of 2 x 106 in 
warm serum free RPMI with penicillin 100U/mL; streptomycin 100ug/mL 
(Sigma-Aldrich) and left for 24 hours at 370C in a 5% CO2 atmosphere. 
 
Neutrophils are known to undergo apoptosis in a time-dependant manner. It 
has previously been shown by our group (Dr Christopher Bassford, 
University of Warwick, 2011) that features of apoptosis as evidenced by 
cellular vacuolation and maximal trypan blue uptake occurred at 20 hours. 
To confirm this, a flow cytometry quantitative assay of the time course of 
neutrophil apoptosis was performed of 4 healthy control neutrophils using 
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Fluorescein Isothiocyanate (FITC) conjugated Annexin V (BD Biosciences, 
Oxford, UK) and violet conjugated Sytox blue (Invitrogen, Paisley, UK).  Cells 
that were annexin only positive (early apoptosis) and double positive (late 
apoptosis) were counted to calculate the percentage of total apoptosis over 
24 hours. Figure 3.3 demonstrates that by 20 hours 78.2% and by 24 hours 
93.8% of neutrophils were apoptotic. Very few cells were necrotic <2% 
(Sytox only positive) at any time point. Therefore in this assay we incubated 
neutrophils for 24 hours to achieve maximal apoptosis.  
 
 
 
 
Figure 3.3:  Time course of neutrophil apoptosis.   
Apoptosis was assessed at 0, 4, 8, 16, 20 and 24 hours. Values represent 
means of 4 duplicate experiments.  
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 Quantification of efferocytosis  
After 24 hours incubation media was removed from the cultured alveolar 
macrophages or peripheral blood monocytes and the cells washed gently 
with serum free media. Cells as expected were adhered to the flat bottom 
wells of the culture plates. The stained apoptotic neutrophils were washed as 
described above and re-suspended in a concentration of 2 x106 cells/mL in 
RPMI 1640 (Sigma-Aldrich). The suspension was then added to the 
mononuclear (MNCs) at 1mL per well thereby flooding the cultured 
mononuclear cells with four fold excess of apoptotic neutrophils. Cells were 
incubated for 90 minutes in a 5% CO2, 37oC atmosphere to allow the 
phagocytosis of the neutrophils. The media was then removed and wells 
washed twice with room temperature PBS (Gibco Invitrogen) to remove any 
non-adherent or non-engulfed neutrophils. Five hundred microliters of 
trypsin solution (TripLETM express, Gibco Invitrogen, Paisley, UK) was added 
to each well and incubated for 15 minutes at 37oC, 5% CO2 atmosphere. Cells 
were visualised under a microscope to ensure that they had detached from 
the culture well floor. If not, they were returned to the incubator and re-
inspected every 5 minutes. The cell suspensions were then pipetted and 
transferred into 5ml polypropylene flow cytometry tubes (FalconTM, Becton 
and Dickinson) and spun at 400g for 4minutes at 40C and re-suspended in 
100ml of PBS (Gibco Invitrogen) and immediately placed on ice and 
examined on a flow cytometer (CyANADP, Beckman Coulter, Brea, California, 
USA). 
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Cells were agitated on a vortex (Varimix, Sciquip, Newtown, UK) immediately 
prior to running on the flow cytometer. Pure alveolar macrophage or 
cultured monocytes and pure stained apoptotic neutrophils were used to set 
forward and side-scatter gating on the flow cytometer. The FL-1 channel that 
detects the FiTC fluorescent spectrum was used to identify CMFDA labelled 
apoptotic neutrophils that had been engulfed by macrophages. An example of 
the flow plots and histograms obtained are shown in Figure 3.4.  A minimum 
of 5000 events (cells gated as MNCs) were counted for each experimental 
condition and the proportion of CMFDA positive cells and hence engulfed 
apoptotic neutrophils presented as and efferocytosis percentage.   
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Figure 3.4: Example flow cytometry plots and histograms of 
efferocytosis. 
Forward-side scatter plot and corresponding histogram of A: Negative 
control alveolar macrophages (AM). B: Positive control CMFDA stained 
apoptotic neutrophils and C: Proportion of AMs that had engulfed CMFDA 
stained apoptotic neutrophils.  
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This flow cytometric assay has been previously validated by our group by 
comparing it with direct fluorescent microscopy and been found to have 
differences in results of less than 10% (Dr Chris Bassford, PhD thesis, 
University of Warwick, 2011). However to ensure validity, intra-assay CV was 
re-assessed by repeating one condition 6 times within the same subject and 
the standard deviation of the measurements being divided by their mean. 
The intra-assay CV was 7.2%.  
 
 MONOCYTE DIFFERENTIATION AND PHENOTYPE 
Isolated peripheral blood monocytes were incubated for 24 hours as 
described above. After which the media was changed and the cells treated 
with the relevant conditions [untreated, 50nmol/L 25(OH)D3 (Merck 
Millipore, Watford, UK), 100ng/mL granulocyte macrophage colony-
stimulating factor (GM-SCF, PeproTech, Rocky Hill, USA), 50ng/mL 
macrophage colony-stimulating factor (M-CSF, PeproTech) with 50ng/mL IL-
10 (PeproTech)] in culture media for a further 72 hours.  After 72 hours the 
supernatant was aspirated and the cells detached with 500mL trypsin 
solution (TripLETM express, Gibco Invitrogen, Paisley, UK) and incubated for 
15 minutes at 37oC, 5% CO2 atmosphere. Cells were visualised under a 
microscope to ensure that they had detached from the culture well floor. If 
not, they were returned to the incubator and re-inspected every 5 minutes. 
The cells were then aspirated into a 96 well flexi-plate at 2 x 105 cells per well 
(a well for cells only, each single immunofluorescent antibody stain, control, 
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treatment conditions in duplicate and isotype controls) and washed twice 
with 100mL PBS (Gibco, Invitrogen) with 1% bovine serum albumin (BSA, 
Sigma-Aldrich, Poole, UK) at 40 C, 400g for 4 minutes (Rotina 46R centrifuge, 
Hettich AG, Bach, Switzerland). Cells were then gently agitated and placed on 
ice and stained with the immunofluorescent antibody panel as shown in 
Table 3.2 for 30 minutes on ice in the dark. After incubation the plate was 
washed twice with 100mL of 1%BSA/PBS as above and cells re-suspended in 
300mL of PBS (Gibco, Invitrogen) and immediately run through a flow 
cytometer (CyANADP, Beckman Coulter, Brea, California, USA). Colour 
compensation and analysis were performed using Summit 4.3 software 
(Dako, Beckman Coulter). The mean fluorescent intensity (MFI) was analysed 
for treated and untreated cells for each antibody stain and the results 
expressed as a fold change in MFI compared with untreated cells.  
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Antibody Clone Isotype Fluorochrome Concentration M1* M2* 
Anti-hCD14 TUK4 Mouse, IgG2a PE Vio770TM 1:20 ++ + 
Anti-hCD80 2D10 Mouse, IgG1 APC 1:11 ++ - 
Anti-hCD206 DCN228 Mouse, IgG1 APC Vio770TM 1:11 ++ + 
Anti-hCD163 GHI/61.1 Mouse, IgG1 VioBlue® 1:11 - ++ 
Anti-hCD16 VEP13 Mouse, IgM VioGreenTM 1:11 _ ++ 
Anti-hCD200R OX108 Mouse, IgG1 Alexa Fluor®488 1:20 _ ++ 
Anti-hMer TK 125518 Mouse, IgG1 PE 1:10 _ ++ 
Table 3.2: Human antibody staining panel used for flow cytometry of cultured monocyte cell surface expression. 
h: human; MerTK: Mer tyrosine kinase receptor; PE: phycoerythrin; APC; allophycocyanin.  
*: The expression of each antigen by MI (classically differentiated) and M2 (alternatively differentiated) mononuclear cells is 
presented as high (++), intermediate (+) and low/negative ( - ). 
 
CD14, CD80, CD206, CD163 and CD16 (Macs, Milteyni Biotech, Auburn, USA); CD200R (AbD Serotec, Bio-Rad, Kidlington, UK);  
Anti-Mer TK (R&D systems, Abingdon, UK)
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 BIOCHEMICAL ASSAYS 
 Vitamin D Levels 
Vitamin D levels (25(OH)D3 and 1,25(OH)2D3) were batch transported on dry 
ice and measured by the Supra-regional Assay Service for Metabolic Bone 
Assays, Biomedical Research Centre, University of East Anglia, Norwich 
Medical School, Norfolk, Norwich, UK. This laboratory has appropriate 
Clinical Pathology Accreditation (CPA UK Ltd) and all assays have been 
validated to national standards. 25(OH)D3 was measured by tandem mass 
spectrometry using the appropriate vitamin D External Quality Assessment 
Scheme (DEQAS) control. 1,25(OH)2D3 levels were measured by enzyme 
immunoassay (EIA) (immunodiagnostic systems Ltd, UK). A summary of the 
validation data provided for these assays is provided in Table 3.3 and 3.4.  
25 (OH)D3 (nmol/L) 
Lower limit of 
detection 
 
Intra-assay CV 
(%) 
Inter-assay CV 
(%) 
Spike recovery 
(%) 
5nmol/L 9.6 9.2 96.1 
Table 3.3: Validation of 25(OH)D3 mass spectrometry assay 
Data courtesy the Professor William Fraser, Biomedical Research Unit, 
University of East Anglia, Norwich, UK. CV: coefficient of variation. 
 
1,25(OH2)3 (pmol/L) 
Lower limit of 
detection 
Intra-assay CV 
(%) 
Inter-assay CV 
(%) 
20pmol/L 10.5 – 15.9 17.6 – 16.3 
Table 3.4: Validation of 1,25(OH2)3 enzyme immunoassay (EIA) 
Data courtesy of Professor William Fraser, Biomedical Research Unit, 
University of East Anglia, Norwich, UK. CV: coefficient of variation. 
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 Vitamin D binding protein   
 Vitamin D binding protein (DBP) was measured by using a commercially 
available ELISA kit (K2314KO1, Immundiagnostik, Bensheim, Germany).  The 
pre-coated 96 well microplate (polyclonal anti-DBP antibodies) was 
manually washed 5 times with 250mL of wash buffer using a multichannel 
pipette (Starlabs, Milton Keynes, UK). Pre-prepared lyophilized 5 standards 
and 2 controls were reconstituted in 500mL of standard dilution buffer and 1 
in 40,000 dilutions of plasma samples prepared by 3 serial dilutions in the 
sample dilution buffer. The enzyme linked antibody (rabbit –anti-DBP, 
peroxidase labelled) was diluted 1:100 in wash buffer.  One-hundred 
microliters of standards, controls and pre-diluted plasma samples were 
added to the pre-coated 96 well plate, covered and incubated for 1 hour on a 
horizontal plate mixer at room temperature.  At the end of the incubation 
period wells were manually washed 5 times with wash buffer as described 
above. One hundred microlitres of the peroxidase labelled antibody were 
added to each well and the plate covered with an adhesive strip and 
incubated for a further hour on a horizontal plate mixer. Following this the 
contents were decanted and plates washed 5 times as described above.  One 
hundred microliters of substrate tetramethylbenzidine (TNB) were added to 
each well and incubated in the dark for 20mintues prior to adding 100mL of 
stop solution. The plate was immediately read at 450nm (against 690nm) 
using a Synergy HT fluorometric plate reader (BioTek, Swindon, UK). The 
DBP concentration was calculated by interpolation of the standard curve and 
correction for sample dilution factor.  
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Spiking experiments were performed in which pooled healthy control plasma 
were measured with and without supplementation with a known 
concentration of DBP. Observed values were compared against expected 
values and the mean spike recovery calculated. Validation experiments were 
performed in a 1 in 40,000 sample dilution. Experiments were performed in 
replicate 12 times intra-assay and known spiked sera compared between 10 
plates. Adding 2 standard deviations of the mean optical density value of 10 
zero standard replicates and calculating the corresponding concentration 
calculated the lower limit of detection. The lower limit of detection, intra and 
inter assay CV and percentage recovery are shown in Table 3.5 and standard 
curve in Figure 3.5. Limitations of this assay include the high sample dilution 
required, reducing its sensitivity and its lack of detection of DBP-Actin 
complexes that may result in lower levels of DBP. 
 
 
 
DBP ng/mL  
Lower limit of 
detection 
 
Intra-assay CV 
(%) 
n=12 
Inter-assay CV 
(%) 
n=10 
Spike recovery  
mean (%) 
n=12 
2.96ng/mL 2.4 27.8 104.8  
Table 3.5: Validation of vitamin D binding protein (DBP) enzyme-linked 
immunosorbent assay. CV: coefficient of variation. 
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Figure 3.5: Standard curve for vitamin D binding protein (DBP) 
 
 Cytokines  
Plasma inflammatory cytokines (IL-6, IL-8, TNF-IL1- and IL-10) were 
measured by a commercially available Magnetic Luminex® Performance 
Assay (LUHM000, R&D Systems, Abingdon, UK) and soluble cytokine 
receptors (sRAGE, TNFR-1 and TNF-2I) by a MILLIPLEX® MAP assay 
(HSCRMAG-32K, Millipore, Billerica, USA). This method uses precise 
concentrations of color-coded magnetic microparticles which have been pre-
coated with analyte specific capture antibodies that allow multiple distinctly 
coloured bead sets to be created.  After capture of the analyte by the beads, a 
biotinylated antibody cocktail specific to the analytes is added. Finally a 
Streptavidin-Phycoerythin conjugate (Streptavidin-PE) that binds to the 
biotinylated antibody is added. A dual laser analyser allows one laser to 
identify the analyte in question and the other quantifies the magnitude of the 
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PE-derived signal. This technique allows measuring of multiple cytokines 
simultaneously in a limited sample volume.  
 
The two kits used above follow similar procedures albeit with slight 
variations. For the inflammatory cytokine kit (LUHM000, R&D Systems), 
standards were created by seven doubling dilutions of the standard cocktails 
provided with calibrator diluent.  Plasma samples were diluted 4 fold in 
calibrator diluent. Microparticle beads were gently vortexed and 50mL made 
up to 5mls with microparticle diluent. Fifty microliters of microparticles 
were added to each well of a 96 well microplate followed by 50L of 
standards or sample, covered with a foil plate sealer and left to incubate for 3 
hours on a horizontal microplate shaker (800rpm). Following incubation the 
plate was washed 3 times with 100L of wash buffer using an automated 
magnetic plate washer (Bioplex ProTM, Bio-rad, Hercules, USA) to ensure 
beads are not washed away.  Fifty microliters of diluted biotin antibody 
cocktail was added to the wells and incubated for a further hour at room 
temperature on a shaker. After the wash step was repeated 50L of 
Streptavidin-PE was added to each well and left to incubate in the dark as 
above for 30mintues. A further wash step was repeated followed by the 
addition of 100L of wash buffer and incubation for 2mins on the shaker as 
above. The plate was then read on a Bioplex® 200 analyser (Bio-rad, 
Hercules, USA). Each bead is assigned a region on the analyser and standard 
concentrations and dilution factor for each analyte is input from which the 
BioRad software package creates a standard curve and using 5 parameter 
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logistic regression determines the concentrations of analytes within the 
samples determined by interpolation, and multiplication by the appropriate 
dilution factor.  
 
In brief the cytokine soluble receptor kit (Millipore, Billerica, USA) uses the 
same method. Microparticle beads were sonicated and 60L were made up to 
3mls with bead diluent. The supplied 96 well microplate was washed 3 times 
with 200L of wash buffer using an automated plate washer (Bioplex ProTM, 
Bio-rad, Hercules, USA). Twenty-five microliters of standards (seven serial 
dilutions), quality controls, samples (1 in 5 dilutions), assay buffer and serum 
matrix were added to the wells followed by 25L of magnetic beads. These 
were sealed and incubated for 2 hours at room temperature as described 
above. The plate was then washed twice with 200L of wash buffer on a 
magnetic automated plate washer (Bioplex ProTM, Bio-rad). Twenty-five 
microliters of detection antibodies were added and incubated for a further 
hour followed by the addition of 25mL of Streptavidin-PE without 
performing a wash step. The plate was then incubated for a further 
30minutes and washed twice followed by the addition of 150L of sheath 
fluid. The plate was analysed on the Bioplex® (Bio-Rad) as described above. 
These assays are calibrated against highly purified recombinant human 
cytokines produced at R&D Systems and Millipore.  
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 ANIMAL STUDIES 
 Ethical statement 
All procedures were performed in accordance to UK laws under the Animal 
[Scientific Procedures] Act 1986 (project licence code 30/2836; personal 
licence number I77F587B4) and with approval and oversight from the local 
animal ethics committee, Named Veterinary Surgeon (NVS) and Named 
Animal Care and Welfare Officer (NAQWO).  The principles of the 3Rs 
(Reduction, Replacement and Refinement) provide the foundations for how 
the animals were cared for and the research was designed.  
 
 Experimental animals and study design 
Male wild-type (WT) C57Bl/6 mice (aged 3-4 week old) were obtained from 
Harlan UK Limited, Oxford, UK and maintained at the Biomedical Services 
Unit (BMSU), Birmingham University, UK.  A maximum of 16 mice were 
obtained at any one time to account for 8 mice per group allocation. Once 
housed the mice were randomly numbered and tagged 1 to 4 per cage in 4 
cages. All experiments were carried out on WT mice that had undergone 
dietary manipulation. Vitamin D deficiency was induced in WT pups by 
feeding them a vitamin D deficient chow (TD 89123, Harlan, USA) or normal 
chow for 6 weeks thus producing 2 experimental arms (n=8 per arm), 
vitamin D deficient mice (VDD) and vitamin D sufficient (VDS) mice. Caecal 
ligation and puncture surgery was carried out on individual mice in batches 
of 2-4 mice at any one time. This was to ensure mice could be monitored 
adequately during and after the procedure. The experimental protocols have 
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been designed to minimise the numbers of animals used but to maximise 
scientific outcome (e.g. the consistent use of C57B6 strain, sex and consistent 
age of animal and interventions to allow comparisons across wild type 
animals and measurements of multiple outcomes in the same animal). 
 
 Housing and husbandry 
All animals were housed in cages of 4 in a 12-hour light and 12-hour dark 
cycle with food and water provided ad libitum. All mice were weighed before 
and 16 hours after surgery.  The health of each individual mouse was 
assessed and documented before, during and after surgery on in-house 
standardised mouse assessment scoring sheets to ensure welfare.  If at any 
time there was concern that the mouse was becoming too unwell, in pain 
despite increased analgesia or distressed a decision was made to stop the 
experiment and euthanise the animal humanly and immediately according to 
Schedule 1 of the Animal (Scientific Procedures) Act 1986.  
 
 Caecal ligation and puncture (CLP) surgery 
Pre-medication was given in the form of subcutaneous buprenorphine 
0.1mg/kg body weight (Temgesic®, Reckitt Benckiser, Wallisellen, 
Switzerland) 15-30 minutes prior to the procedure.  Animals were 
anaesthetised with isoflurane gas (5% with 1.5L/min of oxygen) for 
induction and maintenance (1-3% with 1.5L/min of oxygen) anaesthesia. All 
surgery was performed with aseptic techniques (sterile gown, gloves, drapes,  
and surgical equipment) and in dedicated animal surgical theatres in the 
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BMSU, University of Birmingham. The CLP experimental design was adapted 
from previously published protocols.214 After shaving the fur off the abdomen 
and application of 2% chlorhexidine (AvagardTM, Pymble, Australia) a 
midline laparotomy was performed followed by exposure of the caecum, 
ligation of the lower 30% with 2.0 EthilonTM nylon suture (Ethicon inc) and 
single through-and-through puncture of ligated caecum with a 19G 
microlance needle (Becton Dickinson Ltd). A small amount of faeces was then 
gently expressed by compressing the ligated caecum with forceps prior to 
being placed back into the abdomen and closed with 6.0 Vicryl® (Ethicon inc) 
followed by skin closure with 4.0 Prolene® (Ethicon inc). Surgery was 
performed on heated tables set at 37.5oC. All animals were recovered in heat 
boxes and recovery incubators until sacrificed. Postoperative resuscitation 
was with 0.5mls of fluid (Hartman’s solution, Aqupharm 11®, Animalcare 
Ltd, York, UK) and a further dose of buprenorphine. Animals were reassessed 
6 hours post-operatively and given a further 0.5mls of fluid and sacrificed at 
16 hours post surgery. Sham surgery was identical except for the lack of 
ligation and puncture of the caecum after exteriorisation from the abdomen.  
 
 Sample collection and processing 
At 16 hours post CLP animals were deeply anaesthetised with 5% isoflurane. 
Cardiac puncture was performed and death confirmed. Immediate post-
mortem peritoneal lavage fluid (PLF) was collected by instilling 1.0ml of 
PBS/EDTA (200nM) (Gibco, Invitrogen) into the right and left upper 
quadrant of the abdomen and aspirating back in both lower quadrants. 
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Bronchoalveolar fluid (BALF) was collected by opening the chest cavity and 
neck, dissecting down, manipulating the trachea and inserting a fine bore 
polythene tubing to the level of just above the carina. Lungs were then 
lavaged twice with 0.6mls of PBS/EDTA (200nM) (Gibco, Invitrogen). 
Examination of the caecum was carried out to confirm necrosis and colour of 
liver recorded to ensure adequate sepsis was induced. All samples were 
immediately transferred on ice to the laboratory for processing and analysis. 
 
Cardiac blood was centrifuged at 13,500RPM in a micro-centrifuge (Stuart 
SCF2, Bibby Scientific Ltd, Stone, UK) at for 10 minutes. Prior to 
centrifugation 15ul of whole blood was taken for bacterial culture. The sera 
layer was aspirated and stored at -20oC. PLF and BALF were centrifuged at 
400g for 10minutes. The supernatant was aspirated and stored at -20OC. The 
cell pellet was then re-suspended in PBS/EDTA (200nM) (Gibco, Invitrogen) 
for further analysis.  
 
 Bacterial culture 
One hundred microliters of whole blood, PLF and BALF were diluted in 1ml 
of sterile RPMI 1640 in the first well of corresponding 24 well cell culture 
plates (CoStar®, Corning®). Eight serial dilutions of 1:10 (100mL of preceding 
well into the next well of 1640 RPMI) were sequentially carried out to a 
factor of 108. Twenty microliters of each dilution and neat BALF were plated 
in corresponding pre-prepared Lysogeny broth (LB-Lennox, Sigma-Aldrich) 
agar plates split into eighths and labelled with dilution factors and incubated 
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overnight at 37oC. Culture plates were made in advance by adding 35g of LB-
Lennox powder to 1L of warm distilled water and stirring to dissolve the 
powder. The broth was then autoclaved for 15 minutes at 1210C to sterilise. 
It was then allowed to cool slightly and poured into petri dishes. After 24 
hours of incubating Colony Forming Units (CFU) were counted and CFU/ml 
calculated from the original dilutions and initial total volumes of blood, BALF 
and PLF. An example of a culture plate is given in Figure 3.6. 
 
Figure 3.6: Example of bacterial culture plate for peritoneal lavage fluid  
In this particular plate the colony forming units (CFU) would be read as 7 x 
108  (since this is where the clearest CFUs can be read). The final calculation 
of CFU/mL was determined by the total volume of PLF and the initial dilution 
(1 in 50) prior to serial dilutions being performed: e.g. CFU/mL = (7 x 108 
CFU/1.25mL PLF) x 50 dilution factor = 2.54 x 1010 CFU/mL  
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 Cell identification and enumeration 
The re-suspended BALF and PLF cells were counted on a haemocytometer as 
described in section 3.5.6 and the total number of cells per ml of BALF or PLF 
recorded. Cells were then resuspended to a concentration of 1-2 x 106 cells 
per ml in 2%EDTA/PBS (Gibco, Invitrogen) and 200L plated onto a pre-
labelled 96 well flexiplate (CoStar®). The plate was then centrifuged at 400g 
40C for 4minutes (Rotina 46R centrifuge, Hettich AG) and the cells gently 
agitated to release the cells from the bottom of the plate.  Ten microliters of 
mouse serum (Sigma-Aldrich) was diluted in 1000mL of 2%EDTA/PBS and 
50L added to each well and the plate incubated on ice for 15mintes to block 
non-specific Fc receptor binding.  The plate was then spun as previously and 
anti-mouse antibodies made up in 2%EDTA/PBS (Gibco, Invitrogen) and 
added to the appropriate wells as described in Table 3.6 (control, single 
antibodies and samples). This method has previously been validated by our 
group and therefore was not repeated. The cells were then incubated in the 
dark on ice for a 20minutes after which the plate was spun as described 
above.  
 
Apoptosis of cells was assessed by adding one hundred microliters of 
Annexin V buffer (BD Biosciences, Oxford, UK) to the wells spinning the plate 
as described above followed by the adding Annexin V antibody (BD 
Biosciences at a concentration of 1:100 (in Annexin V buffer) and the plate 
left to incubate for a further 10 minutes in the dark on ice. Cells were then 
washed as above, transferred to polypropylene flow cytometry tubes 
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(FalconTM, Becton and Dickinson Ltd) and were analysed by flow cytometry 
(CyAn™ ADP, Beckman Coulter). SYTOX BlueTM (Molecular ProbesTM, 
Invitrogen) was used to assess cellular necrosis and 30L (1:1500) was 
added prior to running the cells on the flow cytometer. Colour compensation 
and analysis were performed using Summit 4.3 software (Dako, Beckman 
Coulter). Relevant cell identification by markers are summarised in Table 3.7 
and typical flow plots and gating strategy are shown in Figure 3.7. 
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Antibody Clone Isotype Fluorochrome Concentration 
Anti-mF4/80 BM8 Rat, IgG2a kappa PE  1:100 
Anti-mCD11b M1/70 Rat, IgG2b kappa APC 1:1000 
Anti-mCD11c N418 Hamster, IgG PE Cy7 1:150 
Anti-mGr1/Ly6G RB6-8C5 Rat, IgG2b kappa APC Cy7 1:200 
Table 3.6: Mouse antibody staining panel used for flow cytometry to identify cells 
m: mouse; PE: phycoerythrin; APC; allophycocyanin; Cy7 cyanine 7. All markers acquired from eBiosciene, Hatfield, UK.  
 
 
Cell F4/80 CD11b CD11c Gr1 
Alveolar macrophages ++  ++ 
Peritoneal macrophages ++ +  
Neutrophils  ++  ++ 
Table 3.7: Cell surface marker expression strategy for the identification and quantification of murine cells 
The expression of each antigen by peritoneal and bronchoalveolar fluid cells is presented as high (++), intermediate (+) and 
low/negative ( - ).
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Figure 3.7: Gating strategy and flow plot for the identification of cells in  
Macrophages CD11b+F4/80+ CD11c-; Neutrophils CD11b+F4/80-CD11c-Gr1+; 
Apoptosis: Annexin V+ and SYTOX+. 
98 
 
 Ex-vivo macrophage phagocytosis assay 
In brief extracted peritoneal cells underwent red cell lysis using Gibco ACK 
(Gibco, Invitrogen) lysing buffer 100L per sample and incubated at room 
temperature for 5 minutes. The reaction was stopped with 1mL of cold PBS 
(Gibco, Invitrogen) and cells washed with PBS/BSA 2% (Gibco, Invitrogen) at 
400g 40C for 10 minutes, resuspended in PBS/BSA 2% (Gibco, Invitrogen) to 
a concentration of 1 x 106 cells per mL 100L added to 3x 5mL 
polypropylene tubes (FalconTM, Becton and Dickinson Ltd). pHrodo® Green 
labelled Escherichia coliform (E.Coli) bioparticles (Molecular ProbesTM, 
Invitrogen, Paisley, UK) were re-suspended in 2mL of Hanks’ Balanced Salt 
Solution with 20mM HEPES pH 7.4 (Gibco, Invitrogen) and sonicated for 
10minutes. Fifty microliters of the bioparticles were then added to the cells 
and incubated for 30 mins at 370C with one tube incubated on ice (to act as a 
negative control). Following this incubation cells were washed with PBS/BSA 
2% as above. The supernatant was removed and the cell pellet re-suspended 
in 50mL of mouse serum, transferred to a flexiplate to Fc receptor block and 
stained as per cell analysis protocol above except the F4/80 antibody was 
now conjugated to FiTC (Clone BM8, eBiosciences, Oxford, UK) as pHrodo® 
green particles where excitation/emission is similar to that of phycoerythrin 
(PE). Macrophage phagocytosis of the particle results in acidic pH change 
resulting in fluorescence (excitation/emission 509/533nm) that was 
measured by flow cytometry (CyAn™ ADP, Beckman Coulter) as described 
above. The proportion of F4/80+CD11b+ CD11c - gated cells that were also 
pHrodo® positive were presented as a phagocytosis percentage.   
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 Biochemical Assays 
3.9.9.1 Murine vitamin D analysis 
25(OH)D3 was measured by a commercially available direct ELISA (K2109, 
ImmunDiagnostik, Bensheim, Germany). 1,25(OH)2D3 was measured by a 
commercially available EIA (AC-62F1, Immunodiagnostic Systems, Tyne and 
Wear, UK). Calcium was measured by a commercially available colorimetric 
assay  (ab102505, Abcam, Cambridge, UK) Dr Sian Lax (post-doctoral fellow) 
kindly performed all these assays as per manufacturer’s protocols without 
deviation.  All inter and intra assay CVs were reported to be below 10%. The 
25(OH)D3 direct ELISA was not validated for murine plasma and therefore 
underwent internal validation and was found to have an intra assay CV of  
12.8% and inter assay CV of 15.6% and a mean spike recovery of 82%.  
 
3.9.9.2 Cathelicidin related antimicrobial pepetide (CRAMP) assay 
Total CRAMP levels were measured in sera, BALF and PLF by an indirect 
ELISA derived from a method previously used for LL-37 quantification.215 
CRAMP standards of known concentrations and samples were made up to 50 
µl in serum free RPMI 1640 (Sigma-Aldrich) and incubated in Greiner high 
binding plates (Sigma-Aldrich) overnight at 37 °C in an unsealed plate to 
allow adherence. Plates were washed 3 times with PBS (Gibco, Invitrogen) 
containing 0.05% tween-20 detergent (PBST, 0.05%) and blocked in PBST 
containing 1% BSA (Sigma-Aldrich) for 1 hour at room temperature with 
gentle agitation. Rabbit anti-CRAMP antibody (PA-CRPL-100, Innovagen, 
Lund, Sweden) was diluted 1:2500 in PBST (0.05%) and 100 µl added to each 
100 
 
well for 2 hours at room temperature. Plates were again washed 3 times with 
BST (0.05%) and 100µl of goat anti-rabbit horse radish peroxidase (HRP) 
conjugated antibody (7074, Cell Signalling technologies, Denver, USA) diluted 
1:2500 in PBST (0.05%) added per well for 1 hour at room temperature. 
Plates were washed with PBST (0.05%) and HRP activity was measured by 
the addition of TMB (100L per well). Plates were incubated with substrate 
for 10 minutes in the dark before the reaction was stopped by addition of 100 
µl of stop solution (1M HCl). Absorbance values were obtained at 450 nm 
within 10 minutes, (Synergy 2 Gen 5TM, Biotek).  Sample concentrations 
were then extrapolated from the appropriate standard curve.  
 
CRAMP levels were corrected per mg of protein and represented as ng/mg. 
This assay had an intra assay CV of 4.7% and inter assay CV of 14.2% with a 
mean spike recovery of 94.6%.  A limitation of this assay is that it was only 
validated in sera within a range of 0.934ng/ml to 75ng/ml with no 
experiments performed to exclude cross-reactivity.  If the upper limit is 
extended to 200ng/ml the intra-assay CV increased to 18% and lower limit 
decreased to 0.235ng/ml the CV increased to 20.34%.  
 
3.9.9.3 Protein assay 
A Bio-rad® (Hertforshire, UK) simple colorimetric assay was used to 
measure total protein in sera, BALF and PLF. Bovine serum albumin (BSA, 
Sigma-Aldrich) standards of known concentration were made up to 10ul and 
plated along with 10ul of sample. Bio-Rad® solution was diluted 1 in 5 with 
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distilled water and 200ul added to each well which turns blue on contact 
with protein. Absorbance was measured immediately at 595nm (Synergy 2 
Gen 5TM, Biotek). Protein permeability index was calculated as a ratio fluid 
protein to plasma protein. This assay has previously been validated by our 
group and was not repeated but intra assay CV was 7.8% and inter assay CV 
9.1%.  
 
3.9.9.4 Cytokine assays 
Murine serum inflammatory cytokines (IL-6, KC/CXCL-1, TNF MIP-2, VEGF 
and GM-CSF) were measured by a Luminex® screening assay (LXSAMS, R&D 
systems) and BAL sRAGE by a commercially purchased ELISA (MRG00, R&D 
systems). These assays were kindly performed with the assistance of Dr Sian 
Lax (Post-doctoral fellow) as per the manufacturer’s protocols with no 
deviations and have previously been validated by our group and therefore 
not repeated. 
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Preliminary data from this chapter have been presented and published in 
abstract form: 
Parekh D, Lax S, Dancer RCA, Perkins GD, Thickett D 
Vitamin D deficiency and bacterial load in a murine model of sepsis-induced 
lung injury 
The Lancet 2014; Volume 383; Special Issue S1 
Full paper accepted for publication in Critical Care Medicine 
CHAPTER 4                                                                    
EFFECTS OF VITAMIN D DEFICIENCY ON A MURINE 
MODEL OF SEPSIS INDUCED LUNG INJURY 
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4.1 INTRODUCTION 
The acute respiratory distress syndrome (ARDS) is a heterogeneous 
syndrome that occurs in response to a variety of direct pulmonary (e.g. 
pneumonia and aspiration) and non-pulmonary (e.g. sepsis, trauma and 
blood transfusion) injurious events.6,216 Sepsis remains the commonest 
indirect cause of ARDS,17 however only 18-38% of patients with sepsis 
develop ARDS.217 Patient demographics, comorbidities, smoking status and 
genetic factors may determine those at risk of developing ARDS.16 A large 
prospective study has shown patients with sepsis related ARDS were more 
likely to be women and to have diabetes as well as a higher disease severity, 
poorer recovery from lung injury, and higher mortality than non-sepsis 
related ARDS.218 The same study has found age, acute physiology and chronic 
health evaluation (APACHE III) scores, liver cirrhosis, metastatic cancer, 
serum bilirubin and serum glucose to be independent predictors of ARDS 
mortality.  Therefore identifying potential modifiable risk factors may play an 
important role in preventing ARDS and improving outcomes in those with 
established ARDS.  
 
Worldwide vitamin D deficiency is common.219 Epidemiological studies have 
demonstrated that levels of 25-hydoxyviamin D3 (25(OH)D3) are related to 
geography and season.220,221 In a study of middle-aged adults in the United 
Kingdom, 40% had serum 25(OH)D3 concentrations above 30ng/L 
(75nmol/L) in the summer months but this fell to less than 17% in the 
winter.129 The incidence and mortality of sepsis is higher during the winter 
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months when vitamin D levels are lower.222  Vitamin D has important 
pleiotropic effects on human immunity, acting as a modulator of cells of the 
innate and adaptive system.85  Biologically active 1,25(OH)2D3 directly 
enhances signalling to increase the induction of  antimicrobial peptides, 
cathelicidin (LL-37, its active form) and β-defensin by the innate immune 
system.223 CRAMP (cathelicidin related antimicrobial peptide) has been 
widely identified as a vitamin D dependent anti-microbial peptide that binds 
bacteria. Cathelicidin rapidly destroys the lipoprotein membranes of 
microbes enveloped in phagosomes after fusion with lysosomes in 
macrophages.224 Gram-positive bacteria, invasive pneumococcal disease, 
meningococcal disease and group A streptococcal disease are more common 
when 25(OH)D3 levels are low.225 In addition to its direct antimicrobial 
capability, in-vitro and in-vivo studies of LL-37 suggest a broad range of 
activities that could modify innate inflammatory processes and adaptive 
immune responses by neutralising lipopolysaccharide (LPS), and acting as a 
chemoattractant for neutrophils, monocytes and T cells through a formyl 
peptide receptor.85,145 
 
Recent observational studies suggest vitamin D deficiency is common in 
critically ill patients, is associated with adverse outcome 226 and pre-hospital 
vitamin D deficiency is a predictor of sepsis and increases the risk of 
mortality following critical care initiation.227 Additionally, vitamin D 
deficiency has been associated with an increased risk of intensive care 
admission and mortality in patients with pneumonia.228 Severe deficiency 
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(<10ng/ml) before hospitalisation has also been shown to be associated with 
increased risk of hospital acquired infections.229 Furthermore 2 recent meta-
analyses support the association of vitamin D deficiency with increased 
susceptibility for severe infection, sepsis and mortality in the critically 
ill.230,231 
Animal studies to date investigating the role of vitamin D deficiency and its 
supplementation in ARDS and sepsis have conflicting results. In a rat model 
of abdominal sepsis pre-treatment with 1,25(OH)2D3 reduced 
thrombocytopenia232 and disseminated intravascular coagulation in a LPS 
model of sepsis.233 1,25(OH)2D3 inhibited neutrophil but not monocyte 
recruitment by 40% in a hamster model of ARDS, thought to be in part due to 
its inhibitory effects on IL-8.175 It also ameliorated lung damage secondary to 
ischaemia reperfusion injury after femoral artery ligation in rats.176 A further 
study has shown reduced interstitial inflammation and collagen deposition 
post radiotherapy in rats administered vitamin D.177 We have shown in a 
murine intra-tracheal LPS model of lung injury that vitamin D deficiency 
leads to exaggerated lung cellular inflammation and epithelial damage 
resulting in reduced oxygenation.198 Conversely, a recent study of LPS 
induced lung injury in vitamin D deficient mice found no difference in the 
degree of lung injury.180 Issues centred on differing aetiologies of lung injury 
as well as methodology of when lung injury is measured or defined may go 
some way to explaining this apparent contradiction.  
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Murine models of lung injury albeit imperfect are invaluable in investigating 
the mechanism of disease and their potential therapies. In conjunction with 
translational studies and human disease models they can form the basis of 
strong evidence to pursue novel therapies and targets. Unfortunately, no 
single murine model of lung injury represents the complex heterogeneous 
pathophysiology of human ARDS.100 An ideal model would feature a triad of 
1] evidence of neutrophilic alveolitis and alveolar inflammatory response; 2] 
deposition of hyaline membranes or evidence of disruption of the 
alveolar/capillary membrane and 3] formation of microthrombi, indicating 
the presence of endothelial injury.234 We aimed to investigate the role of 
vitamin D deficiency on sepsis and sepsis induced lung injury. For this reason 
we chose the caecal ligation and puncture (CLP) model of sepsis. This is 
recognised as a good murine polymicrobial model of human sepsis235 that in 
the acute phase increases epithelial permeability, with increased neutrophil 
accumulation in the interstitum and alveolar spaces.100 Although it does not 
represent all the features of ARDS it provided us with a model to investigate 
the effects of vitamin D deficiency in both conditions at the same time. 
Furthermore, since murine cathelicidin related antimicrobial peptide 
(CRAMP) is homologous to its human counterpart would provide evidence of 
the functional importance of vitamin D deficiency if these CRAMP levels are 
suppressed.  
 
The observational and experimental studies presented suggest that vitamin D 
deficiency is a determinant of sepsis and ARDS. The aim of this study was to 
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establish if vitamin D deficiency influences innate immune responses and 
exaggerates sepsis induced lung injury in a murine model. 
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4.2 MATERIALS AND METHODS 
Detailed methods are provided in section 3.9 
 Ethical statement and study design 
All procedures were performed in accordance with UK laws under the Animal 
[Scientific Procedures] Act 1986 (project licence code 30/2836; personal 
licence number I77F587B4). Local policies and procedures were followed as 
described in section 3.9.1 and study design as per section 3.9.2. The priori 
study design was to assess if inducing vitamin D deficiency exaggerates 
sepsis and sepsis- induced lung injury secondary to CLP.  Pre-defined 
measurements were lung cellular recruitment and protein permeability 
index, bacterial numbers and cytokine measurements. Secondary 
measurements of macrophage phagocytosis and antimicrobial peptide were 
performed to subsequently investigate the mechanism of exaggerated 
inflammation and sepsis.  
 
 Induction of vitamin D deficiency 
Male wild-type mice (WT) C57Bl/6 (aged 3-4 weeks) were obtained from 
Harlan UK Limited, Oxford, UK and maintained at the Biomedical Servicing 
Unit (BMSU), Birmingham University, UK.  Vitamin D deficiency was induced 
in WT pups by feeding them a vitamin D deficient chow (TD 89123, Harlan, 
USA) or sufficient chow for 6 weeks. All animals were housed in cages of 6 in 
a 12-hour light and 12-hour dark cycle with food and water provided ad 
libitum.  
109 
 
 Surgical procedure 
Detailed methods are described in section 3.9.4. In brief, pre medication was 
given in the form of subcutaneous buprenorphine (Temgesic®, Reckitt 
Benckiser, Wallisellen, Switzerland at, Animalcare Ltd, 0.1mg/kg body 
weight) prior to the procedure.  Animals were anaesthetised and maintained 
with isoflurane gas and oxygen. All surgery was performed with aseptic 
techniques. Midline laparotomy was performed followed by exposure of the 
caecum, ligation of the lower 30% and single through-and-through puncture 
of ligated caecum. A small amount of faeces was gently expressed by 
compressing the ligated caecum prior to being placed back into the abdomen 
and wound closed with non-absorbable sutures. All animals were recovered 
in heat boxes and recovery incubators until sacrificed. Postoperative 
resuscitation was with 0.5mls of fluid (Hartman’s solution, Aqupharm 11®) 
and a further dose of buprenorphine. Animals were reassessed 6 hours post-
operatively and given a further 0.5mls of fluid and sacrificed at 16 hours post 
surgery. Sham surgeries were identical except for the lack of ligation and 
puncture of the caecum after exteriorisation from the abdomen and therefore 
deemed sterile.  
 
 Sample collection and processing 
At 16 hours post CLP animals were deeply anaesthetised with 5% isoflurane. 
Cardiac puncture was performed and death confirmed. Immediate post-
mortem peritoneal and bronchoalveolar lavage was performed (as described 
in section 3.9.5) and the retrieved lavage fluid (PLF and BALF) transferred on 
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ice to the laboratory for further processing and analysis as described in 
section 3.9.5. Post mortem examination of the caecum was carried out to 
confirm necrosis and colour of liver recorded to ensure adequate sepsis was 
induced.  
 
 Bacterial culture 
Whole blood, PLF and BALF were diluted accordingly and incubated at 370C 
in pre-prepared agar plates as described in section 3.9.6.  Colony forming 
units (CFU) were counted at 24 hours and CFU/ml calculated from the 
original dilutions and total starting volumes of samples retrieved.  
 
 Cell analysis 
BALF and PLF was analysed for cellular inflammation by differential cell 
count, neutrophil count and the proportion of neutrophil apoptosis by cell 
surface staining and flow cytometry as described in section 3.9.7 
 
 Protein assay 
A simple colorimetric assay (Bio-rad®, Hertfordshire, UK) to measure total 
protein in sera, BALF and PLF was performed as described in section 3.9.9.3. 
Protein permeability index was calculated as a ratio of fluid protein to plasma 
protein. 
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 Cytokine assays 
Inflammatory cytokines were measured by luminex array (R&D systems, 
Abingdon, UK) as per manufacturer’s protocols. BAL RAGE was measured by 
a commercially purchased ELISA (R&D systems, Abingdon, UK). Detailed 
methods are described in section 3.9.9.4. 
 
 Ex-vivo phagocytosis assay 
Detailed methods can be found in section 3.9.8. In brief after undergoing red 
cell lysis extracted peritoneal cells were plated into a microplate and 
pHrodo® labelled Escherichia coliform (E.Coli) bioparticles added and 
incubated for 30 mins at 370C with a 40C negative control. Phagocytosis of the 
particle results in acidic pH change resulting in fluorescence that was 
measured by flow cytometry. 
 
 Cathelicidin related antimicrobial protein (CRAMP) assay 
Total CRAMP levels were measured in sera, BALF and PLF by an indirect 
ELISA as described in section 3.9.9.2. CRAMP levels were corrected to per mg 
of protein and represented as ng/mg.  
 
 Animal numbers 
Animal numbers were minimised by the consistent use of the C57Bl/6 strain, 
age and sex of animals, lung injury interventions to allow comparisons across 
wild type (WT) mice and measurements of multiple outcomes in the same 
animal. Precise power calculations were not available for the 16 hours CLP 
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time point and therefore initial power calculations for 8 animals in each arm 
(control; deficient; sufficient; sham) were based upon preliminary data 
(verbal communication with Professor David Thickett) of increased lung 
permeability index 24 hours after CLP of 0.46mg/ml allowing the detection of 
a change of 0.09 (20%) between vitamin D sufficient and deficient mice. For 
BALF % neutrophils (mean 68% (SD10.1)) treatment effect would be 15.2% 
at a power of 0.8 p=0.05. To account for a failure rate and procedure 
optimisation a total number of 50 mice were accounted for this study.  A 
failure rate of 10% was anticipated and accounted for the severity of the 
model and requirement to cull the animal perioperatively due to animal 
welfare as well as technical failure in retrieving lavage samples. Experiments 
were performed in batches of 4 mice per arm in view of lack of precise power 
calculations to minimise and justify animal use. This was un-blinded. Surgery 
was not repeated if a result was clearly significant or not to minimise animal 
numbers. Results that have n=12 account for n=4 CLP performed for 
phagocytosis experiments which allowed for cumulative analysis of bacterial, 
CRAMP and cell quantification in mice that had already undergone surgery 
maximising experiment sample utilisation. BALF cell analysis was not 
repeated after n=8 as no lung injury was demonstrated in the first 
experiments. Uneven numbers account for a failure in the experiment for 
reasons described above. 
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 Statistical analysis 
Statistical analysis was performed on GraphPad Prism 6.0© software 
(GraphPad Software, La Jolla, California, USA) Normality was assessed with 
the D'Agostino-Pearson omnibus test. Parametric data were analysed using t-
tests. Non-parametric data were analysed using Mann-Whitney tests and 
Kruskal Wallis ANOVA and Dunn’s test for multiple comparisons. A two-
tailed p-value< 0.05 was considered statistically significant.  
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4.3 RESULTS 
 Murine vitamin D status 
Vitamin D deficiency (VDD) was successfully established in mice fed a 
deficient diet compared to a vitamin D sufficient (VDS) diet (Table 4.1). The 
magnitude of deficiency is similar to that previously reported by our group in 
patients with ARDS.198 Deficiency did not result in a significant effect on 
serum calcium but was associated with reduced circulating bioactive 
1,25(OH)2D3 concentration.  
 
 
   VDD (n=8) VDS (n=7) p-value 
25(OH)D3 (nmol/L) 7.9 
(4.5-9.4) 
50.4 
(48.1-51.9) 
0.0003 
1,25(OH)2D3(pg/ml) 13.4 
(7.3-18.9) 
150.5 
(125.0-175.3) 
0.002 
Calcium (mM) 3.4 
(3.1-4.1) 
3.3 
(3.1-3.4) 
0.69 
Table 4.1: Effects of vitamin D deficient diet on circulating vitamin D 
levels. 
Data presented as medians (interquartile range); VDD (vitamin D deficient); 
VDS (vitamin D sufficient); p-value Mann-Whitney test 
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 Bacterial load 
VDD mice had a significantly higher bacterial load compared to VDS in all 
three compartments: PLF, blood, and (BALF) as measured by CFU/mL 16 
hours after CLP. PLF median [IQR] 856 x 10³ [136 x 10³–237 x 107] vs. 27.1 x 
10³ [3.15 x 10³–1.27 x 107], p=0·037; blood median [IQR] 132 x 103 [5.96 x 
10³–758 x 10³] vs. 0·55 x 10³ [0·0–6.67 x 10³], p=0·019 and BALF median 
[IQR] 2·51 x 10³ CFU per mL [0·93 x 10³–19.2 x 10³] vs. 0·48 x 10³ [0·0–1·71 
x 10³], p=0·011 (Figure 4.1). In sham experiments there was an absence of 
bacteria as measured by CFU/ml in all 3 compartments confirming a sterile 
procedure and surgery (data not shown). 
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Figure 4.1: Effect of VDD on bacterial load in PLF, blood and BALF 
Data presented as box and whisker plots with median and Tukey’s 
distribution, logarithmic scale to allow graphical representation. VDD 
(vitamin D deficient) n=12; VDS (vitamin D sufficient) n=11; p-values: Mann 
Whitney tests. 
 
  
 Cathelicidin related antimicrobial peptide (CRAMP) 
The CLP procedure increases CRAMP levels significantly in PLF, serum and 
BALF in VDS mice. However, significantly lower levels were observed in VDD 
mice supporting the observation that VDD mice have reduced anti-microbial 
capacity (Figure 4.2). Levels corrected for protein were higher in vitamin D 
sufficient mice in BALF and serum but this did not reach significance in PLF. 
PLF VDD median [IQR] 26.7ng/mg [22.1 – 36.9] vs. VDS 30.6ng/mg [16.5 – 
48.9], p=0.684; BALF VDD median [IQR] 2.74ng/mg [0 – 11.47] vs. VDS 
12.98ng/mg [7.36 – 20.9], p=0.007; Serum VDD median [IQR] 0.01ng/mg [0 – 
0.05] vs. VDS 0.17ng/mg [0.03 – 0.47], p=0.02.  
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Figure 4.2: CRAMP (murine cathelicidin) expression in PLF, BALF and 
serum.  
Box and whisker plots with medians and Tukey’s distribution. VDD (vitamin 
D deficient) n=12; VDS (vitamin D sufficient) n=11. Sham n=4 per group. 
CRAMP was undetectable in sham treated sera. 
Sham CLP Sham CLP
0
10
20
30
40
50
60
70
80
90
 P
L
F
 C
R
A
M
P
 n
g
/m
g
VDS
VDD
ns
p=0.01p=0.004
Sham CLP Sham CLP
0
10
20
30
B
A
L
F
 C
R
A
M
P
 n
g
/m
g
·
·
p=0.007
p=0.004ns
Sham CLP Sham CLP
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
S
e
ra
 C
R
A
M
P
 n
g
/m
g
p=0.02
p=0.01ns
118 
 
 Alveolar cellular inflammation 
Little-to-no cellular recruitment into the alveolar compartment was observed 
at this time point (Figure 4.3A-C) however, there was evidence of a mild 
increase in BALF protein permeability index (PPI), suggesting early alveolar 
epithelial leak. This was significantly higher in VDD mice as compared to VDS 
mice (median [IQR] 3.30 [2.69-4.64] vs. 2.09 [1.82-2.90], p=0.014) (figure 
4.3D). 
 
CLP increased the number of alveolar macrophages in proportion to other 
cells but there was no difference between VDD and VDS groups. Neutrophil 
cellular recruitment in the BALF was low and therefore quantification of 
apoptosis and necrosis of neutrophils was not possible.   
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A                        B  
                     C                      D        
Figure 4.3: BALF cellular recruitment and protein permeability index at 16 hours post CLP 
Box and whisker plots with median and Tukey’s distribution. Kruskal-Wallis ANOVA and Dunn’s multiple comparison test. A] Total 
cell count, p=0.57; B] neutrophil count, p= 0.33 and C] alveolar macrophage count, p=0.001. D] BALF protein permeability index 
(PPI). VDD (vitamin D deficient) n=8; VDS (vitamin D sufficient) n=7; UTC (untreated WT control) n= 10 in each group. *p<0.05; 
**p<0.005 compared to UTC
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 Peritoneal cellular inflammation 
Post CLP there was significant cellular recruitment in PLF (Figure 4.4A). As 
major players of the acute inflammatory response, neutrophils and F4/80+ 
macrophages were enumerated within the peritoneal cavity. Sham 
experiments did not significantly increase cellular infiltration. Significantly 
more neutrophils (Figure 4.4B) and F4/80+ macrophages (Figure 4.4C) were 
observed in VDD compared to VDS mice post CLP, with the neutrophil to 
macrophage ratio similar between both groups indicating a global increase in 
inflammatory mediators (Figure 4.4D). PLF PPI was also increased in VDD 
mice this did not reach statistical significance (median [IQR] 46.86 [28.17-
58.33] vs. 29.81 [14.81-54.52], p=0.06) that may be suggestive of more 
vascular damage in VDD mice post CLP (Figure 4.4E). However this increase 
in protein in the peritoneal compartment may also be due to the CLP 
procedure itself as our protein assay did not specifically measure a plasma 
protein such as albumin or IgM. 
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Figure 4.4: PLF cellular recruitment and protein permeability 16 hours 
post CLP.  
Box and whisker plots with median and Tukey’s distribution.  Kruskal-Wallis 
ANOVA with Dunn’s multiple comparisons. A] total cell count p<0.0001; B] 
neutrophil count p<0.0001 and C] macrophage count p<0.0001). D] PLF 
neutrophil/macrophage ratio. E] PLF protein permeability index (PPI). VDD 
(vitamin D deficient) n=12; VDS (vitamin D sufficient) n=11; UTC (untreated 
WT control) n=12 
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4.3.5.1 Neutrophil Apoptosis 
There was a significant increase in the number of apoptotic neutrophils in 
VDD compared to VDS peritoneal lavage fluid (median [IQR] 1.87 x 105 [0.89 
– 4.19 x 105] vs. 0.51 x 105 [0.20 – 0.54 x 105], p=0.007) (Figure 4.5), 
suggesting dysregulated neutrophil apoptosis and clearance of dying cells.   
 
 
 
 
 
 
 
 
Figure 4.5: Peritoneal lavage fluid (PLF) neutrophil apoptosis.  
Box and whisker plot with median and Tukey’s distribution, VDD (vitamin D 
deficient) n=12; VDS (vitamin D sufficient) n=11. p-value; Mann Whitney test. 
 
  
 
 
VDD VDS
0
2×105
4×105
6×105
8×105
1×106
P
L
F
 N
e
u
tr
o
p
h
il 
A
p
o
p
to
ti
c
 C
e
ll 
N
u
m
b
e
r
p=0.007
123 
 
 Macrophage phagocytosis 
To determine whether the increased bacteraemia and/or accumulation of 
apoptotic neutrophils observed in VDD mice was due to impaired clearance 
by peritoneal macrophages, we assessed bacterial phagocytosis following 
CLP. Ex vivo phagocytosis of pHrodo labelled Escherichia coliform bacteria 
(E.Coli.) was significantly reduced in F4/80+ macrophages isolated from PLF 
of VDD compared to VDS mice following CLP (median [IQR] 6.89% [3.12 – 
9.87] vs. 21.12% [17.56 – 24.29], p=0.029) (Figure 4.6). 
 
 
Figure 4.6: Peritoneal lavage fluid (PLF) phagocytosis of pHrodo® 
labelled E.Coli bacteria.  
Box and whisker plot with median and Tukey’s distribution. VDD (vitamin D 
deficient) n=4; VDS (vitamin D sufficient) n=4. p-value: Mann Whitney test.  
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 Biomarkers of inflammation 
There was no difference seen in inflammatory cytokines in PLF (Table 4.2), 
BALF (Table 4.3) or sera (Table 4.4) between VDD and VDS groups. BAL 
soluble receptor for advanced glycation products (sRAGE) concentrations 
were not significantly raised compared to untreated controls (UTC median 
[IQR] 1854pg/ml [1365 – 2219] vs. VDD median [IQR] 686.3pg/ml [245.8 – 
952] vs. VDS median [IQR] 1301pg/ml [662.8 – 3066], p=0.09). 
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 VDD (n=8) VDS (n=7) p-value 
IL-6 
(pg/ml) 
4054 
(1872 – 8000) 
4181 
(521.5 – 7107) 
0.61 
KC/CXCL-1 
(pg/ml) 
1056 
(597.8 – 1793) 
1603 
(81.8 – 4146) 
0.90 
TNF-
(pg/ml) 
16.2 
(4.64 – 55.7) 
6.61 
(2.12 – 9.82) 
0.29 
IL1 
(pg/ml) 
181.4 
(86.8 – 309.7) 
74.4 
52.6 – 150) 
0.12 
VEGF 
(pg/ml) 
120.1 
(58.5 – 149.5) 
107.1 
(59.3 – 139.7) 
0.60 
Table 4.2: PLF biomarkers of inflammation 
Data presented as median (interquartile range), Mann-Whitney U tests. 
 
 VDD (n=8) VDS (n=7) p-value 
IL-6 
(pg/ml) 
12.9 
(5.7 – 14.0)  
19.1 
(5.8 – 23.4) 
0.52 
KC/CXCL-1 
(pg/ml) 
52.1 
(15.15 – 142) 
155.0 
(62.3 – 256.6) 
0.23 
TNF-
(pg/ml) 
2.34 
(0.74 – 3.28) 
1.25 
(0.81 – 4.20) 
0.75 
MIP-2 
(pg/ml) 
6.95 
(0 – 17.9) 
15.1 
(2.33 – 40.2) 
0.41 
VEGF 
(pg/ml) 
167.6 
(115.1 – 201.7) 
185 
(102.0 – 227.4) 
0.91 
GM-CSF 
(pg/ml) 
1.19 
(1.02 – 1.27) 
1.11 
(1.02 – 227.4) 
0.54 
Table 4.3: BALF biomarkers of inflammation 
Data presented as median (interquartile range), Mann-Whitney U tests. 
 
 VDD (n=8) VDS (n=7) p-value 
IL-6 
(pg/ml) 
1561 
(212.8 – 9894) 
3284 
(1171 – 21,089) 
0.39 
KC/CXCL-1 
(pg/ml) 
12,476 
(2322 – 45,200) 
13,164 
(10,457 – 45,200) 
0.86 
TNF-
(pg/ml) 
17.1 
(7.18 – 53.9) 
19.2 
(9.32 – 52.5) 
0.44 
MIP-2 
(pg/ml) 
13.7 
(10.9 – 16.2) 
14.1 
(13.6 – 16.2) 
0.84 
VEGF 
(pg/ml) 
700 
(162.1 – 2322) 
2291 
(530 – 4244) 
0.33 
 
GM-CSF 
(pg/ml) 
3.94 
(2.80 – 18.4) 
4.92 
(4.08 – 7.52) 
0.44 
Table 4.4: Serum biomarkers of inflammation 
Data presented as median (interquartile range), Mann-Whitney U tests. 
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4.4 DISCUSSION 
In this study we sought to establish whether inducing vitamin D deficiency by 
diet prior to injury in mice leads to exaggerated sepsis, lung injury and 
enhanced cellular inflammation/dysfunction. In the clinically relevant CLP 
model of early sepsis, VDD was associated with exaggerated bacterial growth 
in the peritoneal cavity, elevated systemic bacteraemia as well as increased 
bacterial translocation to the alveolar compartment. This was associated 
with abnormal protein permeability of the peritoneal and alveolar capillary 
barrier.  In the PLF, there was exaggerated cellular inflammation in VDD mice 
with evidence of impaired antibacterial responses in terms of CRAMP release 
and the ability of peritoneal macrophages phagocytosis of E.coli. These 
cellular changes resulted in increased accumulation of apoptotic neutrophils 
in the PLF. These data support our hypothesis that VDD is mechanistically 
important in driving sepsis. 
 
We successfully established severe deficiency in the mice, with levels of 
25(OH) D3 similar to those who have ARDS.198  This deficiency was reflected 
also in reduced circulating 1,25(OH)2D3, the bioactive form of vitamin D.  
 
Previous animal studies have utilised different experimental models of lung 
injury to investigate the role of vitamin D replacement with varying 
results.175,176 However, there is only one study to our knowledge that has 
shown a benefit of 1,25(OH)2D3 treatment on sepsis induced coagulopathy in 
a CLP model in rats.232 Our group has recently shown a detrimental effect of 
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vitamin D deficiency with exaggerated lung injury and reduced oxygenation 
in a intra-tracheal LPS direct murine lung injury model.198   
 
Vitamin D is known to be a stimulator of antimicrobial peptides143 with 
human LL-37 (cathelicidin) and defensin-2 expression dependent on 
circulating levels of 25(OH)D3.144 This study confirms that deficiency in 
vitamin D results in lower systemic and local circulating levels of CRAMP in 
the lung and blood. This confirms the findings of Jeng et al. of lower levels of 
LL-37 in vitamin D deficient patients on the intensive care unit with sepsis.236 
This has been recently confirmed in a further prospective study of critically 
ill patients in which lower 25(OH)D3 levels were associated with decreased 
cathelicidin peptide and 90-day mortality.237 In our study this difference was 
not as pronounced in the PLF and may be accounted for by overwhelming 
bacteraemia in the peritoneum. However an increased concentration of 
CRAMP may be one explanation for overall reduced bacteria in VDS mice.  
 
Vitamin D3 has been shown to have the ability to stimulate the differentiation 
of premature monocytes to mature phagocytic macrophages.150 Macrophages 
are the ‘first responder’ cells of the innate immune system and are recruited 
to the site of infection forming the first line of defence towards pathogens. 
Vitamin D deficiency is known to rescue the phagocytic potential of 
macrophages to mycobacteria238. We have shown that macrophage 
phagocytosis of labelled E.Coli is reduced in vitamin D deficient mice post 
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CLP. This may be a second reason to account for the increased bacterial 
numbers seen in the deficient mice.  
 
Protein permeability index was increased in the lung 16 hours post CLP in 
VDD mice suggesting a breakdown in epithelial-endothelial integrity and 
protein leak that is consistent with the onset of early lung injury. However 
unfortunately at 16 hours post injury there was no evidence of neutrophil 
alveolitis, a hallmark of ARDS. There was also no rise in BALF sRAGE, a 
marker of Type 1 epithelial cell damage compared to untreated control mice. 
Taken together it can be concluded that 16 hours post CLP does not replicate 
all the features of human ARDS and is not an ideal model to study the disease.  
 
Although BALF cellular recruitment did not occur at this time-point there 
was a significant influx of cells to the peritoneum. Despite a larger number of 
macrophages and neutrophils recruited to the PLF in VDD mice, the overall 
neutrophil to macrophage ratio remained the same between both groups. 
Interestingly the number of apoptotic neutrophils in the VDD PLF was 
significantly higher, suggesting dysregulated neutrophil apoptosis or delayed 
clearance. Both of which could be important mechanistically in both ARDS 
and sepsis. The resolution of inflammation is dependent on the action of 
macrophages to ingest apoptotic neutrophils, a process termed efferocytosis, 
and prevent the release of their pro-inflammatory intra-cellular contents 
during secondary necrosis.95 Furthermore, uptake of apoptotic cells is part of 
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an anti-inflammatory process96 and there is evidence that a defect in the 
process of efferocytosis is a cause of on-going inflammation in ARDS 97-99. 
Vitamin D3 is believed to be anti-inflammatory and 1,25(OH)2D3 has been 
shown to reduce the production of inflammatory cytokines and chemokines 
(IL-8 and CXCL-10) from stimulated epithelial cells by modulating NF-kb 
signalling.155,156 We did not find a difference in the inflammatory cytokine 
milieu between vitamin D sufficiency and deficiency in this study. This could 
be partly explained by low n numbers. 
 
Recent studies have shown an association between vitamin D deficiency and 
incidence of sepsis230,231 with a suggestion that vitamin D deficiency may be a 
predictor of sepsis and increases mortality.227 Bacteraemic sepsis is more 
common in winter months when vitamin D levels are lowest.222 Sepsis 
remains the most common cause of indirect ARDS and vitamin D deficiency is 
common in the critically ill.226 To date, human studies have indicated an 
association however direct causality is yet to be proven, as vitamin D levels 
may also be influenced by being critically ill and may itself, be a marker of 
severity of illness.  This study confirms that vitamin D deficiency is a 
predeterminant of sepsis and mechanistically provides evidence that the 
deficiency is of functional importance. 
 
The major limitation of this study was the CLP time point. In the UK, the 
regulatory framework for animal experiments dictated that we could not 
keep VDD animals alive post-CLP for more than 16 hours due to serious 
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adverse events (increased severity of illness and mortality seen at 24 hours 
in VDD mice in our preliminary experiments) so we were only able to model 
early sepsis using this technique and unable to assess if the effects seen could 
be abrogated by vitamin D3 replacement therapy. However, a limitation of 
this study is the absence of pre-treatment, restoration of vitamin D 
sufficiency.  Ideally, lung histology would have been extremely informative to 
assess interstitial neutrophil accumulation, alveolar epithelium and space.  
However this facility and expertise was not available.  Finally the protein 
assay performed was not specific to a large plasma protein and measured 
total protein and therefore not specific for vascular leak and may in the 
peritoneum be confounded by the puncturing of the bowel in the CLP 
procedure that could be improved by measuring lavage albumin or IgM. 
 
In conclusion, this study confirms that pre-existing vitamin D deficiency may 
be a modifiable risk factor of sepsis and identifies increased antimicrobial 
peptide, decreased macrophage phagocytosis of bacteria, dysregulated 
apoptosis and or clearance and decreased barrier integrity as potential 
cellular mechanisms that may account for the associations seen in clinical 
studies.   
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CHAPTER 5                                                                          
THE VITAMIN D TO PREVENT ACUTE LUNG INJURY 
FOLLOWING OESOPHAGECTOMY TRIAL 
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5.1 INTRODUCTION 
The acute respiratory distress syndrome (ARDS) remains an important cause 
of morbidity and mortality in the critically ill patient.2,3 Preclinical trials of 
pharmacological therapies have shown promise but failed to demonstrate 
clinical efficacy in treating established ARDS.6,48 Early recognition of patients 
at risk of and preventing ARDS has become a focus of research in recent 
years,239,240 with the development of prediction scores43,241 prevention 
trials44,51 and a growing evidence of other potential biological therapies to 
prevent ARDS.240  
 
ARDS is common after oesophagectomy,105 which is used to treat 
oesophageal cancer.  Access to the oesophagus during surgery is attained by 
deflation of one lung and maintenance of one-lung ventilation (OLV). This 
exposes the ventilated lung to oxidative stress and high inflation pressures 
risking the development of ventilator-induced lung injury (VILI).115 
Ventilation with higher tidal volumes and peak pressures not only cause the 
alveoli to overstretch in a process called volutrauma but also cause 
biotrauma leading to recruitment of neutrophils and local production and 
release of inflammatory mediators,242 which can spill over into the systemic 
circulation.243,244 In the perioperative setting, mechanical ventilation itself 
can induce an inflammatory response245 which can compound the local and 
systemic response induced by major surgery and contribute to the 
inflammatory cascade that leads to the development of lung injury and 
systemic organ failure.246 High inspired oxygen leads to increased reactive 
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oxygen species (ROS) production247 which causes alveolar cellular 
dysfunction and damage.248,249 There is also evidence to suggest a synergistic 
effect of hyperoxia and high tidal volume ventilation with increased alveolar-
capillary permeability, neutrophil accumulation and pro-inflammatory 
mediator release.250,251 Concurrently the deflated lung is exposed to a period 
of ischaemia followed by reperfusion which causes endothelial damage, 
release of ROS and inflammatory mediators252 and is associated with 
postoperative ARDS.115 Furthermore, evidence suggests that the 
pathophysiological changes of lung injury post oesophagectomy are similar 
to that of ARDS caused by other precipitants115 – with increased pulmonary 
capillary permeability112, neutrophilic alveolitis,116,253 and release of 
plasma254 and pulmonary110 pro-inflammatory cytokines.  To this effect, the 
model has already been utilised in a clinical trial to assess the effect of 
salmeterol on preventing lung injury post oesophagectomy.51  
 
Studies report a high prevalence of vitamin D deficiency in the critically ill134 
with an association with increased rates of infection,227,229 acute respiratory 
failure,197 acute kidney failure255 and mortality.226 Vitamin D is an activator of 
immune responses that may play a role in the pathogenesis of ARDS.85 In 
humans, 25-hydroxyvitamin D3 (25(OH)D3) bound to its binding protein 
(DBP) is the most abundant circulating metabolite which requires 
hydroxylation to the active 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] by the 
mitochondrial enzyme 25(OH)D-1-alpha (CYP27B1).118  Its target, the 
vitamin D receptor (VDR) as well as CYP27B1 are now known to be 
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expressed by cells of the innate and adaptive immune system as well as by 
respiratory epithelial cells.174 We have recently shown that patients with 
ARDS post-oesophagectomy have lower levels of 25(OH)D3 (ARDS 16.97 
nmol/L vs no ARDS 25.46 nmol/L, p=0.014) and severe deficiency of less 
than 20nmol/L was associated with an increased risk of ARDS (OR=4.2 (95% 
CI 1.13 to 15.9; p=0.032) after adjustment for gender, age, diagnosis, staging 
data, and smoking pack-years.198  Severe deficiency was also associated with 
increased markers of alveolar epithelial damage.  There are currently no 
human studies investigating the role of vitamin D replacement to treat or 
prevent ARDS.   
 
The primary aim of this study was to determine if pre-treatment with a single 
high dose of vitamin D is safe and effective and investigate its effects on 
biomarkers of early acute lung injury and other clinical outcomes post 
oesophagectomy, in a group of patients at high risk of developing the 
condition.  
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5.2 MATERIALS AND METHODS 
5.2.1 Trial Conduct 
The vitamin D treatment to prevent lung injury post-oesophagectomy 
(VINDALOO) trial was a randomised double blind, placebo-controlled trial. 
Patients were recruited from October 3, 2012 until January 26, 2015 at three 
large tertiary hospitals in the United Kingdom. National research ethics was 
approved by South Birmingham Research Ethics Committee (REC 
12/WM/0092). The trial is registered on the International Standard 
Randomised Controlled Trial Registry (ISRCTN27673620) and European 
Union database of randomised Controlled Trials (2012-000332-25). The 
study was conducted in accordance with the trial protocol which has 
previously been published116 (Appendix). 
 
5.2.2 Patient recruitment 
Patients were identified through the upper gastrointestinal multi-disciplinary 
meetings and pre-operative clinics. Patients were eligible if they were 
undergoing a planned thoracic oesophagectomy and aged 18 or older if male, 
aged 55 or more than 2 years since menopause if female and were able and 
willing to give written informed consent.  Patients with a known intolerance 
of vitamin D, sarcoidosis, tuberculosis, lymphoma, hyperparathyroidism, or 
nephrolithiasis, known serum corrected calcium >2.65 mmol/L,  undergoing 
haemodialysis, or had a known diagnosis of chronic obstructive pulmonary 
disease (COPD) with an FEV1 less than 50% predicted or resting oxygen 
saturations of less 92% were ineligible.  Patients taking the following 
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concomitant medication were also excluded – more than 1,000IU 
(25mcg)/day vitamin D supplementation a month preceding or more than 
10mcg/day in the 2 months preceding enrolment; cardiac glycoside, 
carbamazepine, phenobarbital, phenytoin, primidone, or long-term 
immunosuppressant therapy; thiazide diuretic at a dose higher than 
recommended in the British National Formulary. If agreeable, written 
informed consent was gained following a face to face discussion.  
 
5.2.3 Randomisation and blinding 
Drug (oral cholecalciferol oily solution Vigantol, 300,000 IU [7.5mg]) and 
matching placebo (Miglyol 812 oil, the vehicle for cholecalciferol in Vigantol) 
were supplied and packaged by Novalabs (Leicester, UK). The trial drug 
manufacturer produced the randomisation sequence using a block size of 10 
with equal allocation between active and placebo groups. Drug boxes were 
supplied to centres in blocks of 10 thus ensuring an equal allocation between 
active and placebo groups. Treatment packs were held by the pharmacy at 
each centre and patients randomised sequentially by allocating them to the 
next numbered treatment pack held at the centre. Patients, clinical and 
research staff were unaware of which arm of the study a patient was 
allocated. Active and placebo treatment packs and their contents were 
identical in appearance. The protocol allowed for emergency un-blinding in 
the event of significant concerns about patient safety.  
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Subjects could withdraw from the trial or the trial treatment at any time 
without prejudice. If a subject withdrew from the trial treatment, then they 
were followed-up wherever possible and data collected as per protocol until 
the end of the trial. The only exception to this was where the subject also 
explicitly withdrew consent for follow-up.  
 
5.2.4 Drug administration 
Subjects received either 300,000 IU [7.5mg] of oral cholecalciferol (vitamin 
D3) or placebo 3-18 days prior to planned oesophagectomy.  The trial drug 
was administered and observed being taken by subjects by a qualified 
member of the trial team.  
 
5.2.5 Primary Outcome 
The primary outcome was change in extravascular lung water index (EVLWI) 
measured by PiCCO® thermodilution catheter at the end of surgery 
(measured within one hour post-operatively).  Full details are given in 
sections 3.2 and 3.3. The changes in lung compliance that are a cardinal 
feature of ARDS occur as a result of accumulation of EVLW. The PiCCO® 
EVLWI is an indirect measure of fluid in the interstitium and alveolar space87 
and has been shown to be an independent risk factor for mortality in 
ARDS,210,256 and used as an outcome measure in other clinical trials in 
ALI51,61,114 as well as post-thoracotomy.257   
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5.2.6 Secondary outcomes 
The trial secondary outcomes were clinical markers indicative of lung injury: 
PaO2:FiO2 ratio, development of ARDS during the first 28 days, ventilator and 
organ failure free days, survival (28 and 90 day), safety and tolerability of 
vitamin D supplementation and plasma vitamin D status (25(OH)D3, 
1,25(OH)2D3, vitamin D binding protein (DBP) levels). Further PiCCO® 
parameters of pulmonary vascular permeability index (PVPI) post-
operatively as well as EVLWI and PVPI at day 1 post-operatively (measured 
at 9am on Day 1) were collected. PVPI was a measurement not stated a priori 
in the published trial protocol prior to commencing the study. However 
PiCCO® readings determine a value for PVPI at the same time as EVLWI and it 
was felt that this would be an important outcome to capture relevant to lung 
injury that can differentiate non-hydrostatic pulmonary oedema.209,211 
 
Since commencing recruitment the new Berlin criteria for the diagnosis of 
ARDS have been defined11 and this was used to identify post-operative ARDS 
as 1) presence of bilateral opacities—not fully explained by effusions, 
lobar/lung collapse, or nodules, 2) respiratory failure not fully explained by 
cardiac failure or fluid overload 3) PaO2/FiO2 ratio < 300mmHg (40kPa) Hg 
and ventilation with positive end-expiratory pressure (PEEP) or CPAP > 5 cm 
H2O (may be non-invasive ventilation).  Ventilator free days were defined in 
accordance with the ARDSnet criteria as the number of calendar days after 
initiating unassisted breathing to day 28 after randomisation.258 Organ 
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failure free days are defined in a similar manner to ventilator free days with 
an organ failure free day being a day without evidence of non-respiratory 
organ failure.  Organ failure was defined as a sequential organ failure 
assessment (SOFA) score of greater than 3.259 Hospital mortality was 
assessed as the number of patient deaths at 30 and 90 days. Furthermore an 
exploratory study of plasma indices of endothelial and alveolar epithelial 
injury and plasma inflammatory response were measured by ELISA.  
 
5.2.7 Perioperative Care and PiCCO® measurements 
Patients were managed according to routine anaesthetic and surgical practice 
of the medical teams involved. A conservative fluid strategy was adopted. A 
PiCCO® catheter was inserted into the right femoral artery in the anaesthetic 
room prior to surgery commencing and the first readings (preoperative) 
taken prior to knife-to skin. Post-operative readings were taken after skin 
closure within 1 hour post-operatively and postoperative day 1.  Full details 
are provided in section 3.2 and 3.3.  
 
5.2.8 Data collection 
Demographic and background data were collected from electronic and paper 
patient medical records and by direct patient consultation. Operative data 
was collected by direct observation and from the anaesthetic charts.  Post-
operative data were collected from critical care charts, electronic and paper 
medical records.  All the data was recorded in each subjects case report form 
(CRF).  Physiological parameters were recorded daily for the first 7 days. All 
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post-operative physiological parameters were recorded as those taken at 
8am on the morning of the day concerned. Chest radiographs were reviewed 
for radiological evidence of ARDS where the PaO2/FiO2 ratio was less than 
300mmHg and there was absence of cardiac failure prior to un-blinding.  
 
5.2.9 Sample collection and processing 
Blood was drawn pre-trial drug administration, immediately pre- and post-
operatively, on the morning of day 1 and day 3 or 4.  These were immediately 
transferred to the laboratory and processed as described in section 3.4.1 and 
3.5.1. 
 
5.2.10 Vitamin D status 
25(OH)D3 was measured by tandem mass spectrometry using the 
appropriate vitamin D External Quality Assessment Scheme (DEQAS) control 
as described in section 3.8.1. 25(OH)D3 levels below 50nmol/l (20 ng/ml) 
were regarded as deficient. 25(OH)D3 levels between 50 and 75nmol/l (30 
ng/ml) were regarded as insufficient, with levels above 75nmol/l (30ng/ml) 
designated sufficient levels.260 1,25(OH)2D3 levels were measured by enzyme 
immunoassay (EIA) (immunodiagnostic systems Ltd, UK) as described in 
section 3.8.1 and DBP was measured by ELISA (immundiagnostik, Germany).   
 
5.2.11 Biological indices of lung injury and systemic inflammation 
Plasma inflammatory cytokines (IL-6, IL-8, TNFIL1 and IL-10) were 
measured by Magnetic Luminex® Performance Assays (R&D Systems, UK). 
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Soluble receptors for advanced glycation products (sRAGE), TNF-1 ad TNF-2 
were measured by MILLIPLEX® MAP assays (Millipore, USA). Detailed 
methods described in section 3.8.3. 
 
5.2.12 Statistical analysis 
There are no direct data to predict the effect size of vitamin D replacement 
upon EVLWI. In our groups preliminary data our patients undergoing 
oesophagectomy had a mean post-operative EVLWI of 10.1 ml/kg and 
standard deviation of 2.9 ml/kg.   For the study to be able to detect an 
increase of 20% EVLWI from pre-post-operative with a power of 80% at a 
significance level of 0.05 we required 34 patients in each arm to reach the 
primary endpoint.  An additional six patients were recruited to each arm to 
allow for dropouts such as open/close cases, unexpected deaths, and other 
difficulties with data collection. Thus we intended to recruit 40 patients to 
each arm of the study. 
 
Data were analysed using graphpad PRISM 6© software.  Normality was 
tested using the D’Agostino-pearson omnibus test. Differences between 
continuously distributed data, was tested using unpaired t-tests or Mann-
Whitney tests for non-parametric equivalents. Paired samples were tested 
using paired t-test or the Wilcoxon ranked sign test. Chi-squared tests (or 
Fisher’s Exact tests) were used for categorical variables. Two-tailed p-values 
of 0.05 were considered as significant. Results from normally distributed 
data are shown as mean ± standard deviation and presented as bar charts or 
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dot-plots. Non-parametric results are presented as median with interquartile 
range (IQR) and box and whisker plots with Tukey’s distribution.  
Transformation of non-parametric data was not deemed appropriate due to 
the outliers and clear non-normality of the variables from normality testing.  
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5.3 RESULTS 
5.3.1 Patient recruitment and characteristics 
A total of 79 patients were enrolled in the study by January 26, 2015.  Follow-
up of outcomes, collation of endpoints and chest radiographs continued until 
June 2015. A total of 39 patients were assigned to the placebo arm and 40 to 
vitamin D. Participants CONSORT flow diagram is shown in Figure 5.1. All 
patients received their intended randomised trial treatment. One patient 
(2.6%) in the placebo arm withdrew prior to surgery and 2 (5%) in the 
vitamin D arm did not proceed to surgery post-randomisation due to medical 
reasons (one developed unrelated ischaemic leg and the other was deemed 
unfit for surgery post adjuvant chemotherapy). Thirty-five patients in the 
placebo arm and 33 in the vitamin D arm went on to complete 
oesophagectomy. One patient (2.6%) in the placebo arm and 3 (7.9%) in the 
vitamin D arm had inoperable malignancy. Two patients (5.3%) in the 
placebo arm and 1 (2.6%) in the vitamin D arm were converted to 
gastrectomy intra-operatively with 1 further patient (2.6%) in the vitamin D 
arm in whom we were unable to place a PiCCO2® catheter due to anatomical 
reasons. These patients were withdrawn from the study as they did not 
receive OLV and meet primary endpoint (EVLWI reading at the end of 
surgery). However since they received treatment they were included in the 
analysis of efficacy and safety of high-dose vitamin D replacement. 
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Figure 5.1: Patient CONSORT flow diagram. 
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Patient baseline characteristics were well matched for age, sex, smoking 
status and lung function (Table 5.1).  All procedures were performed for 
malignancy and the predominant cell type of adenocarcinoma. There was no 
significant difference between placebo and vitamin D arms in baseline pre-
drug 25(OH)D3 (mean (SD) 48.8(22.8) vs. 46.8(26.3)nmol/L, p=0.44) and 
1,25(OH)2D3 (mean (SD) 98.1(37.2) vs 82.8(34.3)pmol/L, p=0.08) 
concentrations. 
 
In those that completed surgery, groups were also well matched for operative 
and anaesthetic management as detailed in Table 5.2.  Duration of surgery 
and OLV, maximum tidal volumes, peak airway pressure and cumulative fluid 
balance were  similar between arms.   
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  Placebo (n=39) Vitamin D3 (n=40) 
Age, years Mean (SD) 65.3 (8.7) 63.1 (10.0) 
Sex Male – n (%) 31 (79.5) 36 (90.0) 
Ethnicity Caucasian – n (%) 36 (92.3) 40 (100.0) 
BMI, kg/m2 Mean (SD) 26.6 (4.5) 28.4 (5.6) 
Smoker 
Pack years 
 
 
 
 
Median (IQR) 
Never – n (%) 
Former – n (%) 
Current – n (%) 
Unknown – n (%) 
 
20 (0-40) 
10 (25.6) 
24 (61.5) 
4 (10.3) 
1 (2.6) 
 
15 (0-36.2) 
11 (27.5) 
20 (50.0) 
8 (20.0) 
1 (2.5) 
Diagnosis Adenocarcinoma – n 
(%) 
Squamous cell – n 
(%) 
32 (82.1) 
7 (17.9) 
35 (87.5) 
5 (12.5) 
TMN staging 
tumour 
n – (%) 
1 
2 
3 
4 
 
2 (5.1) 
2 (5.1) 
34 (87.2) 
1 (2.6) 
 
7 (17.5) 
4 (10.0) 
27 (67.5) 
2 (5.0) 
TMN staging nodes n – (%) 
0 
1 
2 
3 
 
17 (43.6) 
19 (48.7) 
1 (2.6) 
2 (5.1) 
 
13 (32.5) 
24 (60.0) 
3 (7.5) 
0 (0) 
Preoperative 
chemotherapy 
n – (%) 33 (84.6) 32 (80.0) 
Lung function 
FEV1, L/s 
FVC, L 
 
Mean (SD) 
Mean (SD) 
 
2.9 (0.6) 
4.3 (0.8) 
 
3.2 (0.7) 
4.5 (0.8) 
Table 5.1: Patient baseline characteristics.  
SD, standard deviation; IQR, interquartile range 
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  Placebo (n=35) Vitamin D3 (n=33) 
Tumour location 
 
 
n – (%) 
Mid oesophagus 
Oesophageal/gastric 
junction 
 
3 (8.6) 
32 (91.4) 
 
 
6 (18.2) 
27 (81.8) 
 
Surgical approach n – (%) 
Open 
MIO 
 
22 (62.9) 
13 (37.1) 
 
22 (66.7) 
11 (33.3) 
ASA grade n – (%) 
I 
II 
III 
IV 
 
1 (2.9) 
29 (82.8) 
4 (11.4) 
1 (2.9) 
 
1 (3.0) 
22 (66.7) 
10 (30.3) 
0 (0) 
Duration of one-
lung ventilation, 
minutes 
Median (IQR) 151.0 (124.5 – 
196.3) 
150.0 (130.0 – 
183.8) 
Duration of 
surgery, minutes 
Mean (SD) 357.4 (69.7) 386.5 (67.2) 
Cumulative fluid 
balance at end of 
surgery, Litres 
Median (IQR) 2.7 (2 – 3.7) 
 
3.3 (2.5 – 4.3) 
Maximum FiO2 Median (IQR) 0.85 (0.68 – 0.9) 0.80 (0.65 – 0.9) 
Maximum tidal 
volume, ml/kg 
predicted body 
weight 
Mean (SD) 7.4 (1.5) 7.8 (1.3) 
PEEP, cm H2O Mean (SD) 5.29 (2.6) 5.17 (2.2) 
Peak airway 
pressure, cm H2O 
Mean (SD) 26.2 (4.3) 26.8 (5.5) 
 
Table 5.2: Anaesthetic and operative characteristics.   
SD, standard deviation; IQR, interquartile range; MIO, minimally invasive 
oesophagectomy; FiO2, fraction of inspired oxygen; PEEP, positive end-
expiratory pressure.  
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5.3.2 Primary Outcome 
There was a significant rise in pre-operative to post-operative absolute 
EVLWI in the placebo group (from median 6.3 [5.3 – 7.7] to 7.1 [6.0 – 
9.5]ml/kg, p=0.0002; Wilcoxon signed rank test) compared to the vitamin D 
treated group (from median 6.2 [5.3 – 7.5] to 6.8 [5.8 – 7.6]ml/kg, p=0.12; 
Wilcoxon signed rank test) in which a significant rise was not seen (Figure 
5.2).  There was no difference in absolute EVLWI values between placebo and 
vitamin D arms at preoperative, postoperative or postoperative day 1 time 
points (Table 5.3).  
 
Figure 5.2: Box and whisker plot of absolute extravascular lung water 
index (EVLWI) values pre to postoperatively.  
Placebo n=35, vitamin D3 n=33. Data presented as medians with Tukey’s 
distribution. Circles and triangles represent outlying values. P-values 
represent Wilcoxon matched-pairs signed rank test. 
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EVLWI (ml/kg) 
median (IQR) 
Placebo 
n=35 
Vitamin D3 
n=33 
p-value 
Preoperative 6.3 (5.3- 7.7) 6.2 (5.3 -7.7) 0.819 
Postoperative 7.1 (6.0 – 9.5) 6.9 (5.8 – 7.7) 0.269 
Day 1 5.9 (5.0 – 7.7) 5.7 (4.9 – 7.6) 0.596 
Table 5.3: Absolute extravascular lung water index (EVLWI) values 
between treatment arms.  
Placebo n=35 and vitamin D3 n=33 at preoperative and postoperative points; 
placebo n=32 and vitamin D3 n=31 at day 1 time point due to loss of PiCCO 
catheter. IQR – interquartile range; p-value represents Man-Whitney test.  
 
 
Our primary endpoint was EVLWI at the end of the operation. However, to 
account for the varying baseline preoperative EVLWI values between 
patients the absolute and fold changes in EVLWI were analysed. . Vitamin D3 
treatment attenuated the increase from baseline in EVLWI seen after surgery, 
however this effect is not seen at day 1 postoperatively (Figure 5.3); Absolute 
change in EVLWI median 1.0 [IQR 0.4 -1.8] vs. 0.4 [IQR -0.4 – 1.2] ml/kg, 
p=0.05 in placebo compared to treatment groups preoperatively to 
postoperatively and -0.3 [IQR -1.7 – 0.6] vs. -0.4 [IQR -1.8 – 0.7] ml/kg, p=0.78 
preoperatively to day 1.  
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Figure 5.3: Dot-plot showing fold change in extravascular lung water 
index (EVLWI) between treatment arms. 
Fold changes shown from pre to postoperative and preoperative to day 1. 
Black lines and square dots for placebo (n=35); blue lines and triangle dots 
for vitamin D3 treatment (n=33); data presented as medians and interquartile 
ranges; p-values represent Mann Whitney tests.    
 
 
     
 
5.3.3 Secondary Outcomes 
5.3.3.1 Pulmonary vascular permeability index (PVPI) 
The rise seen in PVPI was significantly higher pre to postoperative in patients 
who received placebo (median 1.5 [IQR 1.3 – 1.7] to 2.0 [IQR 1.6 – 2.1], 
p=0.0002, Wilcoxon ranked sign test) compared to vitamin D3 (median 1.7 
[IQR 1.4 – 2.0] to 1.8 [IQR 1.6 – 2.1], p=0.36, Wilcoxon ranked sign 
test)(Figure 5.4). There was no difference seen in absolute values of PVPI 
preoperatively, postoperatively and at day 1 between the two treatment 
arms (Table 5.4).  
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Figure 5.4: Box and whisker plot of absolute values pulmonary vascular 
permeability index (PVPI) pre to postoperatively.  
Placebo n=35, vitamin D3 n=33. Data presented as medians with Tukey’s 
distribution. Circles and triangles represent outlying values. P-values 
represent Wilcoxon matched-pairs signed rank test. 
 
 
PVPI  
median (IQR) 
Placebo 
n=35 
Vitamin D3 
n=33 
p-value 
Preoperative 1.5 (1.3 – 1.7) 1.7 (1.4 – 2.0) 0.06 
Postoperative 2.0 (1.6 – 2.1) 1.8 (1.6 – 2.0) 0.31 
Day 1 1.4 (1.1 – 1.6) 1.4 (1.1 – 1.9) 0.59 
Table 5.4: Absolute pulmonary vascular permeability (PVPI) values 
between treatment arms.  
Placebo n=35 and vitamin D3 n=33 at preoperative and postoperative points; 
placebo n=32 and vitamin D3 n=31 at day 1 time point due to loss of PiCCO2 
catheter. IQR – interquartile range; p-value represents Mann-Whitney test. 
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In order to account for baseline variability absolute and fold changes from 
baseline were analysed.  Vitamin D3 treatment significantly reduced the 
change in PVPI postoperatively compared to placebo, however this effect was 
not seen at day 1 (Figure 5.5); Absolute change in PVPI in placebo compared 
to treatment groups median 0.4 [IQR 0 – 0.7] vs. 0.1 [IQR -0.15 – 0.35], p=0.02 
preoperatively to postoperatively and -0.1 [IQR -0.3 – 0.2] vs. -0.2 [IQR -0.4 – 
0.1], p=0.28 preoperatively to day 1.   
 
 
Figure 5.5: Dot-plot showing fold change in pulmonary vascular 
permeability index (PVPI) between treatment arms.  
Fold changes shown from pre to postoperative and preoperative to day 1. 
Black lines and square dots for placebo (n=35); blue lines and triangle dots 
for vitamin D3 treatment (n=33); data presented as medians and interquartile 
ranges; p-values represent Mann Whitney tests.        
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5.3.3.2 PaO2/FiO2 Ratio 
There was no significant difference seen in PaO2/FiO2 ratio between the two 
groups postoperatively and at day 1 (figure 5.6). No significant difference 
was seen when the results were analysed for those patients that were 
25(OH)D3 deficient post receiving trial drug irrespective of the treatment arm 
they were allocated. 
 
Figure 5.6: Bar chart of PaO2/FiO2 ratio by treatment group.  
Data presented as mean and standard deviation. Placebo n=35, vitamin D3 
n=33.  
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5.3.3.3 Development of ARDS 
This study was not powered to investigate the development of ARDS but was 
included as a secondary outcome measure. In total 8 out of 68 (11.8%) 
patients developed ARDS with all of them occurring within 4 days of surgery 
with 5/8 (62.5%) within the first 24 hours postoperatively. There was no 
difference in ARDS rates between placebo and vitamin D3 treatment arms 
(placebo 4 [11.4%] of 35 compared with vitamin D3 4 [12.1%] of 33; odds 
ratio 0.94; 95% CI 0.21 – 4.09). There was no significant difference in the 
post treatment 25(OH)D3 concentration between the groups (median ARDS 
61.5 (IQR 57.7 – 78.5) nmol/L vs. no ARDS median 58.4 (IQR 37.3 – 78.9) 
nmol/L, p=0.77).  
 
5.3.3.4 Clinical outcomes. 
There was an increase in ICU length of stay in the vitamin D3 treated group 
compared to placebo group; however hospital length of stay was not 
significantly different (Table 5.5). Thirty and 90-day survival was similar 
between the groups with 1 death in the placebo group at 30-days and 2 at 90 
days compared with vitamin D3 arm with no deaths at 30-days and 2 deaths 
at 90-days (Table 5.5). There was no difference seen in ventilator and organ 
failure free days (data not shown) 
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 Placebo 
n=35 
Vitamin D3 
n=33 
p-value 
ITU LOS, days 
Median (IQR) 
4 (3 – 6) 5 (3 – 10) 0.052 
Hospital LOS, days 
Median (IQR) 
13 (10 – 20) 13 (11 – 23) 0.739 
30-day mortality, 
n(%) 
1 (2.9) 0 (0) 1.0 
90-day mortality, 
n(%) 
2 (5.8) 2 (6.1) 1.0 
Table 5.5: Length of stay and survival.  
IQR, interquartile range; p-values represent Mann Whitney tests and Fisher’s 
exact test for categorical data. 
 
5.3.3.5 Safety and tolerability  
The trial medication was well tolerated with 4 of 79 (5.1%; 2 placebo and 2 
vitamin D3) patients who received the drug developing self-limiting 
gastrointestinal upset in the form of episodes of diarrhea and nausea up to 24 
hours post drug administration . This was felt in part due to the vehicle 
Miglyol 812 oil for vitamin D3 in Vigantol acting as a laxative. There were no 
episodes of hypercalcaemia post drug administration.  
 
The frequency of serious adverse effects (SAEs) and adverse effects (AEs) 
was similar between the groups (Table 5.6). There were no reported SAEs 
related to the trial medication or suspected unexpected serious adverse 
events (SUSARs). 
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 Placebo 
n=35 
Vitamin D3 
n=33 
p-value 
Total SAEs 7 (20.0%) 11 (33.3%) 0.28 
Anastamotic leak 8 (22.8%) 6 (18.2%) 0.77 
Other surgical 
complication 
2 (5.7%) 5 (15.2%) 0.25 
Pneumonia 14 (40%) 14 (42.4) 1.0 
Other Respiratory 
complication 
7 (20.0%) 4 (12.1%) 0.51 
Sepsis 2 (5.7%) 1 (3.0%) 1.0 
Cardiac complication 10 (28.6%) 4 (12.1%) 0.14 
Table 5.6: Adverse events summarised by treatment group.  
SAEs, serious adverse events; other surgical complications include wound 
infection and intra-operative surgical complications, para-oesophageal 
herniation; other respiratory complications include pneumothorax or 
effusion requiring drainage, undefined respiratory failure, and pulmonary 
embolus; cardiac complications include arrhythmias requiring chemical or 
electrical treatment and myocardial infarction.  
 
5.3.3.6 Plasma markers of inflammation and epithelial damage 
There were no differences seen in perioperative markers of systemic 
inflammation (IL-6, IL-8, TNFor IL-10) between the groups, apart from a 
greater IL-6 in the cholecalciferol arm which then normalized by day 1. There 
was no difference in soluble RAGE between the groups, a marker of type 1 
epithelial injury. There was also no difference in antimicrobial peptide LL-37 
between the two arms at any time point. TNF receptor 1 (p=0.05) and 2 
(p=0.02) levels were significantly higher at day 1 in vitamin D3 treated 
patients. (Table 5.7)   
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 Time-
point 
Placebo Vitamin D3 p-
value 
IL-6 
(pg/ml) 
Pre-op 
Post-op 
Day 1 
9.5 (8.5 – 11.3) 
296.4 (188.5 – 488.5) 
240.5 (133.8 – 444.4) 
9.8 (8.5 – 11.3) 
546.3 (202.8 – 920) 
249.0 (153.4 – 451.4) 
0.18 
0.05 
0.88 
IL-8 
(pg/ml) 
 
Pre-op 
Post-op 
Day 1 
48.9 (35.6 – 58.9) 
87.1 (60.9 – 133.1) 
85.3 (68.0 – 122.0) 
44.4 (36.7 – 53.1) 
102.0 (74.3 – 156.0) 
85.0 (68.5 – 151.6) 
0.22 
0.17 
0.97 
TNF 
(pg/ml) 
Pre-op 
Post-op 
Day 1 
12.5 (11.0 – 13.5) 
10.5 (9.5 – 11.5) 
11.5 (10.4 – 13.6) 
12.5 (11.25 – 13.5) 
11.0 (10.0 – 12.5) 
12.0 (10.5 – 13.0) 
0.96 
0.14 
0.54 
IL-10 
(pg/ml) 
Pre-op 
Post-op 
Day 1 
15.0 (14.0 – 16.5) 
66.0 (31.5 – 106.5) 
27.0 (21.0 – 36.4) 
15.0 (14.0 – 17.5) 
43.0 (31.0 – 76.0) 
26.5 (23.5 – 37.0) 
0.39 
0.31 
0.67 
TNFR-1 
(pg/ml) 
Pre-op 
Post-op 
Day 1 
392 (254 – 577) 
806 (520 – 1302) 
724 (468 – 1179) 
391 (300 – 596) 
1181 (683 – 1443) 
886 (606 – 1694) 
0.49 
0.09 
0.05 
TNFR-2 
(pg/ml) 
Pre-op 
Post-op 
Day 1 
2365 (2003 – 3677) 
3112 (2263 – 4879) 
3807 (2403 – 4980) 
2865 (2211 – 4340) 
4148 (3125 – 5488) 
5130 (3607 – 6864) 
0.26 
0.12 
0.02 
LL-37 
(ng/ml) 
Pre-op 
Post-op 
Day 1 
3.7 (1.7 – 12.6) 
5.8 (2.5 – 7.9) 
14.6 (5.2 – 23.0) 
5.6 (2.5 – 11.5) 
4.6 (2.3 – 11.9) 
9.4 (3.6 – 19.0) 
0.63 
0.93 
0.52 
sRAGE 
(pg/ml) 
Pre-op 
Post-op 
Day 1 
43.0 (36.0 – 58.6) 
51.0 (37.6 – 67.4) 
35.3 (28.8 – 44.3) 
42.0 (33.9 – 51.3) 
52.5 (39.0 – 91.0) 
39.9 (30.6 – 64.1) 
0.57 
0.76 
0.13 
Table 5.7: Comparison of plasma markers of inflammation and 
epithelial damage.  
Data presented are medians (interquartile range): Bold results are 
significant. P-values represent Mann Whitney tests.  
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Postoperative sRAGE levels were raised significantly in both groups 
suggesting Type 1 epithelial damage however there was no difference in 
sRAGE levels between the arms postoperative, day 1 or at day 3/4.  
 
5.3.4 Efficacy of high dose vitamin D replacement 
There was no difference between groups in 25(OH)D3 levels before trial 
medication administration (placebo median 43.2 (IQR 35.0 – 69.0) vs. median 
vitamin D3 treated 42.7 (IQR 30.2 – 62.1) nmol/L, p=0.65). High dose 
300,000IU of cholecalciferol (vitamin D3) resulted in successful increase in 
plasma 25(OH)D3 concentrations to sufficient levels in those that received 
treatment compared to placebo (median 74.8 [IQR 58.0 – 90.3] compared to 
38.6 [IQR 31.3 – 58.6] nmol/L, p<0.0001). By day 3/4 there is a global 
decrease in 25(OH)D3 levels however there were persistently higher 
concentrations present in the vitamin D3 treated arm (Figure 5.7).  
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Figure 5.7: Scatter plot of efficacy of high dose vitamin D3 
supplementation on 25(OH)D3 concentrations.   
Black lines and square dots for placebo (n=38 pre-drug, preoperative; n=29 
Day 3/4); blue lines and triangle dots for vitamin D3 treatment (n=38 pre-
drug, pre-operative; n=23 day 3/4); Data presented as median and 
interquartile range, p-values comparing groups represent Mann Whitney 
tests and within groups Wilxocon matched pairs rank test. horizontal dotted 
line at 50nmol/L to show deficiency; 75nmol/L to show sufficiency.  
 
There was no difference between arms in pre-trial medication administration 
1,25(OH)2D3 concentrations (mean placebo 98.2 (SD 37.2) vs. 84.7 (SD 33.7) 
pmol/L, p=0.12)(Figure 5.8). Treatment with vitamin D3 resulted in a 
significant increase in 1,25(OH)2D3 levels but there was no significant 
difference seen  in concentrations between placebo and vitamin D3 treatment 
groups (mean 91.9 (SD 32.4) vs. 104.9 (SD 36.9) pmol/L, p=0.12). There was 
a decrease in 1,25(OH)2D3  in the placebo group by day 3/4 however levels 
were maintained in the vitamin D3 arm, thus by day 3/4 the levels were 
significantly lower in the placebo group (mean  66.3 (SD 32.5) vs. 98.03 (SD 
51.2) pmol/L, p=0.009)(Figure 5.8) 
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Figure 5.8: Scatter plot of efficacy of high dose vitamin D3 
supplementation on 1,25(OH)2D3 concentrations.  
Black lines and square dots for placebo (n=38 pre-drug, preoperative; n=29 
Day 3/4); blue lines and triangle dots for vitamin D3 treatment (n=38 pre-
drug, pre-operative; n=23 day 3/4); Data presented as mean and standard 
deviation, p-values between groups represent unpaired t-tests and paired t-
tests within groups; horizontal dotted line at 50nmol/L to show deficiency; 
75nmol/L to show sufficiency.  
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There was no difference between arms in DBP levels at any timepoint. There 
was a significant drop in DBP level at day 3 in both groups. (Figure 5.9) 
 
 
 
Figure 5.9: Scatter plot of efficacy of high dose vitamin D3 
supplementation plasma vitamin D binding protein (DBP) 
concentrations.  
Black lines and square dots for placebo (n=38 pre-drug, preoperative; n=29 
Day 3/4); blue lines and triangle dots for vitamin D3 treatment (n=38 pre-
drug, pre-operative; n=23 day 3/4); Data presented as median and 
interquartile range, p-values comparing groups represent Mann Whitney 
tests and within groups Wilxocon matched pairs rank test. 
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5.3.5 Post Hoc analysis of EVLWI and PVPI 
Only 2 patients who received vitamin D had levels of 25(OH)D3 <50nmol/L 
post trial drug administration which is the level below which deficiency is 
defined.  However some patients in the placebo group had 25(OH)D3 levels 
above 50nmol/L pre drug administration. Therefore a sub-group analysis of 
all the patients (placebo and treatment arm) was performed based on 
25(OH)D3 concentration post drug administration to determine if there is a 
threshold effect above which the beneficial effects of 25(OH)D3 on EVLWI 
and PVPI are seen.  
 
Patients who remained deficient in 25(OH)D3 (<50nmol/L) irrespective of 
the treatment arm they were allocated to had a significantly higher increase 
in EVLWI at the end of the operation compared to those that were sufficient 
(median absolute increase EVLWI 1.2 [IQR 0.9 – 2.0] vs. 0.4 [IQR -0.4 – 1.4] 
ml/kg, p=0.008)(Figure 5.10).   
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Figure 5.10: Box and whisker plot of fold change in extravascular lung 
water index in 25(OH)D3 deficient and sufficient patients.  
25(OH)D3 <50nmol/L n=22; 25(OH)D3 >50nmol/L n=46. Data presented as 
medians with Tukey’s distribution. Circles and triangles represent outlying 
values. P-values represent Mann Whitney test. 
 
Patients who remained deficient in 25(OH)D3 (<50nmol/L) irrespective of 
the treatment arm they were allocated to had a significantly higher increase 
in PVPI at the end of the operation compared to those that were sufficient 
(median absolute increase PVPI 0.4 [IQR 0.3 – 0.6] vs. 0.1 [IQR -0.1 – 0.4] 
ml/kg, p=0.014)(Figure 5.11) 
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Figure 5.11: Box and whisker plot of fold change in pulmonary vascular 
permeability index (PVPI) in 25(OH)D3 deficient and sufficient patients.  
25(OH)D3 <50nmol/L n=22; 25(OH)D3 >50nmol/L n=46. Data presented as 
medians with Tukey’s distribution. Circles and triangles represent outlying 
values. P-values represent Mann Whitney test. 
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5.4 DISCUSSION 
The main finding of this phase II randomised placebo controlled clinical trial 
was that high dose oral vitamin D3 (300,000IU cholecalciferol [vigantol®]) 
treatment pre-oesophagectomy prevented an increase in postoperative 
EVLWI and PVPI.  Although the a priori primary outcome of postoperative 
EVLWI was not significantly different between placebo and treatment 
groups, there was a significant rise and fold change in EVLWI and PVPI in the 
placebo group compared to the treatment group.  Furthermore, this effect 
was more significant in patients with vitamin D3 deficiency (25(OH)D3 levels 
less than 50nmol/L).  Thus, suggesting vitamin D3 may have a protective role 
on the alveolar epithelial and endothelial membrane and its actions may have 
a threshold effect.  
 
Vitamin D3 treatment did not prevent the development of ARDS. The 
incidence of ARDS in this cohort was 11.7%. This study was not powered to 
investigate clinical outcomes so it is perhaps not unsurprising that no 
differences were seen between groups with respect to oxygenation, number 
of ventilator- or organ failure free days, ICU or hospital length of stay or 
survival.  Importantly treatment was well tolerated with no difference in the 
rate of serious adverse events.  
 
There are several potential reasons why preoperative treatment with vitamin 
D3 and rendering patients non-deficient may attenuate the increase in 
postoperative EVLWI and PVPI.  1,25(OH)2D3 has been shown to upregulate 
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transcription of proteins required for the formation of claudins and E-
cadherin in epithelial cells of the skin138 and intestine140,141 which are 
required for normal function of gap, tight and adherens junctions. This may 
also have a role in the lung protecting the epithelial barrier to prevent 
alveolar fluid influx and facilitate clearance.85 Alveolar epithelial cells possess 
the ability to convert circulating 25(OH)D3 to 1,25(OH)2D3 and activate VDR 
responsive genes.123 Recently it has been shown that physiologically relevant 
doses of 25(OH)D3 stimulated wound repair, cellular proliferation and 
reduced sFasL induced cell death of type 2 alveolar epithelial cells in-vitro.198 
Both indicating that vitamin D3 has a direct protective role on the alveolar 
epithelium. There may also be a protective mechanism on the pulmonary 
endothelium as 1,25(OH)2D3 is able to decrease expression of ICAM-1 and 
prevent neutrophil adhesion, migration and therefore initiation of lung 
injury.142 Once an injury has occurred clearance of neutrophils and alveolar 
fluid occurs by resident and recruited macrophages.  Macrophages 
constitutively express the VDR and 1-hydroxylase (CYP27B1) and vitamin 
D3 stimulates the differentiation of mature phagocytic macrophages.120,150 
Although much of this evidence comes from increased phagocytosis of 
pathogens vitamin D3 may increase macrophage resolution of inflammatory 
cells and debris however more studies are required to elucidate this potential 
effect.  
 
There was a greater increase in immediate postoperative IL-6 levels in the 
vitamin D3 compared to placebo treated arms that had returned to similar 
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levels by day 1.  Other markers of systemic inflammation and epithelial 
damage were not altered by treatment with vitamin D3.. These results are a 
surprise as vitamin D3 has been shown to be anti-inflammatory by reducing 
NF- signalling and TLR signalling.154 Overall this study did not show an 
anti-inflammatory effect of vitamin D3 treatment on circulating cytokines and 
confirms the findings of 2 other studies which failed to reveal a relationship 
between circulating cytokines and 25(OH)D3 levels261 or vitamin D 
replacement.262 Significantly higher levels of soluble receptors TNFRI and 
TNFRII were found in the vitamin D3 treated group at day 1 which is slightly 
more difficult to explain but may explain vitamin D3 effects on promoting 
resolution of inflammation.   
 
High dose 300,000IU of vitamin D3 successfully increased 25(OH)D3 
concentrations to what is classified as sufficient (50nmol/L). This led to a 
corresponding and sustained rise in 1,25(OH)2D3 concentration  
perioperatively. However plasma levels of 25(OH)D3 and 1,25(OH)2D3 
decreased post-operatively by day 3 but continued to remain higher in the 
vitamin D3 treated arm. This drop could be explained by increased 
consumption post-operatively although may also be accounted for by 
decreasing levels of DBP seen at day 3 or a dilution effect due to 
perioperative fluid administration. Evidence exists of local synthesis of 
1,25(OH)2D3 by normal human macrophages on stimulation with IFN-
gamma.151 However evidence is lacking of the effects of acute inflammatory 
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processes on plasma and cellular 25(OH)D3 levels and its conversion to 
1,25(OH)2D3.  
 
The major limitation of this study is the change in the 25(OH)D3 levels of this 
cohort of patients on which this study design was based. The baseline levels 
were much higher than those seen in the preliminary observational study on 
which the trial was powered. Furthermore the magnitudes of changes in 
EVLWI were also smaller possibly reflecting improved surgical technique and 
anaesthetic management or may reflect the higher baseline 25(OH)D3 levels 
seen in these patients if our hypothesis is correct. Despite this significantly 
lower change in EVLWI and PVPI were seen in this study.  Future vitamin D 
studies need to carefully consider if vitamin D concentrations and deficiency 
confirmed prior to enrolment. 
 
In summary this phase II randomised controlled trial demonstrates the 
beneficial effects of cholecalciferol replacement on biomarkers of lung injury 
post a high risk insult and provides the first proof of concept that treatment 
pre-injury may prevent the development of ARDS and large relevant clinical 
trials are justified.  
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CHAPTER 6                                                                             
IN-VITRO AND IN-VIVO EFFECTS OF VITAMIN D ON 
MACROPHAGE FUNCTION  
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6.1 INTRODUCTION 
Macrophages are important mediators of the acute respiratory distress 
syndrome (ARDS), forming the first line of response to pulmonary 
inflammation and infection. The nature of this response is intimately tied to 
the ongoing inflammatory cascade that ensues in the acute phase of the 
disease.263 In recent years macrophage function and phenotype are being 
increasingly recognised as important in the resolution and repair phase from 
ARDS.90 Human studies of macrophage function in ARDS are limited, 
however, analysis of serial bronchoalveolar lavage fluid (BALF) from patients 
with ARDS has shown increased alveolar macrophage number is associated 
with survival264 and an immature monocyte-like cellular phenotype 
associated with reduced oxygenation and mortality.265 More recently Brittan 
et al. have confirmed the presence of increased immature monocyte-like cells 
compared to mature alveolar macrophages post exposure to inhaled 
lipopolysaccharide (LPS) in healthy volunteers.266 Furthermore patients with 
neutropenia-related sepsis and ARDS have deactivation of alveolar 
macrophages which is associated with poor survival267, suggesting 
macrophages may also play a central role in the development of ARDS. 
 
Ingestion of apoptotic cells by macrophages termed ‘efferocytosis’ is vital in 
maintaining lung tissue homeostasis, resolving damaging inflammation and 
hastening tissue repair.268 Neutrophils have long been considered the key cell 
type in the pathogenesis and propagation of ARDS.1,54 Persistent neutrophilia 
and dysregulated macrophage clearance of apoptotic neutrophils leads to a 
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delayed clearance of neutrophilic injury, secondary necrosis and a prolonged 
inflammatory insult and tissue damage.98,269 The release of damage-
associated molecular patterns (DAMPs), such as heat shock proteins (HSPs), 
high mobility group box 1 (HMGB-1) and mitochondrial and DNA peptides by 
the process of secondary necrosis propagates a second wave of inflammation 
and tissue damage.268 Inhibition of HMGB-1 in animal models has been 
shown to attenuate lung injury in pneumonia,270,271 ventilator-induced lung 
injury (VILI),272 and sepsis.273-275 In humans, HMGB-1 concentration at 
presentation post severe trauma has been shown to predict the risk of 
developing acute lung injury.276 It is important to note that although 
neutrophil apoptosis may induce alveolar epithelial barrier dysfunction in 
early ARDS, apoptosis may also be a pre-requisite in the response to injury by 
limiting the duration of pulmonary inflammation by sequestrating cytokines 
and endotoxins277 and stimulation of a pro-resolution alternatively activated 
M2 macrophage phenotype.278 Furthermore, efferocytosis itself induces the 
production of anti-inflammatory mediators IL-10 and TGF- that dampen 
pro-inflammatory responses.279 Therefore, up-regulating efferocytosis and 
increasing macrophage maturation may be a strategy to reduce inflammation 
and promote resolution of ARDS.  
 
Tissue macrophages are derived from circulating monocytes and dependent 
on the microenvironment and stimulus undergo classical M1 activation or 
alternative M2 activation.280 The M1 phenotype is induced by pro-
inflammatory Th1 cytokines such as IFN and toll-like receptor (TLR) ligands 
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such as LPS. M1 macrophages produce high levels of proinflammatory 
cytokines, reactive oxygen species (ROS), inducible nitric oxide synthase 
(iNOS) and have strong bactericidal activity, conversely M2 macrophages are 
induced by Th2 cytokines, IL-4 and IL-13 and produce anti-inflammatory IL-
10 and are characterised by efficient phagocytic activity with a high 
expression of scavenging molecules.278,280,281 Studies to identify 
subpopulations of human macrophages are limited.  However further subsets 
of M1 and M2 macrophages have been described,89 with a discrete subset of 
alternatively activated (M2c) macrophages induced by macrophage colony 
stimulating factor (M-CSF) or glucocorticoids that display an increased 
efferocytosis phenotype and can be identified by reduced CD14  and 
increased expression of CD163, CD16, CD206, CD200R282,283 and the Mer 
tyrosine kinase (MerTK) efferocytosis receptor.284,285 It has also been shown 
that M1 macrophages can be polarised by granulocyte macrophage colony 
stimulating factor (GM-SCF) and distinguished by increased CD14 and CD80 
expression.282,283 Importantly, evidence now suggests that these cells present 
a huge degree of heterogeneity and plasticity and can be present in 
continuum and determined by the microenvironment and cytokine and 
cellular milieu.278 
 
Vitamin D has profound effects on the innate immune system. It stimulates 
the differentiation of precursor monocytes to mature phagocytic 
macrophages supported by the differential expression of the vitamin D 
receptor (VDR) and 1-hydroxylase during human macrophage 
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differentiation.85,150 Vitamin D is known to rescue and enhance the 
phagocytic potential of macrophages to bacteria in-vitro but its effects upon 
neutrophil efferocytosis are unclear.238,286 Localised synthesis of 1,25(OH)2D3 
by normal human macrophages on stimulation with IFN suggests an 
intracrine system exists for the action of vitamin D in normal monocytes and 
macrophages.85,143,151 IL-1 and TNF production induced by TLR-3 agonists 
from monocyte derived macrophages are inhibited to the same extent by 
25(OH)D3 and 1,25(OH)2D3 suggesting that the vitamin D metabolites may 
have a rapid anti-inflammatory action and that local intracellular activation 
of 25(OH)D3 can be anti-inflammatory.85,287 The ability of 1,25(OH)2D3 to 
directly inhibit NF- signaling and suppress macrophage TLR expression 
suggests that vitamin D may also play a key role as a feedback regulator of 
macrophage responses.85,153,154 It has also been shown that 1,25(OH)2D3 
affects differentiation, maturation and function of monocyte-derived 
dendritic cells by inhibiting differentiation and maturation into antigen 
presenting cells.288  
 
Our group has previously reported low 25(OH)D3 levels in patients 
undergoing oesophagectomy are associated with elevated postoperative 
systemic inflammation as measured by levels of IL-6 and HMGB1 and 
increased alveolar epithelial dysfunction.198 Unpublished data from the group 
(PhD thesis, Dr Christopher Bassford, University of Warwick, 2011) has 
found that in-vitro HMGB-1 suppresses human alveolar macrophage 
efferocytosis in a dose dependent manner suggesting that elevated HMGB-1 
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may slow the resolution of neutrophilic injury resulting in exaggerated 
secondary necrosis of neutrophils.  
 
The evidence presented suggests that treatment with vitamin D could have a 
favorable effect in ARDS by up-regulating macrophage resolution of 
neutrophilic injury. The primary objective of this study was to investigate if 
vitamin D3 can modulate macrophage efferocytosis in-vitro and in-vivo. The 
second objective was to investigate the potential role of vitamin D3 in 
modulating a monocyte differentiation to a pro-resolving phenotype.  
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6.2 MATERIALS AND METHODS 
6.2.1 In-vitro studies 
6.2.1.1 Efferocytosis Assays 
Lung tissue samples were acquired as part of the Midlands Lung Tissue 
Collaborative as described in section 3.4.3 and processed to isolate human 
alveolar macrophages as described in section 3.5.4. Cells were treated for 24 
hours and the effects of untreated media control [UTC, RPMI 1640 with 10% 
foetal bovine serum (FBS, Sigma-Aldrich, Poole, UK)], 25(OH)D3: 50nmol/L 
and 100nmol/L (Merck Millipore, Watford, UK), 1,25(OH)2D3: 50nmol/L and 
100nmol/L (Merck Millipore) and 150ng/mL HMGB-1 (Abcam, Cambridge, 
UK) on alveolar macrophage capacity to engulf apoptotic neutrophils was 
assessed by flow cytometry as described in section 3.6. The number of 
macrophages that had engulfed a neutrophil was calculated as an 
efferocytosis percentage (E%).   
 
ARDS bronchoalveolar lavage fluid (BALF) from 4 patients (section 3.5.4) 
was pooled and mixed 1:1 with RPMI 1640 media and 10%FBS (Sigma-
Aldrich). Macrophages were incubated with ARDS BALF and 50nmol/L 
25(OH)D3 (Merck Millipore)  alone and in combination and efferocytosis 
assessed after 24 hours.  Macrophage apoptosis was assessed to by Annexin 
V/Sytox staining on the flow cytometry using the same methods as described 
for murine cell apoptosis in section 3.9.7.  
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6.2.1.2 Monocyte differentiation and phenotype 
Peripheral blood monocytes were extracted from healthy human volunteers 
and cultured as described in section 3.4 and 3.5. The effect of 50nmol/L 
25(OH)D3 (Merck Millipore), 50ng/mL GM-CSF (PeproTech, Rocky Hill, USA, 
50ng/mL) and 50ng/mL M-CSF (PeproTech) with 10ng/mL IL-10 
(PeproTech) on monocyte differentiation and phenotype was assessed by cell 
surface marker expression by flow cytometry as described in section 3.7.  
 
6.2.2 In-vivo studies 
Patients enrolled in a randomised placebo controlled trial investigating the 
effects of pre-operative high dose vitamin D3 (cholecalciferol, 300,000IU) on 
postoperative extravascular lung water post oesophagectomy116 (described 
in previous chapter) were recruited to a bronchoscopic sub-study. A further 
9 patients that were enrolled in a preliminary dosing study were also 
included in the correlation analysis (Open label dosing study to optimise 
vitamin d levels prior to oesophagectomy, REC 11/WM/0330, EudracT 2011-
004199-12). Bronchoscopy and bronchoalveolar lavage were performed at 
the end of the operation as described in section 3.4.2 and alveolar 
macrophages isolated as described in section 3.5.5.  
 
Blood was taken pre-drug dosing, pre-operative, post-operative, day 1 and 
day 3/4. Peripheral monocytes were isolated as described in section 3.5.2 
Efferocytosis was assessed on alveolar macrophages and monocytes as 
described in section 3.7. 
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6.2.3 Statistical analysis 
Data were analysed using GraphPad Prism 6.0© software (GraphPad 
Software, La Jolla, California, USA). Data were initially tested for normality 
using the D'Agostino-Pearson test. Normally distributed data were analysed 
using t-tests and presented as mean (standard deviation) and bar-charts. 
Non-parametric data were analysed using Wilcoxon signed-rank test, Mann-
Whitney test or Friedman’s ANOVA and Dunn’s multiple comparison tests 
when comparing multiple groups. Non-parametric data are presented as 
median (interquartile range) and box and whisker plot with Tukey’s 
distribution. Linear associations were tested using Spearman’s correlation 
coefficient. A two-tailed p-value of <0.05 was considered statistically 
significant.  
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6.3 RESULTS 
6.3.1 In-vitro studies 
6.3.1.1 Vitamin D and efferocytosis 
Alveolar macrophage (obtained from lung resection samples) efferocytosis 
was increased in response to 25(OH)D3 (50nmol/L) compared to untreated 
control, UTC [mean E% 37.1 (23.9) vs. 27.4 (18.3), p=0.014, paired t tests]. 
The same effect was seen for 1,25(OH)2D3 (50nmol/L) [mean E% 33.7 (18.5) 
vs 27.4% (18.3), p=0.036, paired t-test] after 24 hours incubation. The data is 
presented in Figure 6.1 as non-parametric as fold change was not normally 
distributed.  The in-vitro macrophage studies were not blinded to stimulation 
and performed on alveolar macrophages isolated from lung resection 
samples. 
 
Dosing experiments were performed which showed no effect on increasing 
the concentration of both 25(OH)D3 and 1,25(OH)2D3 to 100nmol/L (Figure 
6.2). Therefore a dose of 50nmol/L was used for all the experiments. Ethanol 
was used as the vehicle carrier for the 25(OH)D3 and 1,25(OH)2D3 in-vitro  
and this did not have an effect on efferocytosis. Due to baseline variability in 
efferocytosis in untreated control samples between each donor subject cells 
(Figure 6.3), differences in fold change from control were assessed and 
paired statistical tests performed. 
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Figure 6.1: In-vitro effect of vitamin D on alveolar macrophage 
efferocytosis.  
Alveolar macrophages obtained from lung resection samples. Results 
expressed as a proportion of control. Box and whisker plot with Tukeys 
distribution. Friedman’s ANOVA (p=0.006, n=10) *p<0.05 compared to UTC 
(Dunn’s multiple comparisons). 25(OH)D3 (50nmol/L) and 1,25(OH)2D3 
(50nmol/L). UTC=untreated media control; Black triangle: outlier 
 
 
Figure 6.2: Dosing effects of vehicle, 50nmol/L and 100nmol/L of 
vitamin D.  
Alveolar macrophages obtained from lung resection samples. Results 
expressed as a proportion of control. Box and whisker plots with Tukey’s 
distribution. Friedman’s ANOVA (p=0.07, n=5) *p<0.05 compared to UTC 
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(Dunn’s multiple comparisons). Vehicle=Ethanol: UTC; untreated media 
control. 
 
 
Figure 6.3: Baseline untreated alveolar macrophage efferocytosis 
variation.  
Dot plot shows the huge variation in efferocytosis seen in untreated alveolar 
macrophages where each number on the x-axis represents an individual 
patient’s sample.  
 
 
 
Alveolar macrophages from lung resection specimen also demonstrated 
heterogeneous responses to exogenous vitamin D at basal state as shown in 
Figure 6.4. Cellular viability was unchanged between the samples. 
Unfortunately the vitamin D levels of the donors of lung tissue were not 
measured. Donor baseline demographics: age, sex, smoking status and lung 
function did not correlate with efferocytosis in this cohort, data not shown.  
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A 
 
B 
 
Figure 6.4: Graphs demonstrating the heterogeneous response of 
alveolar macrophage to exogenous vitamin D3 
A] 50nmol/L 25(OH)D3; B] 50nmol/L 1,25(OH)2D3. Dotted line delineates 
5% efferocytosis change from control to try and identify responder vs. non-
responders to vitamin D3 treatment.  
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6.3.1.2 ARDS lavage fluid and vitamin D 
ARDS BALF suppressed alveolar macrophage efferocytosis compared to 
media control (median [IQR] E% 8.6 [7.74 - 13.9] vs 27.3% [18.2 - 32.2], 
p=0.031; Wilcoxon rank signed test). Addition of 50nmol/L of 25(OH)D3 with 
ARDS BALF for 24 hours rescued efferocytosis to levels similar to that of 
25(OH)D3 treatment alone (median [IQR] E% 18.4 [14.7 - 36.1] vs 25.1  [18.2 
– 38.9], p=0.218; Wilcoxon rank signed test) and significantly higher than 
that of BALF suppression (Figure 6.4). Macrophage apoptosis was assessed 
after incubation with 50% pooled ARDS BALF to ensure viability and this was 
confirmed to be maintained at >85%. Although 100% concentration of 
pooled ARDS dropped cell viability to <50%. 
 
Figure 6.5: The effect of 25(OH)D3 on ARDS BALF induced suppression 
of efferocytosis.  
Results presented as a proportion of control. Box and whisker plot with 
Tukey’s distribution. Friedman’s ANOVA (p<0.002, n=6); *p<0.05 compared 
to UTC (Dunn’s multiple comparisons). Within group analysis by Wilcoxon 
rank sign paired test. UTC=untreated media control. 
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6.3.1.3 HMGB-1 and vitamin D 
A dosing study confirmed that HMGB-1 suppression of efferocytosis is dose 
dependent (Figure 6.6). Subsequently, HMGB-1 150ng/ml significantly 
suppressed efferocytosis compared to cells incubated with media control 
(median [IQR] E% 8.2 [7.2 – 17.1] vs 22.3 [20.1 – 28.9], p=0.031; Wilcoxon 
rank signed test](Figure 6.7) but treatment with 50nmol/L of 25(OH)D3  did 
not attenuate the HMGB-1 effects, suggesting that vitamin D effects on 
improving alveolar macrophage efferocytosis are HMGB-1 independent and 
other mechanisms are in play. 
 
 
 
Figure 6.6: Dose response of HMGB-1 on macrophage efferocytosis.  
Dose response of 10, 50,100 and 150ng/mL 
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Figure 6.7: Effects of ARDS BALF and 25(OH)D3  on efferocytosis.  
Results presented as proportion of control. Box and whisker plot with 
Tukey’s distribution. Friedman’s test ANOVA (p<0.001, n=6); *p<0.05 
compared to UTC (Dunn’s multiple comparison). Within group analysis by 
Wilcoxon rank sign paired tests. UTC=untreated media control.  
 
6.3.1.4 Monocyte derived macrophages 
To determine if 25(OH)D3 can differentiate macrophages to an M2 
phenotype, normal human monocytes were isolated and incubated with 
50nmol/L 25(OH)D3  for 4 days. 25(OH)D3  promoted monocyte maturation 
into a cellular phenotype that was high in the expression of CD16, CD163, 
CD200R but low in the expression of CD80 (Figure 6.8). These cells had 
surface marker expression profiles similar to cells stimulated with M-CSF and 
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Il-10 and not GM-CSF, confirming a typical alternatively activated 
macrophage. There was no difference in the expression of CD14 and CD206 
between the cells and no significant up regulation of the efferocytosis 
receptor MerTK (Figure 6.9), suggesting that other receptors or pathways are 
likely to be responsible for the increase in efferocytosis seen in response to 
vitamin D in the previous experiments.  
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Figure 6.8: Cell surface expression profile of monocyte derived 
macrophages stimulated with 25(OH)D3.   
Data presented as fold change from UTC. Box and whisker plots with median 
and Tukey’s distribution. Friedman ANOVA’s with Dunn’s multiple 
comparisons. n=6, *p<0.05 compared to UTC; #p<0.05 compared to M-CSF. 
UTC: untreated media control; M-CSF: macrophage colony-stimulating factor; 
GM-CSF: granulocyte macrophage colony-stimulating factor. 
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Figure 6.9: MerTK expression is not increased by 25(OH)D3.  
Data presented as fold change from control. Box and whisker plot with 
median and Tukey’s distribution; Friedman’s ANOVA (p=0.007, n=6); *p<0.05 
compared to UTC; p<0.05 compared to M-CSF (Dunn’s multiple comparison). 
UTC: untreated media control; M-CSF: macrophage colony-stimulating factor; 
GM-CSF: granulocyte macrophage colony-stimulating factor. 
 
6.3.2 In-vivo studies 
Twenty-five patients were recruited to a bronchoscopic sub-study of the 
vitamin D to prevent acute lung injury following oesophagectomy  
(VINDALOO) trial. After un-blinding the trial 15 subjects had received 
placebo and 10 high dose vitamin D treatment (oral liquid cholecalciferol 
300,000IU) as per trial protocol. Groups were equally matched in baseline 
characteristics similar to chapter 5 and therefore data not represented. 
  
Cholecalciferol treatment successfully increased plasma 25(OH)D3 
concentration to sufficient levels compared to patients that received placebo 
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[mean 81.9 (5.7) vs 47.2 (9.3) nmol/L, p=0.003, unpaired t-test)] (Figure 
6.10). This was represented in a corresponding rise in 1,25(OH)2D3 levels 
compared to placebo [mean 124.5 (11.3) vs 91.0 (7.4) pmol/L, p=0.016, 
unpaired t-test]. Thus, confirming both successful replenishment and 
physiological effect.  
A 
 
B 
 
Figure 6.10: Plasma concentration of vitamin D levels post treatment. 
Bar charts with mean and standard deviations. A] 25(OH)D3 levels; B] 
1,25(OH)2D3 levels. p-values represent unpaired t-tests.  
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6.3.2.1 Alveolar macrophage efferocytosis 
Alveolar macrophage efferocytosis was not significantly different when 
comparing placebo to vitamin D treated groups [mean E% 31.3 (3.98) vs 39.6 
(8.15), p=0.32; unpaired t-test] (Figure 6.11). However the 25(OH)D3 levels 
at enrolment in this patient cohort were higher than previously reported198 
with a mean 25(OH)D3 level of 51.2 (4.86) nmol/L which is classified as 
insufficient rather than deficient (<50nmol/L).  
 
 
 
Figure 6.11: Effects of placebo vs treatment on alveolar macrophage 
efferocytosis.  
Bar chart with mean and standard deviation. Placebo n=15, Treatment n=10.  
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We therefore analysed the results in 2 groups based on 25(OH)D3 
concentration post treatment (deficient <50nmol/L and sufficient 
>50nmol/L). This demonstrates that if the 25(OH)D3 concentration was 
lower than 50nmol/L post treatment then ex-vivo alveolar macrophage 
efferocytosis was significantly lower than those with levels >50nmol/L 
[mean E% 18.5 (2.9) vs. 38.9 (4.8), p=0.01; unpaired t-test](Figure 6.12).  
 
 
Figure 6.12: Efferocytosis is lower in patients with 25(OH)D3 deficiency 
compared to sufficient patients. 
Box and whisker plots with median and Tukey’s distribution. Deficient 
<50nmol/L n=8, sufficient >50nmol/L n=17; p=0.01 unpaired t-test.  
 
Due to the imbalance in the proportion of placebo and active treatment in 
this group, further subdivision of the placebo arm into placebo deficient and 
placebo sufficient demonstrated a significantly higher efferocytosis 
percentage in the vitamin D sufficient group (median [IQR] E% 37.6 [34.7-
45.5] vs. 15.5 [11.0 – 27.1], p=0.0006, Mann-Whitney test)(Figure 6.13) with 
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the placebo sufficient group having a similar E% compared to the treated 
group (median [IQR] E% 35.2 [13.3 – 64.8], p=0.69).  Furthermore, plasma 
25(OH)D3 levels post treatment and pre-operatively showed a weak positive 
correlation to efferocytosis (n=34, Spearman r=0.469 p=0.005) (Figure 6.14). 
This correlation included 9 further experiments from a preceding open label 
dosing study198 that weren’t included in the analysis of the samples obtained 
from the randomised control trial as this was a dose escalation study. 
Samples and experiments were processed in the same standardised 
methodology described.    
 
 
 
Figure 6.13: Placebo treated patients with sufficient 25(OH)D3 levels 
have higher efferocytosis compared to deficient. 
Box and whisker plot with median and Tukey’s distribution. Placebo deficient 
<50nmol/L n=7, placebo sufficient >50nmol/L n=8 and Treated n=10. 
P=0.0006, Mann-Whitney test.   
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Figure 6.14: Correlation of post dose 25(OH)D3 concentration and 
efferocytosis. n=34, Spearman r=0.469,  p=0.005.  
 
 
6.3.2.2 Monocyte efferocytosis 
Pre-drug administration, pre-operative and day 3/4 monocytes were isolated 
and efferocytosis was assessed after 24 hours of culture for 23 patients (11 
placebo; 12 treatment arm) There was no difference seen between placebo 
and cholecalciferol treated groups in ex-vivo cultured monocyte efferocytosis 
at 24 hours at any time-point. Post-treatment 25(OH)D3 concentration 
irrespective of allocated treatment arm and level of deficiency did not relate 
to monocyte efferocytosis as seen with alveolar macrophages.  
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6.4 DISCUSSION 
There are no studies reported investigating the effects of vitamin D3 
(25(OH)D3) on human alveolar macrophage function and specifically 
efferocytosis in the context of acute inflammation. In this study we have 
shown that 25(OH)D3 and 1,25(OH)2D3 at a dose of 50nmol/L can increase 
the efferocytosis potential of macrophages in-vitro and 50nmol/L of 
25(OH)D3 promotes pro-resolving M2 differentiation of peripheral monocyte 
derived-macrophages.  At basal un-stimulated state macrophage response is 
heterogeneous. Unfortunately in this study we were unable to account for the 
vitamin D levels of the donors of lung tissue that may account for the variable 
macrophage responses seen to vitamin D treatment.  Smoking and chronic 
obstructive airways disease (COPD) are known to reduce efferocytosis.289,290 
However, this small study was not powered to detect a difference between 
smoking status, lung function and efferocytosis. 
 
Most of the in-vitro studies to date that have investigated the effects of 
vitamin D3 on the modulation of the innate immune system have 
concentrated on treatments using 1,25(OH2)D3 or synthetic analogs291. 
However, it is evident from macrophage/monocyte responses to infection 
that actions of vitamin D3 are likely to be due to the local activation of 
25(OH)D3, the major circulating form and accepted determinant of vitamin D 
status.196 Local cellular 25(OH)D3 activation may be influenced by genetic 
polymorphisms of both the 1- hydroxylase enzyme (CYP27B1) and the 
vitamin D receptor (VDR) in individuals. This is evident in patients with 
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tuberculosis where improved sputum conversion time was seen in a specific 
subset of patients with a single nucleotide polymorphism (SNP) within the 
VDR gene and not in the overall cohort that were supplemented with vitamin 
D3.292 Therefore the varying efferocytosis responses seen in this study may 
be accounted for in part by individual genetic polymorphisms of elements of 
the vitamin D metabolic pathway.  
 
We have demonstrated for the first time that alveolar macrophage 
efferocytosis is suppressed by ARDS BALF and HMGB-1. Treatment with 
25(OH)D3 attenuated the effect of ARDS BALF but not HMGB-1, suggesting 
that the actions of vitamin D on rescuing efferocytosis are independent of 
HMGB-1. Whilst this is a surprising result as 1,25(OH)2D3 has been shown to 
dampen NFinduced Type-1 pro-inflammatory cytokine release,154,156 there 
are many other determinants of efferocytosis that may be implicated 
including induction of other efferocytosis receptors (e.g. Lipoxin A4, ALX, 
Stabilins), bridge molecules (Gas6, protein S and collectins), enhancing Rac 1 
GTPase signalling, activation of the peroxisome proliferator-activated 
receptor (PPARand retinoid X receptor (RXR)279 The effects of 25(OH)D3 
are mediated by activation of the VDR. VDR and its ligand 1,25(OH)2D3, 
dimerise with the retinoid X receptor (RXR) and attach to specific genomic 
sequences termed vitamin D response elements (VDRE).85 The transcription 
of VDR target genes results in cell growth inhibition, induces apoptosis, 
controls proliferation and differentiation.118,120,121,293  The mechanism by 
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which efferocytosis is attenuated with 25(OH)D3 treatment in-vitro warrants 
further investigations. 
 
This study shows that 25(OH)D3 induced monocyte maturation towards an 
M2 alternatively activated phenotype as defined by cell surface markers. This 
is in keeping with previous studies that have shown that vitamin D can 
modulate monocyte maturation to mature phagocytic macrophages.150 This 
effect would be in keeping with our hypothesis that vitamin D3 acts to 
promote an anti-inflammatory and resolution phenotype and also supports 
the increased efferocytosis seen in the alveolar macrophages in this study. 
However the expression of the efferocytosis receptor MerTK was not 
increased in this study and therefore other mechanisms and pathways as 
discussed above need to be further investigated.  
 
The in-vivo study of high dose cholecalciferol replacement did not show a 
difference in alveolar macrophage efferocytosis between placebo and 
cholecalciferol treatment arm. However, subjects who had vitamin D 
deficiency (<50nmol/L) irrespective of treatment arm had lower macrophage 
efferocytosis. Furthermore, subjects in the placebo group that had 25(OH)D3 
concentrations of >50nmol/L had efferocytosis levels similar to that of the 
treatment arm. Suggesting that vitamin D actions on alveolar macrophage 
efferocytosis are dependent on being deficient and sufficient circulating 
concentrations may act as a negative feedback loop on the cellular actions of 
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vitamin D. This finding would support the idea that vitamin D metabolism in 
the macrophage has an intracrine control mechanism.127  
 
There was no effect of in-vivo cholecalciferol on monocyte efferocytosis. This 
may be due to the fact that these cells were only incubated for 24 hours and 
may have represented immature poorly differentiated cells or the actions of 
vitamin D3 on promoting monocyte efferocytosis require further adequate 
inflammatory stimulation. In hindsight these experiments should have been 
done after 3/4 days of incubation similar to the phenotype experiments. To 
elucidate and investigate this further efferocytosis could have been 
determined in-vitro on monocyte-derived macrophages with different 
inflammatory stimuli and potential attenuating effects of vitamin D3 tested. 
 
In conclusion, this study has demonstrated for the first time that vitamin D3 
enhances macrophage efferocytosis in-vitro and in-vivo and is dependent on 
baseline vitamin D status. Vitamin D3 also increased the expression of 
markers of a pro-resolving phenotype on monocyte-derived macrophages. 
Further studies are required to confirm this and investigate the potential 
mechanistic pathways and whether vitamin D3 can modulate already 
differentiated alveolar macrophages to a pro-resolving phenotype. These 
results support and may go some way in explaining the reduced change in 
extravascular lung water seen post-oesophagectomy in the cholecalciferol 
arm of the VINDALOO Trial (chapter 5).   
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THESIS SUMMARY 
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7.1 OVERVIEW 
ARDS is a severe inflammatory condition that remains an important cause of 
respiratory failure and morbidity and mortality in the critically ill. The 
paucity of effective pharmacological therapies for ARDS combined with the 
public health impact make the development of effective therapies a major 
unmet health need. Identifying and treating modifiable pre-determinants of 
ARDS is a potential important strategy for the management of this condition.  
 
Vitamin D deficiency is common, is associated with sepsis and ARDS and 
replacement therapy cheap and easy. However, whether this association is 
causal is yet to be discerned. This thesis investigated three important 
questions related to the mechanistic relevance of vitamin D deficiency and its 
treatment on ARDS: 1] Does vitamin D deficiency exaggerate the 
inflammatory response and lung injury in a murine model of sepsis? 2] Can 
vitamin D replacement improve biomarkers and therefore prevent ARDS in a 
relevant human model? 3] Does vitamin D influence the innate immune 
response and resolution of neutrophilic injury? 
 
7.2 MURINE MODEL OF SEPSIS  
In this study of CLP induced polymicrobial sepsis, mice that were vitamin D3 
deficient pre-injury demonstrated an increase in bacterial load in the 
peritoneum with associated increased bacteraemia and bacterial 
translocation to the lung. We observed reduced levels of the murine 
cathelicidin antimicrobial peptide, CRAMP (in blood and alveolar 
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compartments) in vitamin D deficient mice that might explain the reduced 
bacterial load seen. This confirms findings of studies of other cell types and 
models of the role of vitamin D3 in modulating antimicrobial peptide release. 
However this is not reflected in our human study.   
 
Although the organisms grown in the bacterial cultures were not qualified, 
we have shown defective ex-vivo macrophage phagocytosis of E.Coli bacteria 
from vitamin D3 deficient mice. The effect of vitamin D3 on macrophage 
phagocytosis of mycobacteria has been established however; this is the first 
study to our knowledge to demonstrate this effect on E.Coli.  This may be due 
to reduced levels of cathelicidin, which has been shown to increase 
macrophage phagocytosis of pseudomonas294 and mycobacterium238 or 
secondary to suppressed macrophage TLR and PRR responses to bacterial 
challenge.154  
 
We have also demonstrated an increased number of apoptotic neutrophils in 
vitamin D deficient peritoneal lining fluid, suggesting defective clearance by 
macrophages, termed efferocytosis or increased neutrophil apoptosis. 
Prolonged presence of apoptotic neutrophils can perpetuate inflammation 
due to secondary necrosis and further release of pro-inflammatory cytokines 
that then cause further damage of the surrounding epithelial-endothelial 
barrier and organ dysfunction. Furthermore vitamin D3 deficient mice had 
increased protein permeability in bronchoalveolar and peritoneal lavage 
fluid, suggesting defective barrier integrity of the epithelial-endothelial 
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membrane, which may also account for the increased bacterial translocation 
seen in the vascular and alveolar compartments.  Surprisingly we did not 
observe an exaggerated pro-inflammatory cytokine response in vitamin D3 
deficient mice suggesting that vitamin D3 effects are primarily driven by its 
action on cellular and barrier function. 
 
Although there was evidence of early alveolar capillary leak, this was small 
and we can confirm that this model of murine sepsis at this time point does 
not induce the pathophysiological changes of ARDS and cannot be 
recommended for future studies of the condition. It is however a good model 
of early sepsis and maybe useful in ARDS studies if used in conjunction with 
secondary injurious models such as an intra-tracheal acid/LPS 
challenge/pneumonia.  
 
Since the mice were deficient in vitamin D3 prior to the initiation of sepsis our 
findings add strength to the argument that vitamin D3 is causal rather than an 
effect of sepsis or critical illness that has been suggested by observational 
studies to date. These experiments also support the hypothesis that vitamin 
D deficiency is a mechanistic driver of sepsis and inflammation by decreasing 
cellular macrophage phagocytosis and barrier integrity and the need for 
more translational studies and a clinical trial of vitamin D treatment in sepsis. 
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7.3 VITAMIN D TO PREVENT ACUTE LUNG INJURY TRIAL 
This study investigated the hypothesis that a single high-dose of oral 
cholecalciferol (vitamin D3) pre-operatively would prevent the increase seen 
in extravascular lung water post-oesophagectomy. The secondary aim was to 
evaluate the effect of cholecalciferol on other biomarkers of lung injury, 
clinical outcomes and vitamin D status (circulating concentrations of 
25(OH)D3, and 1,25(OH2)D. 
 
The randomised placebo controlled trial demonstrated that patients treated 
with cholecalciferol had significantly lower increases in EVLWI post-
oesophagectomy. This occurred in parallel with a reduced increase in PVPI, a 
marker of alveolar epithelial capillary leak. Increases in EVLWI and PVPI 
were more pronounced if post-treatment 25(OH)D3 concentration, irrelevant 
of study arm was <50nmol/L. This is a level that is widely regarded as being 
the cut-off for deficiency and may represent a threshold level of benefit.   
Treatment with cholecalciferol conferred no benefit on clinical outcomes and 
incidence of ARDS, however this trial was not powered to investigate these 
outcomes. This study did not show a convincing effect on pro-inflammatory 
cytokine response which supports our finding of no difference in pro-
inflammatory cytokines between vitamin D3 deficiency and sufficiency in the 
murine sepsis model.  
 
This trial provides the first proof of concept that in humans at risk of ARDS 
secondary to oesophagectomy preoperative treatment with cholecalciferol 
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successfully replenishes 25(OH)D3 to sufficient concentrations and reduces 
biomarkers of alveolar epithelial injury. This adds support for the need for a 
large multi-centre trial powered to investigate patient clinical outcomes.  
 
The level of vitamin D3 deficiency, incidence of ARDS and magnitude of 
increases in EVLWI in the current study were much lower than our previous 
cohorts. This may in part reflect improved nutrition pre-operatively and 
better perioperative surgical and anaesthetic management.  This makes the 
feasibility of further studies in this model more complex and has already 
informed the design of follow-on studies of statin therapy in this patient 
group (Dr Murali Shyamsundar, Queen’s University Belfast). Despite this it 
does prove the mechanistic importance of vitamin D sufficiency in protecting 
the alveolar epithelial barrier from injury and could be translated to a 
treatment trial in ARDS or prevention trial in groups at risk of ARDS in whom 
vitamin D3 status could be measured rapidly to identify deficiency and hence 
most likely to benefit from treatment. 
  
Finally we can confirm that a high dose of 300,000IU cholecalciferol can 
successfully replenish 25(OH)D3 concentration to levels deemed sufficient 
and that this correlates with an increase in the active 1,25(OH2)D3 metabolite.  
However there is a drop in these levels post-operatively by day 3 and 
suggests that future replacement trials should investigate whether a regular 
interval-dosing regime has greater clinical efficacy. 
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7.4 IN-VITRO AND IN-VIVO MACROPHAGE STUDIES 
Clearance of apoptotic neutrophils is an important macrophage function in 
the resolution of inflammation. We have for the first time demonstrated in-
vitro increased efferocytosis of primary human alveolar macrophages in 
response to incubation with 25(OH)D3 and 1,25(OH2)D3.  Interestingly basal 
state efferocytosis and response to vitamin D3 stimulation is heterogeneous 
and may reflect the vitamin D status of the donors of the cells or genetic 
polymorphisms in the VDR and regulating enzymes of the vitamin D pathway.  
We have confirmed that BALF from patients with ARDS suppresses 
efferocytosis and shown that treatment with 25(OH)D3 can attenuate this 
effect suggesting a possible mechanistic role for vitamin D3 in the resolution 
of inflammation in ARDS. HMGB-1 has been found to be present in ARDS 
BALF and is released from activated macrophages and necrotic cells.  This 
study confirms HMGB-1 dose-dependent decreased efferocytosis in-vitro that 
is not rescued by 25(OH)D3. Therefore it is likely that 25(OH)D3 increases 
efferocytosis by means of other pathways that need further elucidating.  In 
support of the findings of increased efferocytosis we have shown for the first 
time that 25(OH)D3 increases the expression of  M2 pro-resolution phenotype 
surface markers on peripheral blood monocyte differentiated  macrophages 
in-vitro. 
 
In parallel to the randomised control trial, the in-vivo effect of cholecalciferol 
(vitamin D3) on alveolar macrophage efferocytosis was assessed.  No 
difference was seen in efferocytosis between placebo and cholecalciferol 
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treated groups, however patients who were deficient (<50nmol/L) 
irrespective of treatment arm had lower efferocytosis. This is supported by 
the finding of a positive correlation between 25(OH)D3 plasma concentration 
and alveolar macrophage efferocytosis. This also complements the finding of 
increased EVLWI and PVPI in patients who remained deficient post 
treatment and suggests that pre-insult vitamin D3 deficiency confers an 
increased risk of exaggerated injury and dampened macrophage resolution of 
neutrophilic injury. Future studies therefore need to be able to identify 
deficiency prior to treatment, as these patients are most likely to benefit. 
Finally a similar effect was not seen on monocyte efferocytosis suggesting 
that the effects of vitamin D3 may require cellular differentiation in the 
presence of sufficient levels of vitamin D3 
  
7.5 THESIS LIMITATIONS 
The work presented in this thesis had a number of limitations that are 
summarised below. 
 
Due to the severity of the model and local and UK regulations, a major 
limitation of the murine study was that we were unable to extend the time-
point post CLP to induce sufficient lung injury. At 24 hours mice were too 
unwell and therefore we had to reduce this to 16 hours and therefore we did 
not observe significant cell recruitment and neutrophilic alveolitis. Lung 
histology and markers of endothelial damage may have provided evidence of 
early lung injury. Furthermore although we have shown the effects of vitamin 
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D3 deficiency in a murine model of sepsis and potential mechanisms this 
needs to be confirmed in other sepsis and murine models. Finally pre-injury 
replacement of vitamin D3 would have provided much more strength to the 
evidence and argument of its potential functional importance in preventing 
sepsis.  
 
The clinical trial was limited by the fact that the baseline vitamin D3 
deficiency of the patient cohort, magnitude of changes in EVLWI and 
incidence of ARDS were much lower than the cohort that this study was 
powered on and designed. A major weakness of the study is that lung water 
measurements were only carried out until post-operative day 1 and may 
have missed patients developing ARDS beyond this time-point.  This study 
was a phase II biomarker study and therefore although provides proof of 
concept and mechanistic insights needs validation in other models and a 
large clinical trial of prevention and treatment of ARDS.  
 
The macrophage cells studies are limited by the fact that donor vitamin D 
levels were unknown and may have influenced the efferocytosis responses 
seen. This should be tested in further studies. Furthermore despite the in-vivo 
assays being blinded the in-vitro studies were not blinded.  
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7.6 FUTURE RESEARCH 
The work presented in this thesis provides evidence and a compelling 
argument for the role of vitamin D deficiency in promoting exaggerated 
responses to sepsis and acute inflammation and the potential beneficial 
effects of replacing vitamin D3 but requires more work to determine 
mechanistic pathways, cellular responses to vitamin D3 and determine 
clinical efficacy in disease: 
1] Murine treatment studies are required in valid models of sepsis. 
Combining a 2 hit model of CLP and intra-tracheal pneumonia may better 
serve to model all the elements of ARDS and sepsis. Assessing physiological 
measures of injury (e.g. oxygen saturations, lactate) may be beneficial and 
more translatable.  
2] A dosing study in sepsis and ARDS is required to assess the optimal 
dosing and maintenance strategy in this critically ill population as vitamin D3 
concentrations have been shown to drop on admission to critical care and 
confirmed in our oesophagectomy population. 
3] Genetic studies of the variable responses to treatment and 
replacement are required as there may be some patients who are more likely 
to benefit over others.  
4]  Measuring vitamin D3 status takes at least a few days and developing 
a bedside test may be useful to determine at the point of admission to 
hospital patients that may benefit from treatment as this may only be 
beneficial in patients who are deficient below a threshold. 
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5] More studies are required to ascertain the ‘sufficient’ level that 
confers a cellular benefit as this may reflect why some vitamin D3 
replacement trials have proven negative.  
6] A large clinical trial with relevant clinical outcome measures is 
required in both ARDS and sepsis. 
7]  More mechanistic studies are required to determine the and pathways 
of increased efferocytosis and to determine if the pro-resolution phenotype 
seen in monocyte derived macrophages confers a functional benefit.  
 
7.7 CONCLUSIONS 
In conclusion, the studies presented in this thesis aimed to elucidate if 
vitamin D deficiency is a mechanistic driver of ARDS and if treatment with 
vitamin D3 may protect against exaggerated inflammation and promote its 
resolution. Using murine and human models complemented with in-vitro 
cellular studies it has been demonstrated that vitamin D deficiency promotes 
defective resolution of infection and inflammation and treatment protects 
lung barrier integrity and improves cellular resolution of neutrophilic injury. 
It is hoped that the results from these studies will add credence to the 
argument that vitamin D deficiency is not simply a consequence of critical 
illness but a mechanistic driver of inflammation, and lead to large clinical 
trials in ARDS and sepsis that may lead to a simple, cheap and safe treatment.  
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AECC  American European consensus conference (on ARDS) 
ALI  Acute lung injury 
AM  Alveolar macrophage 
ANOVA One-way analysis of variance  
APACHE Acute Physiology and Chronic Health Evaluation 
APC  Allophycocyanin 
ARDS  Acute respiratory distress syndrome  
BALF  Broncho-alveolar lavage fluid 
BALTI  Beta-Agonist Lung Injury Trial 
BMI   Body mass index 
BSA  Bovine serum albumin 
CI  Cardiac index 
CFU  Colony forming unit 
CLP  Caecal ligation and puncture 
CO   Cardiac output 
COPD  Chronic obstructive pulmonary disease 
CO2  Carbon dioxide 
CPAP   Continuous positive airway pressure 
CRAMP Cathelicidin related antimicrobial peptide  
CRP   C-reactive protein 
CV   Coefficient of variation 
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CXR  Chest radiograph 
Cy7  Cyanine 
DAMPs Danger-associated molecular patterns 
DBP  Vitamin D binding protein 
DNA  Deoxyribose nucleic acid 
E%  Efferocytosis percentage 
ECMO  Extracorporeal membrane oxygenation 
E.Coli  Escherichia Coliform 
EDTA  Ethylenediaminetetraacetic acid 
EIA  Enzyme immunoassay 
ELISA  Enzyme linked immunosorbent assay 
EVLW   Extra vascular lung water 
EVLWI  Extra vascular lung water index 
FBS  Foetal bovine serum 
FEV1   Forced expiratory volume in one second 
FiO2  Fraction of inspired oxygen  
FiTC  Fluorescein Isothiocyanate  
FVC   Forced vital capacity   
GM-CSF  Granulocyte macrophage colony- stimulating factor 
GEDI   Global end diastolic index 
GEDV   Global end diastolic volume 
HFOV  High Frequency Oscillation Ventilation 
HMGB-1 High mobility group box protein-1 
HRP  Horse radish peroxidase 
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HRQOL Health related quality of life 
ICAM  Intercellular adhesion molecule 
ICU  Intensive care unit 
IFN   Interferon  
IL   Interleukin 
iNOS  Inducible nitric oxide synthase 
IQR   Interquartile range 
ITBV   Intra thoracic blood volume 
ITTV   Intra thoracic thermal volume 
LIPS  Lung injury prevention score 
LOS   Length of stay 
LPS   Lipopolysaccharide 
MAP   Mean arterial pressure 
M-CSF  Macrophage colony-stimulating factor  
MDM  Monocyte derived macrophage 
MFI  Mean fluorescent index 
MIP  Macrophage inflammatory protein 
MLTC  Midlands lung tissue collaborative 
MMP  Matrix metallopeptidase 
MNC  Mononuclear cells 
MPO   Myeloperoxidase 
n   Number 
NF-  Nuclear factor-kappa beta 
NLR  NOD-like recptor 
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OD   Optical density 
OLV   One lung ventilation 
OR   Odds ratio 
PAF  Platelet activating factor 
PAMPs Pathogen-associated molecular patterns 
PAOP  Pulmonary artery occlusion pressure 
PaO2  Arterial oxygen pressure 
PBS  Phosphate buffered saline 
PBV   Pulmonary blood volume 
PCR  Polymerase chain reaction 
PE  Phycoerythrin 
PEEP  Positive end-expiratory pressure 
P:F ratio Ratio of plasma oxygen pressure to inspired oxygen pressure 
PiCCO2  Pulse contour continuous cardiac output 2 
PLF  Peritoneal lavage fluid 
PMN  Polymorphic neutrophil 
PRR  Pattern recognition receptor 
PTV  Pulmonary thermal volume 
PBV  Pulmonary blood volume 
PVPI   Pulmonary vascular permeability index 
ROS  Reactive oxygen species 
RAGE  Receptor for advanced glycation end products 
RPMI  Roswell Park Memorial Institute (cell culture media)  
rpm   Rotations per minute 
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RR   Relative risk 
RXR  Retinoid X receptor 
SD   Standard deviation 
SOFA  Sequential organ system failure assessment 
TNB  Tetramethylbenzidine 
TLR   Toll like receptor 
TNFR  Tumour necrosis factor receptor 
TNF-  Tumor necrosis factor alpha
UK   United Kingdom 
USA   United States of America 
UTC  Untreated control 
VDD  Vitamin D deficient 
VDS  Vitamin D sufficient 
VDR  Vitamin D receptor 
VDRE  Vitamin D response elements 
VEGF  Vascular endothelial growth factor 
VFD  Ventilator free day 
VILI  Ventilator induced lung injury 
VINDALOO Vitamin D to prevent acute lung injury post oesophagectomy 
VT  Tidal volume 
vWF   von Willebrand factor 
WT  Wild-type 
 
 
213 
 
  
CHAPTER 9                                                           
REFERENCES 
214 
 
1. Ware LB, Matthay MA. The acute respiratory distress syndrome. N 
Engl J Med 2000;342:1334-49. 
2. Herridge MS, Tansey CM, Matte A, et al. Functional disability 5 years 
after acute respiratory distress syndrome. The New England journal of 
medicine 2011;364:1293-304. 
3. Rubenfeld GD, Herridge MS. Epidemiology and outcomes of acute lung 
injury. Chest 2007;131:554-62. 
4. Ventilation with lower tidal volumes as compared with traditional 
tidal volumes for acute lung injury and the acute respiratory distress 
syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 
2000;342:1301-8. 
5. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory 
distress in adults. Lancet 1967;2:319-23. 
6. Parekh D, Dancer RC, Thickett DR. Acute lung injury. Clinical medicine 
2011;11:615-8. 
7. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of 
the adult respiratory distress syndrome. Am Rev Respir Dis 1988;138:720-3. 
8. Bernard GR, Artigas A, Brigham KL, et al. The American-European 
Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, 
and clinical trial coordination. American journal of respiratory and critical 
care medicine 1994;149:818-24. 
9. Esteban A, Fernández-Segoviano P, Frutos-Vivar F, et al. Comparison 
of clinical criteria for the acute respiratory distress syndrome with autopsy 
findings. Ann Intern Med 2004;141:440-5. 
10. Villar J, Kacmarek RM. Positive end-expiratory pressure after 
uncomplicated coronary artery bypass grafting: a two-edge sword. Minerva 
Anestesiol 2012;78:743-5. 
11. Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory 
distress syndrome: the Berlin Definition. JAMA : the journal of the American 
Medical Association 2012;307:2526-33. 
215 
 
12. Nunes S, Ruokonen E, Takala J. Pulmonary capillary pressures during 
the acute respiratory distress syndrome. Intensive Care Med 2003;29:2174-
9. 
13. Ferguson ND, Meade MO, Hallett DC, Stewart TE. High values of the 
pulmonary artery wedge pressure in patients with acute lung injury and 
acute respiratory distress syndrome. Intensive Care Med 2002;28:1073-7. 
14. Thille AW, Esteban A, Fernández-Segoviano P, et al. Comparison of the 
Berlin definition for acute respiratory distress syndrome with autopsy. Am J 
Respir Crit Care Med 2013;187:761-7. 
15. Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress 
syndrome. J Clin Invest 2012;122:2731-40. 
16. Lewandowski K, Lewandowski M. Epidemiology of ARDS. Minerva 
Anestesiol 2006;72:473-7. 
17. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of 
acute lung injury. N Engl J Med 2005;353:1685-93. 
18. Valta P, Uusaro A, Nunes S, Ruokonen E, Takala J. Acute respiratory 
distress syndrome: frequency, clinical course, and costs of care. Crit Care Med 
1999;27:2367-74. 
19. Luhr OR, Antonsen K, Karlsson M, et al. Incidence and mortality after 
acute respiratory failure and acute respiratory distress syndrome in Sweden, 
Denmark, and Iceland. The ARF Study Group. Am J Respir Crit Care Med 
1999;159:1849-61. 
20. Villar J, Blanco J, Añón JM, et al. The ALIEN study: incidence and 
outcome of acute respiratory distress syndrome in the era of lung protective 
ventilation. Intensive Care Med 2011;37:1932-41. 
21. Sigurdsson MI, Sigvaldason K, Gunnarsson TS, Moller A, Sigurdsson 
GH. Acute respiratory distress syndrome: nationwide changes in incidence, 
treatment and mortality over 23 years. Acta Anaesthesiol Scand 2013;57:37-
45. 
216 
 
22. Phua J, Badia JR, Adhikari NK, et al. Has mortality from acute 
respiratory distress syndrome decreased over time?: A systematic review. 
Am J Respir Crit Care Med 2009;179:220-7. 
23. Matthay MA, Brower RG, Carson S, et al. Randomized, placebo-
controlled clinical trial of an aerosolized beta(2)-agonist for treatment of 
acute lung injury. Am J Respir Crit Care Med 2011;184:561-8. 
24. Gao Smith F, Perkins GD, Gates S, et al. Effect of intravenous beta-2 
agonist treatment on clinical outcomes in acute respiratory distress 
syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet 
2012;379:229-35. 
25. Erickson SE, Martin GS, Davis JL, Matthay MA, Eisner MD. Recent 
trends in acute lung injury mortality: 1996-2005. Critical care medicine 
2009;37:1574-9. 
26. Spragg RG, Bernard GR, Checkley W, et al. Beyond mortality: future 
clinical research in acute lung injury. Am J Respir Crit Care Med 
2010;181:1121-7. 
27. Amato MB, Barbas CS, Medeiros DM, et al. Effect of a protective-
ventilation strategy on mortality in the acute respiratory distress syndrome. 
The New England journal of medicine 1998;338:347-54. 
28. Villar J, Kacmarek RM, Pérez-Méndez L, Aguirre-Jaime A. A high 
positive end-expiratory pressure, low tidal volume ventilatory strategy 
improves outcome in persistent acute respiratory distress syndrome: a 
randomized, controlled trial. Crit Care Med 2006;34:1311-8. 
29. Wiedemann HP, Wheeler AP, Bernard GR, et al. Comparison of two 
fluid-management strategies in acute lung injury. N Engl J Med 
2006;354:2564-75. 
30. Toy P, Gajic O, Bacchetti P, et al. Transfusion-related acute lung injury: 
incidence and risk factors. Blood 2012;119:1757-67. 
31. Brun-Buisson C, Minelli C, Bertolini G, et al. Epidemiology and 
outcome of acute lung injury in European intensive care units. Results from 
the ALIVE study. Intensive care medicine 2004;30:51-61. 
217 
 
32. Nuckton TJ, Alonso JA, Kallet RH, et al. Pulmonary dead-space fraction 
as a risk factor for death in the acute respiratory distress syndrome. N Engl J 
Med 2002;346:1281-6. 
33. Zilberberg MD, Epstein SK. Acute lung injury in the medical ICU: 
comorbid conditions, age, etiology, and hospital outcome. Am J Respir Crit 
Care Med 1998;157:1159-64. 
34. Cooke CR, Kahn JM, Caldwell E, et al. Predictors of hospital mortality in 
a population-based cohort of patients with acute lung injury. Crit Care Med 
2008;36:1412-20. 
35. Brown LM, Calfee CS, Matthay MA, Brower RG, Thompson BT, 
Checkley W. A simple classification model for hospital mortality in patients 
with acute lung injury managed with lung protective ventilation. Critical care 
medicine 2011;39:2645-51. 
36. Davidson TA, Caldwell ES, Curtis JR, Hudson LD, Steinberg KP. 
Reduced quality of life in survivors of acute respiratory distress syndrome 
compared with critically ill control patients. JAMA 1999;281:354-60. 
37. Fan E, Dowdy DW, Colantuoni E, et al. Physical complications in acute 
lung injury survivors: a two-year longitudinal prospective study. Crit Care 
Med 2014;42:849-59. 
38. Gao L, Barnes KC. Recent advances in genetic predisposition to clinical 
acute lung injury. Am J Physiol Lung Cell Mol Physiol 2009;296:L713-25. 
39. Calfee CS, Matthay MA, Eisner MD, et al. Active and passive cigarette 
smoking and acute lung injury after severe blunt trauma. American journal of 
respiratory and critical care medicine 2011;183:1660-5. 
40. Moss M, Bucher B, Moore FA, Moore EE, Parsons PE. The role of 
chronic alcohol abuse in the development of acute respiratory distress 
syndrome in adults. JAMA 1996;275:50-4. 
41. Quartin AA, Campos MA, Maldonado DA, Ashkin D, Cely CM, Schein 
RM. Acute lung injury outside of the ICU: incidence in respiratory isolation on 
a general ward. Chest 2009;135:261-8. 
218 
 
42. Levitt JE, Bedi H, Calfee CS, Gould MK, Matthay MA. Identification of 
early acute lung injury at initial evaluation in an acute care setting prior to 
the onset of respiratory failure. Chest 2009;135:936-43. 
43. Gajic O, Dabbagh O, Park PK, et al. Early identification of patients at 
risk of acute lung injury: evaluation of lung injury prediction score in a 
multicenter cohort study. Am J Respir Crit Care Med 2011;183:462-70. 
44. Kor DJ, Talmor DS, Banner-Goodspeed VM, et al. Lung Injury 
Prevention with Aspirin (LIPS-A): a protocol for a multicentre randomised 
clinical trial in medical patients at high risk of acute lung injury. BMJ Open 
2012;2. 
45. Peter JV, John P, Graham PL, Moran JL, George IA, Bersten A. 
Corticosteroids in the prevention and treatment of acute respiratory distress 
syndrome (ARDS) in adults: meta-analysis. Bmj 2008;336:1006-9. 
46. Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of 
corticosteroids for persistent acute respiratory distress syndrome. N Engl J 
Med 2006;354:1671-84. 
47. Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in 
early severe ARDS: results of a randomized controlled trial. Chest 
2007;131:954-63. 
48. Boyle AJ, Mac Sweeney R, McAuley DF. Pharmacological treatments in 
ARDS; a state-of-the-art update. BMC Med 2013;11:166. 
49. Bassford CR, Thickett DR, Perkins GD. The rise and fall of beta-
agonists in the treatment of ARDS. Crit Care 2012;16:208. 
50. Perkins GD, McAuley DF, Thickett DR, Gao F. The beta-agonist lung 
injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J 
Respir Crit Care Med 2006;173:281-7. 
51. Perkins GD, Gates S, Park D, et al. The Beta Agonist Lung Injury Trial 
(BALTI) Prevention: A Randomized Controlled Trial. American journal of 
respiratory and critical care medicine 2014. 
219 
 
52. Williams JG, Maier RV. Ketoconazole inhibits alveolar macrophage 
production of inflammatory mediators involved in acute lung injury (adult 
respiratory distress syndrome). Surgery 1992;112:270-7. 
53. Ketoconazole for early treatment of acute lung injury and acute 
respiratory distress syndrome: a randomized controlled trial. The ARDS 
Network. Jama 2000;283:1995-2002. 
54. Grommes J, Soehnlein O. Contribution of neutrophils to acute lung 
injury. Molecular medicine 2011;17:293-307. 
55. Kawabata K, Hagio T, Matsuoka S. The role of neutrophil elastase in 
acute lung injury. Eur J Pharmacol 2002;451:1-10. 
56. Zeiher BG, Artigas A, Vincent JL, et al. Neutrophil elastase inhibition in 
acute lung injury: results of the STRIVE study. Crit Care Med 2004;32:1695-
702. 
57. Iwata K, Doi A, Ohji G, et al. Effect of neutrophil elastase inhibitor 
(sivelestat sodium) in the treatment of acute lung injury (ALI) and acute 
respiratory distress syndrome (ARDS): a systematic review and meta-
analysis. Intern Med 2010;49:2423-32. 
58. Bursten SL, Federighi D, Wald J, Meengs B, Spickler W, Nudelman E. 
Lisofylline causes rapid and prolonged suppression of serum levels of free 
fatty acids. J Pharmacol Exp Ther 1998;284:337-45. 
59. Randomized, placebo-controlled trial of lisofylline for early treatment 
of acute lung injury and acute respiratory distress syndrome. Crit Care Med 
2002;30:1-6. 
60. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins 
and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 
2007;7:358-68. 
61. Craig TR, Duffy MJ, Shyamsundar M, et al. A randomized clinical trial of 
hydroxymethylglutaryl- coenzyme a reductase inhibition for acute lung 
injury (The HARP Study). American journal of respiratory and critical care 
medicine 2011;183:620-6. 
220 
 
62. McAuley DF, Laffey JG, O'Kane CM, et al. Simvastatin in the acute 
respiratory distress syndrome. N Engl J Med 2014;371:1695-703. 
63. Truwit JD, Bernard GR, Steingrub J, et al. Rosuvastatin for sepsis-
associated acute respiratory distress syndrome. N Engl J Med 
2014;370:2191-200. 
64. Zarbock A, Ley K. The role of platelets in acute lung injury (ALI). Front 
Biosci (Landmark Ed) 2009;14:150-8. 
65. Erlich JM, Talmor DS, Cartin-Ceba R, Gajic O, Kor DJ. Prehospitalization 
antiplatelet therapy is associated with a reduced incidence of acute lung 
injury: a population-based cohort study. Chest 2011;139:289-95. 
66. Kor DJ, Erlich J, Gong MN, et al. Association of prehospitalization 
aspirin therapy and acute lung injury: results of a multicenter international 
observational study of at-risk patients. Crit Care Med 2011;39:2393-400. 
67. Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early 
acute respiratory distress syndrome. N Engl J Med 2010;363:1107-16. 
68. Cross LJ, O'Kane CM, McDowell C, Elborn JJ, Matthay MA, McAuley DF. 
Keratinocyte growth factor in acute lung injury to reduce pulmonary 
dysfunction--a randomised placebo-controlled trial (KARE): study protocol. 
Trials 2013;14:51. 
69. Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem (stromal) cells for 
treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 2015;3:24-32. 
70. Bellingan G, Maksimow M, Howell DC, et al. The effect of intravenous 
interferon-beta-1a (FP-1201) on lung CD73 expression and on acute 
respiratory distress syndrome mortality: an open-label study. Lancet Respir 
Med 2014;2:98-107. 
71. Gajic O, Frutos-Vivar F, Esteban A, Hubmayr RD, Anzueto A. Ventilator 
settings as a risk factor for acute respiratory distress syndrome in 
mechanically ventilated patients. Intensive Care Med 2005;31:922-6. 
221 
 
72. Wrigge H, Uhlig U, Zinserling J, et al. The effects of different ventilatory 
settings on pulmonary and systemic inflammatory responses during major 
surgery. Anesth Analg 2004;98:775-81, table of contents. 
73. Hager DN, Krishnan JA, Hayden DL, Brower RG. Tidal volume 
reduction in patients with acute lung injury when plateau pressures are not 
high. Am J Respir Crit Care Med 2005;172:1241-5. 
74. Serpa Neto A, Cardoso SO, Manetta JA, et al. Association between use 
of lung-protective ventilation with lower tidal volumes and clinical outcomes 
among patients without acute respiratory distress syndrome: a meta-
analysis. Jama 2012;308:1651-9. 
75. Lellouche F, Dionne S, Simard S, Bussieres J, Dagenais F. High tidal 
volumes in mechanically ventilated patients increase organ dysfunction after 
cardiac surgery. Anesthesiology 2012;116:1072-82. 
76. Fernandez-Perez ER, Keegan MT, Brown DR, Hubmayr RD, Gajic O. 
Intraoperative tidal volume as a risk factor for respiratory failure after 
pneumonectomy. Anesthesiology 2006;105:14-8. 
77. Futier E, Constantin JM, Paugam-Burtz C, et al. A trial of intraoperative 
low-tidal-volume ventilation in abdominal surgery. N Engl J Med 
2013;369:428-37. 
78. Peek GJ, Mugford M, Tiruvoipati R, et al. Efficacy and economic 
assessment of conventional ventilatory support versus extracorporeal 
membrane oxygenation for severe adult respiratory failure (CESAR): a 
multicentre randomised controlled trial. Lancet 2009;374:1351-63. 
79. Briel M, Meade M, Mercat A, et al. Higher vs lower positive end-
expiratory pressure in patients with acute lung injury and acute respiratory 
distress syndrome: systematic review and meta-analysis. JAMA 
2010;303:865-73. 
80. Sud S, Sud M, Friedrich JO, et al. High frequency oscillation in patients 
with acute lung injury and acute respiratory distress syndrome (ARDS): 
systematic review and meta-analysis. BMJ 2010;340:c2327. 
81. Ferguson ND, Cook DJ, Guyatt GH, et al. High-frequency oscillation in 
early acute respiratory distress syndrome. N Engl J Med 2013;368:795-805. 
222 
 
82. Young D. High-frequency oscillation for ARDS. N Engl J Med 
2013;368:2234. 
83. Guérin C, Reignier J, Richard JC, et al. Prone positioning in severe acute 
respiratory distress syndrome. N Engl J Med 2013;368:2159-68. 
84. Wheeler AP, Bernard GR, Thompson BT, et al. Pulmonary-artery 
versus central venous catheter to guide treatment of acute lung injury. N Engl 
J Med 2006;354:2213-24. 
85. Parekh D, Thickett DR, Turner AM. Vitamin D deficiency and acute 
lung injury. Inflamm Allergy Drug Targets 2013;12:253-61. 
86. Tomashefski JF. Pulmonary pathology of acute respiratory distress 
syndrome. Clin Chest Med 2000;21:435-66. 
87. Craig TR, Duffy MJ, Shyamsundar M, et al. Extravascular lung water 
indexed to predicted body weight is a novel predictor of intensive care unit 
mortality in patients with acute lung injury. Crit Care Med 2010;38:114-20. 
88. Berkowitz DM, Danai PA, Eaton S, Moss M, Martin GS. Accurate 
characterization of extravascular lung water in acute respiratory distress 
syndrome. Crit Care Med 2008;36:1803-9. 
89. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation 
and polarization. Frontiers in bioscience : a journal and virtual library 
2008;13:453-61. 
90. Herold S, Mayer K, Lohmeyer J. Acute lung injury: how macrophages 
orchestrate resolution of inflammation and tissue repair. Front Immunol 
2011;2:65. 
91. Laskin DL, Sunil VR, Gardner CR, Laskin JD. Macrophages and tissue 
injury: agents of defense or destruction? Annu Rev Pharmacol Toxicol 
2011;51:267-88. 
92. D'Alessio FR, Tsushima K, Aggarwal NR, et al. CD4+CD25+Foxp3+ 
Tregs resolve experimental lung injury in mice and are present in humans 
with acute lung injury. The Journal of clinical investigation 2009;119:2898-
913. 
223 
 
93. Schwartz MD, Moore EE, Moore FA, et al. Nuclear factor-kappa B is 
activated in alveolar macrophages from patients with acute respiratory 
distress syndrome. Crit Care Med 1996;24:1285-92. 
94. Moine P, McIntyre R, Schwartz MD, et al. NF-kappaB regulatory 
mechanisms in alveolar macrophages from patients with acute respiratory 
distress syndrome. Shock 2000;13:85-91. 
95. Haslett C. Granulocyte apoptosis and its role in the resolution and 
control of lung inflammation. Am J Respir Crit Care Med 1999;160:S5-11. 
96. Kono H, Rock KL. How dying cells alert the immune system to danger. 
Nat Rev Immunol 2008;8:279-89. 
97. Fialkow L, Fochesatto Filho L, Bozzetti MC, et al. Neutrophil apoptosis: 
a marker of disease severity in sepsis and sepsis-induced acute respiratory 
distress syndrome. Crit Care 2006;10:R155. 
98. Chopra M, Reuben JS, Sharma AC. Acute lung injury:apoptosis and 
signaling mechanisms. Exp Biol Med (Maywood) 2009;234:361-71. 
99. Cox G, Crossley J, Xing Z. Macrophage engulfment of apoptotic 
neutrophils contributes to the resolution of acute pulmonary inflammation in 
vivo. Am J Respir Cell Mol Biol 1995;12:232-7. 
100. Matute-Bello G, Frevert CW, Martin TR. Animal models of acute lung 
injury. Am J Physiol Lung Cell Mol Physiol 2008;295:L379-99. 
101. Proudfoot AG, McAuley DF, Griffiths MJ, Hind M. Human models of 
acute lung injury. Dis Model Mech 2011;4:145-53. 
102. Tandon S, Batchelor A, Bullock R, et al. Peri-operative risk factors for 
acute lung injury after elective oesophagectomy. Br J Anaesth 2001;86:633-8. 
103. Schilling M, Gassmann N, Sigurdsson G, et al. Role of thromboxane and 
leukotriene B4 in patients with acute respiratory distress syndrome after 
oesophagectomy. Br J Anaesth 1998;80:36-40. 
224 
 
104. Schilling M, Eichenberger M, Maurer C, Sigurdsson G, Büchler M. 
Ketoconazole and pulmonary failure after esophagectomy: a prospective 
clinical trial. Dis Esophagus 2001;14:37-40. 
105. Park DP, Welch CA, Harrison DA, et al. Outcomes following 
oesophagectomy in patients with oesophageal cancer: a secondary analysis of 
the ICNARC Case Mix Programme Database. Crit Care 2009;13 Suppl 2:S1. 
106. Paul DJ, Jamieson GG, Watson DI, Devitt PG, Game PA. Perioperative 
risk analysis for acute respiratory distress syndrome after elective 
oesophagectomy. ANZ J Surg 2011;81:700-6. 
107. Kuwano H, Sumiyoshi K, Sonoda K, et al. Relationship between 
preoperative assessment of organ function and postoperative morbidity in 
patients with oesophageal cancer. Eur J Surg 1998;164:581-6. 
108. Ferguson M, Durkin A. Preoperative prediction of the risk of 
pulmonary complications after esophagectomy for cancer. J Thorac 
Cardiovasc Surg 2002;123:661-9. 
109. Law S, Wong K, Kwok K, Chu K, Wong J. Predictive factors for 
postoperative pulmonary complications and mortality after esophagectomy 
for cancer. Ann Surg 2004;240:791-800. 
110. Sato N, Koeda K, Kimura Y, et al. Cytokine profile of serum and 
bronchoalveolar lavage fluids following thoracic esophageal cancer surgery. 
Eur Surg Res 2001;33:279-84. 
111. Okamura A, Takeuchi H, Matsuda S, et al. Factors affecting cytokine 
change after esophagectomy for esophageal cancer. Ann Surg Oncol 
2015;22:3130-5. 
112. Rocker GM, Wiseman MS, Pearson D, Shale DJ. Neutrophil 
degranulation and increased pulmonary capillary permeability following 
oesophagectomy: a model of early lung injury in man. Br J Surg 1988;75:883-
6. 
113. Perkins GD, Chatterjie S, McAuley DF, Gao F, Thickett DR. Role of 
nonbronchoscopic lavage for investigating alveolar inflammation and 
permeability in acute respiratory distress syndrome. Crit Care Med 
2006;34:57-64. 
225 
 
114. Perkins GD, McAuley DF, Thickett DR, Gao F. The beta-agonist lung 
injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J 
Respir Crit Care Med 2006;173:281-7. 
115. Baudouin S. Lung injury after thoracotomy. Br J Anaesth 2003;91:132-
42. 
116. Parekh D, Dancer RC, Lax S, et al. Vitamin D to prevent acute lung 
injury following oesophagectomy (VINDALOO): study protocol for a 
randomised placebo controlled trial. Trials 2013;14:100. 
117. Perkins GD, Park D, Alderson D, et al. The Beta Agonist Lung Injury 
TrIal (BALTI) - prevention trial protocol. Trials 2011;12:79. 
118. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81. 
119. Wood AM, Bassford C, Webster D, et al. Vitamin D-binding protein 
contributes to COPD by activation of alveolar macrophages. Thorax 
2011;66:205-10. 
120. Hewison M. An update on vitamin D and human immunity. Clinical 
endocrinology 2012;76:315-25. 
121. Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab 
2010;95:471-8. 
122. Chishimba L, Thickett DR, Stockley RA, Wood AM. The vitamin D axis 
in the lung: a key role for vitamin D-binding protein. Thorax 2010;65:456-62. 
123. Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake 
GW. Respiratory Epithelial Cells Convert Inactive Vitamin D to Its Active 
Form: Potential Effects on Host Defense. Journal of Immunology 
2008;181:7090-9. 
124. Adams JS, Sharma OP, Gacad MA, Singer FR. Metabolism of 25-
hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in 
sarcoidosis. J Clin Invest 1983;72:1856-60. 
226 
 
125. Chen S, Sims GP, Chen XX, Gu YY, Lipsky PE. Modulatory effects of 
1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 
2007;179:1634-47. 
126. Sigmundsdottir H, Pan J, Debes GF, et al. DCs metabolize sunlight-
induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine 
CCL27. Nat Immunol 2007;8:285-93. 
127. Hewison M. Vitamin D and the intracrinology of innate immunity. 
Molecular and cellular endocrinology 2010;321:103-11. 
128. Ginde AA, Liu MC, Camargo CA. Demographic differences and trends of 
vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med 
2009;169:626-32. 
129. Hyppönen E, Power C. Hypovitaminosis D in British adults at age 45 y: 
nationwide cohort study of dietary and lifestyle predictors. Am J Clin Nutr 
2007;85:860-8. 
130. Cannell JJ, Vieth R, Umhau JC, et al. Epidemic influenza and vitamin D. 
Epidemiol Infect 2006;134:1129-40. 
131. Muhe L, Lulseged S, Mason KE, Simoes EA. Case-control study of the 
role of nutritional rickets in the risk of developing pneumonia in Ethiopian 
children. Lancet 1997;349:1801-4. 
132. Coussens AK, Wilkinson RJ, Hanifa Y, et al. Vitamin D accelerates 
resolution of inflammatory responses during tuberculosis treatment. Proc 
Natl Acad Sci U S A 2012;109:15449-54. 
133. Finklea JD, Grossmann RE, Tangpricha V. Vitamin D and chronic lung 
disease: a review of molecular mechanisms and clinical studies. Adv Nutr 
2011;2:244-53. 
134. Lee P, Eisman JA, Center JR. Vitamin D deficiency in critically ill 
patients. N Engl J Med 2009;360:1912-4. 
135. Braun A, Chang D, Mahadevappa K, et al. Association of low serum 25-
hydroxyvitamin D levels and mortality in the critically ill. Crit Care Med 
2011;39:671-7. 
227 
 
136. Braun AB, Gibbons FK, Litonjua AA, Giovannucci E, Christopher KB. 
Low serum 25-hydroxyvitamin D at critical care initiation is associated with 
increased mortality. Crit Care Med 2012;40:63-72. 
137. Amrein K, Sourij H, Wagner G, et al. Short-term effects of high-dose 
oral vitamin D3 in critically ill vitamin D deficient patients: a randomized, 
double-blind, placebo-controlled pilot study. Crit Care 2011;15:R104. 
138. Clairmont A, Tessman D, Stock A, Nicolai S, Stahl W, Sies H. Induction 
of gap junctional intercellular communication by vitamin D in human skin 
fibroblasts is dependent on the nuclear Induction of gap junctional 
intercellular communication by vitamin D in human skin fibroblasts is 
dependent on the nuclear vitamin D receptor. Carcinogenesis 1996;17:1389-
91. 
139. Gniadecki R, Gajkowska B, Hansen M. 1,25-dihydroxyvitamin D3 
stimulates the assembly of adherens junctions in keratinocytes: involvement 
of protein kinase C. Endocrinology 1997;138:2241-8. 
140. Pálmer HG, González-Sancho JM, Espada J, et al. Vitamin D(3) 
promotes the differentiation of colon carcinoma cells by the induction of E-
cadherin and the inhibition of beta-catenin signaling. J Cell Biol 
2001;154:369-87. 
141. Kong J, Zhang Z, Musch MW, et al. Novel role of the vitamin D receptor 
in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol 
Gastrointest Liver Physiol 2008;294:G208-16. 
142. Chen SF. 1 alpha, 25-Dihydroxyvitamin D3 decreased ICAM-1 and 
ELAM-1 expressions on pulmonary microvascular endothelial cells and 
neutrophil motivation. J Steroid Biochem Mol Biol 1995;52:67-70. 
143. Hewison M. Vitamin D and the immune system: new perspectives on 
an old theme. Endocrinology and metabolism clinics of North America 
2010;39:365-79, table of contents. 
144. Wang TT, Nestel FP, Bourdeau V, et al. Cutting edge: 1,25-
dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene 
expression. J Immunol 2004;173:2909-12. 
228 
 
145. Zanetti M. Cathelicidins, multifunctional peptides of the innate 
immunity. J Leukoc Biol 2004;75:39-48. 
146. Hansdottir S, Monick MM, Lovan N, Powers L, Gerke A, Hunninghake 
GW. Vitamin D decreases respiratory syncytial virus induction of NF-kappaB-
linked chemokines and cytokines in airway epithelium while maintaining the 
antiviral state. J Immunol 2010;184:965-74. 
147. Fahy RJ, Wewers MD. Pulmonary defense and the human cathelicidin 
hCAP-18/LL-37. Immunol Res 2005;31:75-89. 
148. Shaykhiev R, Beisswenger C, Kandler K, et al. Human endogenous 
antibiotic LL-37 stimulates airway epithelial cell proliferation and wound 
closure. Am J Physiol Lung Cell Mol Physiol 2005;289:L842-8. 
149. Alalwani SM, Sierigk J, Herr C, et al. The antimicrobial peptide LL-37 
modulates the inflammatory and host defense response of human 
neutrophils. Eur J Immunol 2010;40:1118-26. 
150. Kreutz M, Andreesen R, Krause SW, Szabo A, Ritz E, Reichel H. 1,25-
dihydroxyvitamin D3 production and vitamin D3 receptor expression are 
developmentally regulated during differentiation of human monocytes into 
macrophages. Blood 1993;82:1300-7. 
151. Koeffler HP, Reichel H, Bishop JE, Norman AW. gamma-Interferon 
stimulates production of 1,25-dihydroxyvitamin D3 by normal human 
macrophages. Biochem Biophys Res Commun 1985;127:596-603. 
152. Cohen MS, Mesler DE, Snipes RG, Gray TK. 1,25-Dihydroxyvitamin D3 
activates secretion of hydrogen peroxide by human monocytes. J Immunol 
1986;136:1049-53. 
153. Sun J, Kong J, Duan Y, et al. Increased NF-kappaB activity in fibroblasts 
lacking the vitamin D receptor. Am J Physiol Endocrinol Metab 
2006;291:E315-22. 
154. Sadeghi K, Wessner B, Laggner U, et al. Vitamin D3 down-regulates 
monocyte TLR expression and triggers hyporesponsiveness to pathogen-
associated molecular patterns. Eur J Immunol 2006;36:361-70. 
229 
 
155. Beard JA, Bearden A, Striker R. Vitamin D and the anti-viral state. J Clin 
Virol 2011;50:194-200. 
156. Hansdottir S, Monick MM, Lovan N, Powers L, Gerke A, Hunninghake 
GW. Vitamin D decreases respiratory syncytial virus induction of NF-kappaB-
linked chemokines and cytokines in airway epithelium while maintaining the 
antiviral state. Journal of Immunology 2010;184:965-74. 
157. Takahashi K, Nakayama Y, Horiuchi H, et al. Human neutrophils 
express messenger RNA of vitamin D receptor and respond to 1alpha,25-
dihydroxyvitamin D3. Immunopharmacol Immunotoxicol 2002;24:335-47. 
158. O'Kane CM, McKeown SW, Perkins GD, et al. Salbutamol up-regulates 
matrix metalloproteinase-9 in the alveolar space in the acute respiratory 
distress syndrome. Crit Care Med 2009;37:2242-9. 
159. Albaiceta GM, Gutiérrez-Fernández A, Parra D, et al. Lack of matrix 
metalloproteinase-9 worsens ventilator-induced lung injury. Am J Physiol 
Lung Cell Mol Physiol 2008;294:L535-43. 
160. Yamashita CM, Dolgonos L, Zemans RL, et al. Matrix metalloproteinase 
3 is a mediator of pulmonary fibrosis. Am J Pathol 2011;179:1733-45. 
161. Song Y, Qi H, Wu C. Effect of 1,25-(OH)2D3 (a vitamin D analogue) on 
passively sensitized human airway smooth muscle cells. Respirology 
2007;12:486-94. 
162. Dahl B, Schiødt FV, Ott P, et al. Plasma concentration of Gc-globulin is 
associated with organ dysfunction and sepsis after injury. Crit Care Med 
2003;31:152-6. 
163. Wu S, Sun J. Vitamin D, vitamin D receptor, and macroautophagy in 
inflammation and infection. Discov Med 2011;11:325-35. 
164. Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA. Plasticity of CD4(+) 
FoxP3(+) T cells. Curr Opin Immunol 2009;21:281-5. 
165. Zhou L, Chong MM, Littman DR. Plasticity of CD4+ T cell lineage 
differentiation. Immunity 2009;30:646-55. 
230 
 
166. Jeffery LE, Burke F, Mura M, et al. 1,25-Dihydroxyvitamin D(3) and IL-
2 combine to inhibit T cell production of inflammatory cytokines and 
promote development of regulatory T cells expressing CTLA-4 and FoxP3. J 
Immunol 2009;183:5458-67. 
167. Hoyer-Hansen M, Nordbrandt SP, Jaattela M. Autophagy as a basis for 
the health-promoting effects of vitamin D. Trends Mol Med 2010;16:295-302. 
168. Ryter SW, Choi AM. Autophagy in the lung. Proc Am Thorac Soc 
2010;7:13-21. 
169. Wilson CL, Ouellette AJ, Satchell DP, et al. Regulation of intestinal 
alpha-defensin activation by the metalloproteinase matrilysin in innate host 
defense. Science 1999;286:113-7. 
170. Parks WC. Matrix metalloproteinases in lung repair. Eur Respir J Suppl 
2003;44:36s-8s. 
171. Coussens A, Timms PM, Boucher BJ, et al. 1alpha,25-dihydroxyvitamin 
D3 inhibits matrix metalloproteinases induced by Mycobacterium 
tuberculosis infection. Immunology 2009;127:539-48. 
172. González-López A, Albaiceta GM. Repair after acute lung injury: 
molecular mechanisms and therapeutic opportunities. Crit Care 2012;16:209. 
173. Speeckaert M, Huang G, Delanghe JR, Taes YE. Biological and clinical 
aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. 
Clin Chim Acta 2006;372:33-42. 
174. Adams JS, Hewison M. Unexpected actions of vitamin D: new 
perspectives on the regulation of innate and adaptive immunity. Nat Clin 
Pract Endocrinol Metab 2008;4:80-90. 
175. Takano Y, Mitsuhashi H, Ueno K. 1alpha,25-Dihydroxyvitamin D(3) 
inhibits neutrophil recruitment in hamster model of acute lung injury. 
Steroids 2011;76:1305-9. 
176. Shih PK, Chen YC, Huang YC, Chang YT, Chen JX, Cheng CM. 
Pretreatment of vitamin D3 ameliorates lung and muscle injury induced by 
231 
 
reperfusion of bilateral femoral vessels in a rat model. J Surg Res 
2011;171:323-8. 
177. Yazici G, Yildiz F, Iskit A, et al. The effect of vitamin D prophylaxis on 
radiation induced pulmonary damage. J Radiat Res 2011;52:616-21. 
178. Chen Y, Li Q, Liu Y, et al. Attenuation of hyperoxia-induced lung injury 
in neonatal rats by 1α,25-Dihydroxyvitamin D3. Exp Lung Res 2015;41:344-
52. 
179. Zhang M, Dong M, Liu W, et al. 1α,25-dihydroxyvitamin D3 
ameliorates seawater aspiration-induced acute lung injury via NF-κB and 
RhoA/Rho kinase pathways. PLoS One 2014;9:e104507. 
180. Klaff LS, Gill SE, Wisse BE, et al. Lipopolysaccharide-induced lung 
injury is independent of serum vitamin D concentration. PLoS One 
2012;7:e49076. 
181. Black PN, Scragg R. Relationship between serum 25-hydroxyvitamin d 
and pulmonary function in the third national health and nutrition 
examination survey. Chest 2005;128:3792-8. 
182. Porojnicu AC, Robsahm TE, Dahlback A, et al. Seasonal and 
geographical variations in lung cancer prognosis in Norway. Does Vitamin D 
from the sun play a role? Lung Cancer 2007;55:263-70. 
183. Pilz S, Tomaschitz A, Obermayer-Pietsch B, Dobnig H, Pieber TR. 
Epidemiology of vitamin D insufficiency and cancer mortality. Anticancer Res 
2009;29:3699-704. 
184. Brehm JM, Schuemann B, Fuhlbrigge AL, et al. Serum vitamin D levels 
and severe asthma exacerbations in the Childhood Asthma Management 
Program study. J Allergy Clin Immunol 2010;126:52-8.e5. 
185. Nnoaham KE, Clarke A. Low serum vitamin D levels and tuberculosis: 
a systematic review and meta-analysis. Int J Epidemiol 2008;37:113-9. 
186. Laaksi I, Ruohola JP, Tuohimaa P, et al. An association of serum 
vitamin D concentrations < 40 nmol/L with acute respiratory tract infection 
in young Finnish men. Am J Clin Nutr 2007;86:714-7. 
232 
 
187. Hughes DA, Norton R. Vitamin D and respiratory health. Clinical and 
experimental immunology 2009;158:20-5. 
188. Sutherland ER, Goleva E, Jackson LP, Stevens AD, Leung DY. Vitamin D 
levels, lung function, and steroid response in adult asthma. Am J Respir Crit 
Care Med 2010;181:699-704. 
189. Xystrakis E, Kusumakar S, Boswell S, et al. Reversing the defective 
induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant 
asthma patients. J Clin Invest 2006;116:146-55. 
190. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory 
diseases. Lancet 2009;373:1905-17. 
191. Liu PT, Modlin RL. Human macrophage host defense against 
Mycobacterium tuberculosis. Curr Opin Immunol 2008;20:371-6. 
192. Cecchi A, Bonizzoli M, Douar S, et al. Vitamin D deficiency in septic 
patients at ICU admission is not a mortality predictor. Minerva Anestesiol 
2011. 
193. Flynn L, Zimmerman LH, McNorton K, et al. Effects of vitamin D 
deficiency in critically ill surgical patients. Am J Surg 2012;203:379-82; 
discussion 82. 
194. Jeng L, Yamshchikov AV, Judd SE, et al. Alterations in vitamin D status 
and anti-microbial peptide levels in patients in the intensive care unit with 
sepsis. J Transl Med 2009;7:28. 
195. Leaf DE, Raed A, Donnino MW, Ginde AA, Waikar SS. Randomized 
controlled trial of calcitriol in severe sepsis. Am J Respir Crit Care Med 
2014;190:533-41. 
196. Hewison M. Vitamin D and immune function: an overview. Proc Nutr 
Soc 2012;71:50-61. 
197. Thickett DR, Moromizato T, Litonjua AA, et al. Association between 
prehospital vitamin D status and incident acute respiratory failure in 
critically ill patients: a retrospective cohort study. BMJ Open Respir Res 
2015;2:e000074. 
233 
 
198. Dancer RC, Parekh D, Lax S, et al. Vitamin D deficiency contributes 
directly to the acute respiratory distress syndrome (ARDS). Thorax 
2015;70:617-24. 
199. Amrein K, Schnedl C, Holl A, et al. Effect of high-dose vitamin D3 on 
hospital length of stay in critically ill patients with vitamin D deficiency: the 
VITdAL-ICU randomized clinical trial. JAMA 2014;312:1520-30. 
200. Goedje O, Hoeke K, Lichtwarck-Aschoff M, Faltchauser A, Lamm P, 
Reichart B. Continuous cardiac output by femoral arterial thermodilution 
calibrated pulse contour analysis: comparison with pulmonary arterial 
thermodilution. Crit Care Med 1999;27:2407-12. 
201. Isakow W, Schuster DP. Extravascular lung water measurements and 
hemodynamic monitoring in the critically ill: bedside alternatives to the 
pulmonary artery catheter. Am J Physiol Lung Cell Mol Physiol 
2006;291:L1118-31. 
202. Sakka SG, Rühl CC, Pfeiffer UJ, et al. Assessment of cardiac preload and 
extravascular lung water by single transpulmonary thermodilution. Intensive 
Care Med 2000;26:180-7. 
203. Reuter DA, Felbinger TW, Moerstedt K, et al. Intrathoracic blood 
volume index measured by thermodilution for preload monitoring after 
cardiac surgery. J Cardiothorac Vasc Anesth 2002;16:191-5. 
204. Jozwiak M, Teboul JL, Monnet X. Extravascular lung water in critical 
care: recent advances and clinical applications. Ann Intensive Care 2015;5:38. 
205. Huber W, Mair S, Götz SQ, et al. Extravascular lung water and its 
association with weight, height, age, and gender: a study in intensive care 
unit patients. Intensive Care Med 2013;39:146-50. 
206. Katzenelson R, Perel A, Berkenstadt H, et al. Accuracy of 
transpulmonary thermodilution versus gravimetric measurement of 
extravascular lung water. Crit Care Med 2004;32:1550-4. 
207. Tagami T, Kushimoto S, Yamamoto Y, et al. Validation of extravascular 
lung water measurement by single transpulmonary thermodilution: human 
autopsy study. Crit Care 2010;14:R162. 
234 
 
208. Sakka SG, Klein M, Reinhart K, Meier-Hellmann A. Prognostic value of 
extravascular lung water in critically ill patients. Chest 2002;122:2080-6. 
209. Kushimoto S, Taira Y, Kitazawa Y, et al. The clinical usefulness of 
extravascular lung water and pulmonary vascular permeability index to 
diagnose and characterize pulmonary edema: a prospective multicenter 
study on the quantitative differential diagnostic definition for acute lung 
injury/acute respiratory distress syndrome. Crit Care 2012;16:R232. 
210. Tagami T, Nakamura T, Kushimoto S, et al. Early-phase changes of 
extravascular lung water index as a prognostic indicator in acute respiratory 
distress syndrome patients. Ann Intensive Care 2014;4:27. 
211. Monnet X, Anguel N, Osman D, Hamzaoui O, Richard C, Teboul JL. 
Assessing pulmonary permeability by transpulmonary thermodilution allows 
differentiation of hydrostatic pulmonary edema from ALI/ARDS. Intensive 
Care Med 2007;33:448-53. 
212. Perkins GD, Chatterjee S, Giles S, et al. Safety and tolerability of 
nonbronchoscopic lavage in ARDS. Chest 2005;127:1358-63. 
213. Butcher SK, Chahal H, Nayak L, et al. Senescence in innate immune 
responses: reduced neutrophil phagocytic capacity and CD16 expression in 
elderly humans. J Leukoc Biol 2001;70:881-6. 
214. Rittirsch D, Huber-Lang MS, Flierl MA, Ward PA. Immunodesign of 
experimental sepsis by cecal ligation and puncture. Nat Protoc 2009;4:31-6. 
215. Scott A, Weldon S, Buchanan PJ, et al. Evaluation of the ability of LL-37 
to neutralise LPS in vitro and ex vivo. PLoS One 2011;6:e26525. 
216. Calfee CS, Janz DR, Bernard GR, et al. Distinct molecular phenotypes of 
direct vs indirect ARDS in single-center and multicenter studies. Chest 
2015;147:1539-48. 
217. Fein AM, Calalang-Colucci MG. Acute lung injury and acute respiratory 
distress syndrome in sepsis and septic shock. Crit Care Clin 2000;16:289-317. 
218. Sheu CC, Gong MN, Zhai R, et al. Clinical characteristics and outcomes 
of sepsis-related vs non-sepsis-related ARDS. Chest 2010;138:559-67. 
235 
 
219. van Schoor NM, Lips P. Worldwide vitamin D status. Best Pract Res 
Clin Endocrinol Metab 2011;25:671-80. 
220. Shoben AB, Kestenbaum B, Levin G, et al. Seasonal variation in 25-
hydroxyvitamin D concentrations in the cardiovascular health study. Am J 
Epidemiol 2011;174:1363-72. 
221. Sherman SS, Hollis BW, Tobin JD. Vitamin D status and related 
parameters in a healthy population: the effects of age, sex, and season. J Clin 
Endocrinol Metab 1990;71:405-13. 
222. Danai PA, Sinha S, Moss M, Haber MJ, Martin GS. Seasonal variation in 
the epidemiology of sepsis. Crit Care Med 2007;35:410-5. 
223. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin 
antimicrobial peptide (CAMP) gene is a direct target of the vitamin D 
receptor and is strongly up-regulated in myeloid cells by 1,25-
dihydroxyvitamin D3. FASEB journal : official publication of the Federation of 
American Societies for Experimental Biology 2005;19:1067-77. 
224. Kovach MA, Ballinger MN, Newstead MW, et al. Cathelicidin-related 
antimicrobial peptide is required for effective lung mucosal immunity in 
Gram-negative bacterial pneumonia. J Immunol 2012;189:304-11. 
225. Cannell JJ, Hollis BW. Use of vitamin D in clinical practice. Altern Med 
Rev 2008;13:6-20. 
226. Braun AB, Gibbons FK, Litonjua AA, Giovannucci E, Christopher KB. 
Low serum 25-hydroxyvitamin D at critical care initiation is associated with 
increased mortality*. Critical care medicine 2012;40:63-72. 
227. Moromizato T, Litonjua AA, Braun AB, Gibbons FK, Giovannucci E, 
Christopher KB. Association of low serum 25-hydroxyvitamin D levels and 
sepsis in the critically ill. Crit Care Med 2014;42:97-107. 
228. Remmelts HH, van de Garde EM, Meijvis SC, et al. Addition of vitamin d 
status to prognostic scores improves the prediction of outcome in 
community-acquired pneumonia. Clin Infect Dis 2012;55:1488-94. 
236 
 
229. Quraishi SA, Litonjua AA, Moromizato T, et al. Association between 
prehospital vitamin D status and hospital-acquired bloodstream infections. 
Am J Clin Nutr 2013;98:952-9. 
230. de Haan K, Groeneveld AB, de Geus HR, Egal M, Struijs A. Vitamin D 
deficiency as a risk factor for infection, sepsis and mortality in the critically 
ill: systematic review and meta-analysis. Crit Care 2014;18:660. 
231. Upala S, Sanguankeo A, Permpalung N. Significant association between 
vitamin D deficiency and sepsis: a systematic review and meta-analysis. BMC 
Anesthesiol 2015;15:84. 
232. Møller S, Laigaard F, Olgaard K, Hemmingsen C. Effect of 1,25-
dihydroxy-vitamin D3 in experimental sepsis. Int J Med Sci 2007;4:190-5. 
233. Asakura H, Aoshima K, Suga Y, et al. Beneficial effect of the active form 
of vitamin D3 against LPS-induced DIC but not against tissue-factor-induced 
DIC in rat models. Thromb Haemost 2001;85:287-90. 
234. Matute-Bello G, Downey G, Moore BB, et al. An official American 
Thoracic Society workshop report: features and measurements of 
experimental acute lung injury in animals. American journal of respiratory 
cell and molecular biology 2011;44:725-38. 
235. Dejager L, Pinheiro I, Dejonckheere E, Libert C. Cecal ligation and 
puncture: the gold standard model for polymicrobial sepsis? Trends 
Microbiol 2011;19:198-208. 
236. Jeng L, Yamshchikov AV, Judd SE, et al. Alterations in vitamin D status 
and anti-microbial peptide levels in patients in the intensive care unit with 
sepsis. Journal of translational medicine 2009;7:28. 
237. Leaf DE, Croy HE, Abrahams SJ, Raed A, Waikar SS. Cathelicidin 
antimicrobial protein, vitamin D, and risk of death in critically ill patients. Crit 
Care 2015;19:80. 
238. Chandra G, Selvaraj P, Jawahar MS, Banurekha VV, Narayanan PR. 
Effect of vitamin D3 on phagocytic potential of macrophages with live 
Mycobacterium tuberculosis and lymphoproliferative response in pulmonary 
tuberculosis. J Clin Immunol 2004;24:249-57. 
237 
 
239. Ortiz-Diaz E, Festic E, Gajic O, Levitt JE. Emerging pharmacological 
therapies for prevention and early treatment of acute lung injury. Semin 
Respir Crit Care Med 2013;34:448-58. 
240. Beitler JR, Schoenfeld DA, Thompson BT. Preventing ARDS: progress, 
promise, and pitfalls. Chest 2014;146:1102-13. 
241. Levitt JE, Calfee CS, Goldstein BA, Vojnik R, Matthay MA. Early acute 
lung injury: criteria for identifying lung injury prior to the need for positive 
pressure ventilation*. Crit Care Med 2013;41:1929-37. 
242. de Prost N, Ricard JD, Saumon G, Dreyfuss D. Ventilator-induced lung 
injury: historical perspectives and clinical implications. Ann Intensive Care 
2011;1:28. 
243. Michelet P, D'Journo XB, Roch A, et al. Protective ventilation influences 
systemic inflammation after esophagectomy: a randomized controlled study. 
Anesthesiology 2006;105:911-9. 
244. Lin WQ, Lu XY, Cao LH, Wen LL, Bai XH, Zhong ZJ. [Effects of the lung 
protective ventilatory strategy on proinflammatory cytokine release during 
one-lung ventilation]. Ai Zheng 2008;27:870-3. 
245. Ranieri VM, Suter PM, Tortorella C, et al. Effect of mechanical 
ventilation on inflammatory mediators in patients with acute respiratory 
distress syndrome: a randomized controlled trial. Jama 1999;282:54-61. 
246. Imai Y, Parodo J, Kajikawa O, et al. Injurious mechanical ventilation 
and end-organ epithelial cell apoptosis and organ dysfunction in an 
experimental model of acute respiratory distress syndrome. Jama 
2003;289:2104-12. 
247. Turrens JF. Mitochondrial formation of reactive oxygen species. J 
Physiol 2003;552:335-44. 
248. Pagano A, Barazzone-Argiroffo C. Alveolar cell death in hyperoxia-
induced lung injury. Ann N Y Acad Sci 2003;1010:405-16. 
238 
 
249. Carnesecchi S, Deffert C, Pagano A, et al. NADPH oxidase-1 plays a 
crucial role in hyperoxia-induced acute lung injury in mice. American journal 
of respiratory and critical care medicine 2009;180:972-81. 
250. Bailey TC, Martin EL, Zhao L, Veldhuizen RA. High oxygen 
concentrations predispose mouse lungs to the deleterious effects of high 
stretch ventilation. J Appl Physiol (1985) 2003;94:975-82. 
251. Sinclair SE, Altemeier WA, Matute-Bello G, Chi EY. Augmented lung 
injury due to interaction between hyperoxia and mechanical ventilation. Crit 
Care Med 2004;32:2496-501. 
252. Ferrari RS, Andrade CF. Oxidative Stress and Lung Ischemia-
Reperfusion Injury. Oxid Med Cell Longev 2015;2015:590987. 
253. Okawa K, Onda M, Miyashita M, Sasajima K. Systemic and pulmonary 
responses of inflammatory cytokines following esophagectomy. Nihon Ika 
Daigaku Zasshi 1998;65:42-9. 
254. D'Journo XB, Michelet P, Marin V, et al. An early inflammatory 
response to oesophagectomy predicts the occurrence of pulmonary 
complications. Eur J Cardiothorac Surg 2010;37:1144-51. 
255. Braun AB, Litonjua AA, Moromizato T, Gibbons FK, Giovannucci E, 
Christopher KB. Association of low serum 25-hydroxyvitamin D levels and 
acute kidney injury in the critically ill*. Crit Care Med 2012;40:3170-9. 
256. Jozwiak M, Silva S, Persichini R, et al. Extravascular lung water is an 
independent prognostic factor in patients with acute respiratory distress 
syndrome*. Critical care medicine 2013;41:472-80 
10.1097/CCM.0b013e31826ab377. 
257. Licker M, Tschopp JM, Robert J, Frey JG, Diaper J, Ellenberger C. 
Aerosolized salbutamol accelerates the resolution of pulmonary edema after 
lung resection. Chest 2008;133:845-52. 
258. Schoenfeld DA, Bernard GR, Network A. Statistical evaluation of 
ventilator-free days as an efficacy measure in clinical trials of treatments for 
acute respiratory distress syndrome. Crit Care Med 2002;30:1772-7. 
239 
 
259. Vincent JL, de Mendonça A, Cantraine F, et al. Use of the SOFA score to 
assess the incidence of organ dysfunction/failure in intensive care units: 
results of a multicenter, prospective study. Working group on "sepsis-related 
problems" of the European Society of Intensive Care Medicine. Crit Care Med 
1998;26:1793-800. 
260. Marcinowska-Suchowierska E, Walicka M, Talalaj M, Horst-Sikorska 
W, Ignaszak-Szczepaniak M, Sewerynek E. Vitamin D supplementation in 
adults - guidelines. Endokrynol Pol 2010;61:723-9. 
261. Shea MK, Booth SL, Massaro JM, et al. Vitamin K and vitamin D status: 
associations with inflammatory markers in the Framingham Offspring Study. 
Am J Epidemiol 2008;167:313-20. 
262. Yusupov E, Li-Ng M, Pollack S, Yeh JK, Mikhail M, Aloia JF. Vitamin d 
and serum cytokines in a randomized clinical trial. Int J Endocrinol 
2010;2010. 
263. Aggarwal NR, King LS, D'Alessio FR. Diverse macrophage populations 
mediate acute lung inflammation and resolution. Am J Physiol Lung Cell Mol 
Physiol 2014;306:L709-25. 
264. Steinberg KP, Milberg JA, Martin TR, Maunder RJ, Cockrill BA, Hudson 
LD. Evolution of bronchoalveolar cell populations in the adult respiratory 
distress syndrome. Am J Respir Crit Care Med 1994;150:113-22. 
265. Rosseau S, Hammerl P, Maus U, et al. Phenotypic characterization of 
alveolar monocyte recruitment in acute respiratory distress syndrome. Am J 
Physiol Lung Cell Mol Physiol 2000;279:L25-35. 
266. Brittan M, Barr L, Conway Morris A, et al. A novel subpopulation of 
monocyte-like cells in the human lung after lipopolysaccharide inhalation. 
Eur Respir J 2012;40:206-14. 
267. Mokart D, Guery BP, Bouabdallah R, et al. Deactivation of alveolar 
macrophages in septic neutropenic ARDS. Chest 2003;124:644-52. 
268. Schmidt EP, Tuder RM. Role of Apoptosis in Amplifying Inflammatory 
Responses in Lung Diseases. J Cell Death 2010;2010:41-53. 
240 
 
269. Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: 
clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 
2002;2:965-75. 
270. Gong Q, Yin H, Fang M, et al. Heme oxygenase-1 upregulation 
significantly inhibits TNF-alpha and Hmgb1 releasing and attenuates 
lipopolysaccharide-induced acute lung injury in mice. Int Immunopharmacol 
2008;8:792-8. 
271. Gong Q, Xu JF, Yin H, Liu SF, Duan LH, Bian ZL. Protective effect of 
antagonist of high-mobility group box 1 on lipopolysaccharide-induced acute 
lung injury in mice. Scand J Immunol 2009;69:29-35. 
272. Ogawa EN, Ishizaka A, Tasaka S, et al. Contribution of high-mobility 
group box-1 to the development of ventilator-induced lung injury. Am J 
Respir Crit Care Med 2006;174:400-7. 
273. Hagiwara S, Iwasaka H, Hasegawa A, Asai N, Noguchi T. High-dose 
intravenous immunoglobulin G improves systemic inflammation in a rat 
model of CLP-induced sepsis. Intensive Care Med 2008;34:1812-9. 
274. Hagiwara S, Iwasaka H, Hidaka S, Hishiyama S, Noguchi T. Danaparoid 
sodium inhibits systemic inflammation and prevents endotoxin-induced 
acute lung injury in rats. Crit Care 2008;12:R43. 
275. Hagiwara S, Iwasaka H, Togo K, Noguchi T. A neutrophil elastase 
inhibitor, sivelestat, reduces lung injury following endotoxin-induced shock 
in rats by inhibiting HMGB1. Inflammation 2008;31:227-34. 
276. Cohen MJ, Brohi K, Calfee CS, et al. Early release of high mobility group 
box nuclear protein 1 after severe trauma in humans: role of injury severity 
and tissue hypoperfusion. Crit Care 2009;13:R174. 
277. Ariel A, Fredman G, Sun YP, et al. Apoptotic neutrophils and T cells 
sequester chemokines during immune response resolution through 
modulation of CCR5 expression. Nat Immunol 2006;7:1209-16. 
278. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo 
veritas. J Clin Invest 2012;122:787-95. 
241 
 
279. Korns D, Frasch SC, Fernandez-Boyanapalli R, Henson PM, Bratton DL. 
Modulation of macrophage efferocytosis in inflammation. Front Immunol 
2011;2:57. 
280. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage 
activation. Nat Rev Immunol 2008;8:958-69. 
281. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat 
Rev Immunol 2005;5:953-64. 
282. Ambarus CA, Krausz S, van Eijk M, et al. Systematic validation of 
specific phenotypic markers for in vitro polarized human macrophages. J 
Immunol Methods 2012;375:196-206. 
283. Jaguin M, Houlbert N, Fardel O, Lecureur V. Polarization profiles of 
human M-CSF-generated macrophages and comparison of M1-markers in 
classically activated macrophages from GM-CSF and M-CSF origin. Cell 
Immunol 2013;281:51-61. 
284. Zizzo G, Cohen PL. IL-17 stimulates differentiation of human anti-
inflammatory macrophages and phagocytosis of apoptotic neutrophils in 
response to IL-10 and glucocorticoids. J Immunol 2013;190:5237-46. 
285. Zizzo G, Hilliard BA, Monestier M, Cohen PL. Efficient clearance of 
early apoptotic cells by human macrophages requires M2c polarization and 
MerTK induction. J Immunol 2012;189:3508-20. 
286. Walters MR. Newly identified actions of the vitamin D endocrine 
system. Endocr Rev 1992;13:719-64. 
287. Herr C, Branschied M, Vogelmeier C, Bals R. ERS Barcelona meeting 
2010:p4349. 
288. Piemonti L, Monti P, Sironi M, et al. Vitamin D3 affects differentiation, 
maturation, and function of human monocyte-derived dendritic cells. J 
Immunol 2000;164:4443-51. 
289. Hiemstra PS. Altered macrophage function in chronic obstructive 
pulmonary disease. Ann Am Thorac Soc 2013;10 Suppl:S180-5. 
242 
 
290. Hodge S, Hodge G, Ahern J, Jersmann H, Holmes M, Reynolds PN. 
Smoking alters alveolar macrophage recognition and phagocytic ability: 
implications in chronic obstructive pulmonary disease. Am J Respir Cell Mol 
Biol 2007;37:748-55. 
291. Chun RF, Liu PT, Modlin RL, Adams JS, Hewison M. Impact of vitamin D 
on immune function: lessons learned from genome-wide analysis. Front 
Physiol 2014;5:151. 
292. Martineau AR, Timms PM, Bothamley GH, et al. High-dose vitamin 
D(3) during intensive-phase antimicrobial treatment of pulmonary 
tuberculosis: a double-blind randomised controlled trial. Lancet 
2011;377:242-50. 
293. Parekh D, Thickett DR, Turner AM. Vitamin D Deficiency and Acute 
Lung Injury. Inflammation & allergy drug targets 2013. 
294. Nouari W, Ysmail-Dahlouk L, Aribi M. Vitamin D3 enhances 
bactericidal activity of macrophage against Pseudomonas aeruginosa. Int 
Immunopharmacol 2015;30:94-101. 
 
  
243 
 
 
  
CHAPTER 10                                                   
PUBLICATIONS   
244 
 
10.1 PAPERS 
Parekh D*, Patel JM*, Scott A, Lax S, Dancer RC, Perkins GD, Thickett DR.  
Vitamin D deficiency in human and murine sepsis. 
Accepted and in press Critical Care Medicine 
 
Dancer RC*, Parekh D*, Lax S, D'Souza V, Zheng S, Bassford CR, Park D, Bartis 
DG, Mahida R, Turner AM, Sapey E, Wei W, Naidu B, Stewart PM, Fraser WD, 
Christopher KB, Cooper MS, Gao F, Sansom DM, Martineau AR, Perkins GD, 
Thickett DR. Vitamin D deficiency contributes directly to the acute 
respiratory distress syndrome (ARDS). Thorax 2015 Jul;70(7):617-24.  
Parekh D, Dancer RC, Thickett DR. 
Alternatives to animal research in acute lung injury. 
BMJ 2014 Jul 10;349:g4171 
 
Parekh D, Thickett DR, Turner AM.  
Vitamin D deficiency and acute lung injury 
Inflamm Allergy Drug Targets 2013;12:253-61 
 
Parekh D, Dancer RC, Lax S, et al.  
Vitamin D to prevent acute lung injury following oesophagectomy 
(VINDALOO): study protocol for a randomised placebo controlled trial  
Trials 2013;14:100. 
 
Parekh D, Dancer RC, Thickett DR.  
Acute lung injury 
Clinical medicine 2011;11:615-8. 
 
*Denotes Joint First Author 
 
 
10.2 ABSTRACTS 
10.2.1 Oral presentations 
Parekh D, Perkins GD, Thickett DR 
Vitamin D stimulates macrophage efferocytosis and encourages a pro-
resolution phenotype. ERS Lung Science Meeting 2016 
 
Dancer RC*, Parekh D*, Thickett DR 
Vitamin D supplementation reduces perioperative systemic and 
alveolar inflammation in patients undergoing oesophagectomy: Results 
of the VINDALOO Trial. BTS Winter Meeting 2015 
 
245 
 
Parekh D, Lax S, Dancer RCA, Perkins GD, Thickett DR. Vitamin D deficiency 
and bacterial load in a murine model of sepsis-induced lung injury.  
The Lancet. 2014 Feb. Vol 383: Page S15 
 
Parekh D, Wang Q,  D’Souza VK,  Dancer R, Patel  JM, Bartis D, Gao F, Lian Q, 
Jin S, Thickett DR. Lipoxin A4 improves efferocytosis via inhibition of the 
HMGB1 in human alveolar macrophages. British Thoracic Society Winter 
Meeting. Thorax 2014: 69, A54-A55 
 
Dancer RC, Parekh D, Perkins GD, Thickett DR 
Long Term Survival In Patients Who Undergo Oesophagectomy Is Lower 
In Patients Who Develop Post-operative Acute Respiratory Distress 
Syndrome.  British Thoracic Society Winter Meeting. Thorax 69 (Suppl 2), 
A52-A53 
 
Parekh D, Dancer R, Park D, Perkins GD, Thickett DR. Salmeterol prevents 
pneumonia and reduces biomarkers of inflammation/epithelial damage 
but not acute lung injury following oesophagectomy- the results of 
BALTI-prevention trial. European Respiratory Society Annual Congress 
September 2013. European Respiratory Journal 42 (Suppl 57), 1818 
 
*Denotes Joint First Author 
 
 
10.2.2 Poster presentations 
Parekh D, Dancer RC, Perkins GD, Thickett DR, Lax S.  Therapeutic Vitamin 
D Reduces the Severity Of Lipopolysaccharide-Induced Murine Lung 
Injury. American Thoracic Society Congress 2014. Am J Respir Crit Care Med. 
189, A5736 
Parekh D, Dancer RC, Perkins GD, Lax S, Thickett DR.  Effects Of Vitamin D 
Deficiency In A Murine Model Of Sepsis-Induced Lung Injury. American 
Thoracic Society Congress 2014. Am J Respir Crit Care Med. 189, A1646 
Dancer RC,  Parekh D, Calfee CS, McAuley DF, Perkins GD, Thickett DR. 
Current smokers face increased risk of Acute Lung Injury post 
oesophagectomy compared to former smokers-implications for therapy 
and trial design? BTS Winter Meeting. Thorax 2013;68, A142-A142 
Dancer RC, Parekh D, Marntineau A, Perkins GD, Thickett DR 
High dose vitamin D supplementation improves extravascular lung 
water index and in-vivo treg and LL37 responses post-oesophagectomy. 
BTS Winter Meeting. Thorax 2012; 67 (Suppl 2), A38-A38 
246 
 
10.3 PRIZES/FELLOWSHIPS 
European Respiratory Society Lung Science Bursary   2015 
American Thoracic Society International Trainee Scholarship  2014 
British Lung foundation/NAPP ERS Travel Fellowship   2013 
Medical Research Council Research Training Fellowship   2012 
  
247 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX                      
© Royal College of Physicians, 2011. All rights reserved. 615
Clinical Medicine 2011, Vol 11, No 6: 615–18CME Critical care medicine
Acute lung injury (ALI) and the more
severe acute respiratory distress syndrome
(ARDS) are the pulmonary manifestations
of an acute systemic inflammatory process
characterised clinically by pulmonary infil-
trates, hypoxaemia and oedema. It occurs
predominantly in young, previously
healthy people, and is responsible for thou-
sands of adult and paediatric deaths annu-
ally worldwide. Both ALI and ARDS confer
a considerable long-term illness and dis-
ability burden on the individual sufferer
and on society.
Historical background
In 1967 Ashbaugh et al published the first
description of 12 patients with similar clin-
ical, physiological, radiographic and
pathology findings, later described as
ARDS.1 These patients had acute respira-
tory distress, cyanosis refractory to oxygen
therapy, decreased lung compliance and
diffuse pulmonary infiltrates on chest 
x-ray. It is, however, clear that patients with
ARDS had been described before, particu-
larly in the context of battlefield trauma.
Thus, post-traumatic lung injury has been
described as ‘wet lung’ in World War II,
‘shock lung’ or ‘Da-Nang lung’ after a
bloody battle during the Vietnam War.
Definitions
ALI and ARDS are clinical syndromes
characterised by the acute onset (<7 days)
of severe hypoxaemia and bilateral pul-
monary infiltrates in the absence of clinical
evidence of left atrial hypertension. The
severity of the hypoxaemia differentiates
ALI from ARDS. The American/European
Consensus Conference defined patients as
having ALI or ARDS according to the ratio
of partial pressure of oxygen in arterial
blood (PaO2) to the inspired fraction of
oxygen (FiO2) being less than 300 (ALI) or
less than 200 (ARDS) (Table 1).2
Incidence
The overall incidence of ARDS remains
unclear, but most studies suggest approx-
imately 2–8 cases per 100,000 population
per year. ALI is more common, with rates
up to 25 per 100,000 per year reported.
Epidemiologic investigations of both
have predominantly focused on mechan-
ically ventilated patients in intensive care
units (ICU), but recent data suggest
about 9% of patients in respiratory isola-
tion wards meet the criteria for ALI at
some point during their admission.
Patients managed on the wards only had
a much better prognosis than those who
have to be managed in ICU.3
Clinical risk factors for acute 
lung injury
Certain known risk factors such as sepsis,
trauma or multiple traumatic injuries may
lead to the development of ALI and ARDS.
The mode of lung injury can be either direct
or remote to the lung. A list of common
causes is shown in Table 2. However, only a
relatively small proportion of patients with
risk factors actually develop ALI, research
suggesting that genetic, demographic (age),
social (smoking, alcohol abuse) and other
factors play a role in determining who
develops ALI.4,5
In patients in hospital with septic shock,
ALI is associated with delayed goal-
directed resuscitation, delayed antibiotics,
transfusion, alcohol abuse, recent
chemotherapy, diabetes mellitus and base-
line respiratory rate.6 As discussed earlier,
onset of ALI/ARDS is acute, with a diag-
nosis being made after a median of one day
after hospital admission. Patients who
develop ALI/ARDS with pulmonary con-
ditions generally do so more quickly than
extrapulmonary patients.
Pathophysiology
ALI is characterised by neutrophil recruit-
ment to the lung, with both alveolar and sys-
temic release of chemokines (eg CXCL-8,
ENA-78), pro-inflammatory cytokines (eg
interleukin (IL)-1, IL-6, tumour necrosis
factor), acute-phase reactants (eg C-reactive
protein, lipocalin), and matrix remodelling
enzymes (eg MMP-9). Exaggerated neu-
trophilic inflammation is believed to damage
the alveolar-capillary barrier,7–9 leading to
the development of non-cardiogenic
pulmonary oedema which impairs gas
exchange, causing the need for mechanical
ventilation (Fig 1a). The subsequent course
of ARDS is variable. In some patients there is
reabsorption of alveolar oedema fluid and
repair of the injured region of the alveolar
epithelium, followed by clinical recovery
from respiratory failure (Fig 1b). In other
patients alveolar oedema persists, followed
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by organisation of hyaline membranes and
gradual appearance of intra-alveolar fibrosis
and scarring.5
Clinical evaluation
Clinical features suggestive of ALI are
severe dyspnoea, tachypnoea, and resistant
hypoxaemia plus the clinical features of the
initiating injury (eg bowel perforation and
sepsis syndrome). All patients should be
assessed for an underlying cause (particu-
larly pneumonia, sepsis, pancreatitis or
transfusion related lung injury) and treated
promptly. Rigorous examination is
required to look for occult sources of sepsis
such as deep soft tissue infections, and
appropriate diagnostic tests (eg
blood/urine cultures, bronchoalveolar
lavage) performed. If no underlying diag-
nosis is found, invasive lung biopsy is
appropriate to rule out conditions such as
diffuse alveolar haemorrhage that may
respond to immunosuppression.10
Initial management of cases
There is no current licensed therapeutic
treatment for ALI per se. Critical care sup-
port is usually required and treatment of the
underlying condition to remove the under-
lying initiating stimulus for the injury.
Protective ventilation
The ARDSnet trial of lung protective venti-
lation strategy compared a control 
ventilatory strategy with a tidal volume
(Vt) of 12 ml/kg (based on predicted body
weight (PBW)) to a lung protective strategy
using a Vt of 6 ml/kg PBW.
11 The study was
stopped early when an interim analysis
revealed that the mortality rate in the lung
protective group was 22% lower than in the
Fig 1. (a) The normal alveolus (left) and
the injured alveolus (right) in the acute
phase of acute lung injury (ALI) and the
acute respiratory distress syndrome
(ARDS); (b) mechanisms important in the
resolution of ALI and ARDS. ATPase 
adenosine triphosphatase; ENaC 
epithelial sodium channel; IL  interleukin;
MIF  macrophage inhibitory factor; PAF 
platelet activating factor; TNF  tumour
necrosis factor. Reproduced with permission
from the New England Journal of Medicine.9
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control group. These beneficial results
seemed to hold across a wide spectrum of
patients, including septic and non-septic
patients, and also those with different
degrees of lung dysfunction as assessed by
respiratory system compliances. A lung
protective ventilation strategy should
therefore be initiated for all cases of ALI.
Fluid management
Another advance in supportive therapy was
recently reported by the National Heart,
Lung and Blood Institute ARDS Network
with the results of a prospective, randomised
clinical trial evaluating the use of a liberal
versus conservative fluid strategy in patients
with ALI.12 The latter resulted in a significant
increase in ventilator-free days and a non-
significant decrease in mortality (3%). The
conservative fluid management strategy used
diuretics to target a central venous pressure
less than 4 mmHg or a pulmonary artery
occlusion pressure below 8 mmHg.
Non-conventional ventilation
Non-conventional methods of ventilation,
including high frequency ventilation and
liquid ventilation, have not so far proven
effective. An alternative modality, high fre-
quency oscillation ventilation (HFOV), is
increasingly used in some centres.
Although its use other than as a salvage
treatment remains debatable, a recent
updated meta-analysis suggests that it
improves oxygenation, risk of treatment
failure and 30-day mortality compared
with conventional ventilation.13 Ongoing
phase 3 studies of HFOV versus a conven-
tional lung protective ventilation strategy
are due to report next year and should pro-
vide definitive answers about its efficacy. In
contrast, efficacy studies of liquid ventila-
tion have been disappointing and its
optimal clinical use has yet to be defined.
Extracorporeal membrane oxygenation
(ECMO) has been studied in a UK trial
(CESAR) of 180 patients with refractory
hypoxaemia. Patients were randomised to
transfer to a tertiary care centre where 77%
received ECMO or to remain at the refer-
ring centre and be treated with non-proto-
colised ventilator strategies. Compared
with the control group, transferring adult
patients with severe but potentially
reversible respiratory failure to a single
centre specialising in the treatment of
severe respiratory failure for consideration
of ECMO significantly increased survival
without severe disability.14 Considerable
debate is ongoing as to whether this trial
proves the benefit of ECMO per se or the
benefits of managing severe respiratory
failure in specialist centres of excellence.
Failed pharmacological therapies
for acute lung injury
Numerous pharmacological therapies for
established ALI have failed to show benefit
in multicentre clinical trials (examples given
in Table 3). Despite corticosteroids being the
most studied drugs for ALI, overall current
evidence to support their use for treating
early or late ALI is limited because of con-
cern about increased neuromyopathic
events with no mortality benefit.16
Nevertheless, a subsequent trial with low-
dose corticosteroids in early ARDS reported
significant improvement in hypoxaemia and
lung injury scores as early as days 1 and 2.18
There remain uncertainties and conflicting
evidence that still need answers from an ade-
quately powered randomised trial. Therefore,
at present steroids should be considered only
in severe life-threatening refractory hypox-
aemia and not after 14 days of ventilation.
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) remain major
causes of morbidity, mortality and healthcare burden in the critically ill patient
The mode of lung injury can be either direct or remote to the lung and is defined as acute
onset of severe hypoxaemia and bilateral infiltrates in the absence of left atrial hypertension
A lung protective ventilation and conservative fluid management strategy should be
adopted in the management of ALI
High frequency oscillation ventilation and referral for extracorporeal membrane
oxygenation (ECMO) should be considered in severe ARDS
To date no pharmacological therapies have shown benefit in large clinical trials
Key points
KEY WORDS: acute lung injury, acute respiratory distress syndrome
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The future
Since delayed goal-directed therapy of sepsis
is a risk factor for lung injury, greater clinical
benefit may derive from initiating therapy
prior to the onset of severe respiratory
failure. Thus there is renewed interest in
accurate characterisation of high-risk
patient populations and identification of
patients in the early stage of ALI prior to the
need for mechanical ventilation. Clinical
trials are underway such as the Beta Agonist
Lung Injury Trial Prevention (BALTI-
Prevention) which is examining the efficacy
of the long-acting beta-agonist salmeterol
for preventing lung injury in patients at high
risk of ALI (eg those undergoing
oesophagectomy).19
Ongoing research is evaluating the value of
many new therapies, including simvastatin,
keratinocyte growth factor and mes-
enchymal/amniotic fluid stem cells.
Neuromuscular blocking agents have recently
been re-evaluated with favourable results. A
recent trial has shown that cisatracurium
given for 48 hours early in the course of ARDS
with low Vt ventilation may improve out-
comes without significantly increasing the
incidence of muscle weakness.20 Further
studies are required before these approaches
can be adopted in routine practice.
Outcomes
The advent of lung protective ventilation has
resulted in reduced mortality in patients with
ALI. Nevertheless, ALI carries an enormous
burden in both social and fiscal cost,21,22 with
mortality rates still around 40% and signifi-
cant pulmonary impairment in up to 50% of
survivors.9 Debilitating long-term sequelae in
survivors include pulmonary, psychological
and neurologic impairment23 (discussed in
more detail in the accompanying article
Sequelae and rehabilitation after critical illness
(pp xxx–xxx)).
Conclusions
Our understanding of the pathophysiology
of ALI has improved dramatically since the
first defining reports. Large-scale clinical
trials have generated ventilatory strategies
which have resulted in reduced mortality.
Effective specific drug therapy for ALI has
remained elusive despite the establishment
of large clinical trials networks. Hopefully
emerging therapy to prevent or treat ALI
currently under investigation will provide
additional strategies to reduce the burden
of this devastating disease.
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Abstract
Background: Acute lung injury occurs in approximately 25% to 30% of subjects undergoing oesophagectomy.
Experimental studies suggest that treatment with vitamin D may prevent the development of acute lung injury by
decreasing inflammatory cytokine release, enhancing lung epithelial repair and protecting alveolar capillary barrier
function.
Methods/Design: The ‘Vitamin D to prevent lung injury following oesophagectomy trial’ is a multi-centre,
randomised, double-blind, placebo-controlled trial. The aim of the trial is to determine in patients undergoing
elective transthoracic oesophagectomy, if pre-treatment with a single oral dose of vitamin D3 (300,000 IU (7.5 mg)
cholecalciferol in oily solution administered seven days pre-operatively) compared to placebo affects biomarkers of
early acute lung injury and other clinical outcomes. The primary outcome will be change in extravascular lung
water index measured by PiCCOW transpulmonary thermodilution catheter at the end of the oesophagectomy. The
trial secondary outcomes are clinical markers indicative of lung injury: PaO2:FiO2 ratio, oxygenation index;
development of acute lung injury to day 28; duration of ventilation and organ failure; survival; safety and tolerability
of vitamin D supplementation; plasma indices of endothelial and alveolar epithelial function/injury, plasma
inflammatory response and plasma vitamin D status. The study aims to recruit 80 patients from three UK centres.
Discussion: This study will ascertain whether vitamin D replacement alters biomarkers of lung damage following
oesophagectomy.
Trial registration: Current Controlled Trials ISRCTN27673620
Keywords: Acute lung injury, One lung ventilation, Oesophagectomy, Vitamin D
Background
Acute lung injury (ALI) and the more severe acute respira-
tory distress syndrome (ARDS) are common, devastating
clinical syndromes of acute respiratory failure in the critic-
ally ill person. The incidence of ALI is 79 per 100,000 per-
son years with a mortality rate of 30% to 65% [1].
Survivors of ARDS experience a significant reduction in
health-related quality of life, with 46% reported to be un-
able to return to work within 12 months.
ALI is the final common pathway of response to a var-
iety of direct pulmonary insults, such as bacterial /viral
pneumonia and gastric aspiration, or indirect insults,
such as abdominal sepsis or battlefield trauma. Only a
relatively small proportion of patients develop ALI, with
research suggesting that genetic, demographic (age), so-
cial (smoking, alcohol abuse) and other factors play a
role in determining who develops ALI [1,2]. There are
no current readily available tests that can clearly identify
those who are at high risk of ALI and no therapeutic in-
terventions proven to prevent its occurrence.
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One lung ventilation (OLV) as a model for ALI/ARDS
To allow access to the oesophagus during surgery (using
the transthoracic technique), one of the lungs is deflated
and the subject is ventilated through the other lung. This
is known as one-lung ventilation (OLV). There is a high
postoperative incidence of ALI/ARDS [3-5] following
OLV and unlike most insults leading to lung injury the
delivery of OLV is predictably timed, thereby allowing
serial studies to be carried out throughout the period of
stimulus and development of the condition. Preoperative
risk factors including age, respiratory function and
cigarette smoking have been found to be related to the
incidence of postoperative pulmonary complications
[3,6-8]. It is unclear at present why only a percentage of
patients undergoing OLV develop lung injury or why the
lung injury typically occurs 24 to 48 hours after the ces-
sation of OLV. Our data show that the development of
lung injury is, however, associated with a doubling of in-
hospital stay and elevated mortality.
We have extensively modeled the local and systemic in-
flammatory response to transthoracic oesophagectomy in
50 patients undergoing OLV. After OLV, patients have a
neutrophilic alveolitis, with a significant alveolar and sys-
temic inflammatory response. This is associated with the
release of markers of both endothelial and alveolar epithe-
lial dysfunction and an increase in the permeability of the
alveolar barrier. This manifests clinically as increased
extravascular lung water and a fall in oxygenation.
Alveolar levels of surfactant protein D and bronchoal-
veolar lavage fluid (BALF) protein permeability index are
highest in those who develop ALI within 72 hours of
OLV suggesting that peri-operative alveolar epithelial
damage is a risk factor for the subsequent development
of ALI. Immediate post-operative plasma markers of
neutrophilic activation (myeloperoxidase, and matrix
metalloproteinase-9 (MMP-9)) as well as the receptor
for advanced glycation end-products (RAGE, a type I
epithelial cell marker) are similarly raised in those who
develop ALI within 72 hours of OLV. Proposed causative
mechanisms for this injury include the ischaemic/reper-
fusion insult suffered by the collapsed lung, as well as
oxidative stress and barotrauma causing epithelial injury
to the ventilated lung [9]. These mechanisms are import-
ant in the pathogenesis of ALI making OLV a valid
model for studying the pathogenesis of ALI in humans
and exploring therapeutic strategies for preventing lung
injury in a predefined subject population [10,11].
Vitamin D biology
Vitamin D3, or cholecalciferol, is mainly formed in the skin
after exposure to sunlight, then hydroxylated in the liver to
25-hydroxyvitamin D3 (25(OH)D3) and subsequently in the
kidney to 1,25-dihydroxyvitamin D3 (1,25(OH)2D3). When
25(OH)D3 is sufficiently available, 24,25-dihydroxyvitamin
D3 (24,25(OH)2D3) is formed in the kidney which is further
catabolised. Vitamin D metabolites are bound in the circu-
lation to vitamin D binding protein (VDBP) which has a
high affinity for 25(OH)D3, 24,25(OH)2D3 and 1,25(OH)
2D3 and, therefore, regulates free circulating concentrations
of vitamin D metabolites. The biologically active metabolite
1,25(OH)2D3 can also be generated locally within tissues
due to induction of extra-renal cyp27b1 (25(OH)D-1-alpha
hydroxylase) and binds to the vitamin D receptor (VDR)
resulting in modified gene expression.
Epidemiological studies have suggested a role for low
vitamin D status in the risk of developing both viral and
bacterial infection [12,13]. A recent study has further
demonstrated the pleiotropic anti-inflammatory effects of
vitamin D in patients with pulmonary tuberculosis [14].
Published data suggest that vitamin D deficiency is com-
mon in critically ill patients [15], and recent prospective
studies suggest an association with increased morbidity
and mortality [16-18]. Literature on acute vitamin D sup-
plementation in critical illness is lacking but serious ad-
verse events attributable to vitamin D supplementation
are rare [18,19].
Is severe vitamin D deficiency a driver of post-OLV ALI?
Vitamin D has profound effects on human immunity act-
ing as an immune system modulator, preventing excessive
expression of inflammatory cytokines and increasing the
‘oxidative burst’ potential of macrophages, thereby enhan-
cing bacterial killing. Vitamin D also stimulates the release
of antimicrobial peptides such as LL-37 (cathelicidin)
within the lung. LL-37 can also bind to and neutralize lipo-
polysaccharide (LPS), and functions as a chemoattractant
for neutrophils, monocytes and T cells through a formyl
peptide receptor-like molecule [20].
Respiratory epithelial cells convert 25(OH)D3 to 1,25
(OH)2D3 and activate VDR responsive genes increasing
the production of hCAP18 from which LL-37 is cleaved
within 24 hours [21]. In terms of the pathophysiology of
ALI this could be important as LL-37 may drive epithelial
repair responses as well as being an anti-microbial peptide
[22]. Elevating local LL-37 may also be important as a
downstream immunomodulator of vitamin D since it has
recently been shown to reduce Toll-like receptor (TLR)
agonist-mediated neutrophil-derived increases in IL-1β, IL-
6, IL-8 and tumour necrosis factor-alpha (TNF-α) in
addition to stimulating bacterial phagocytosis [23]. The
ability of 1,25(OH)2D3 to directly inhibit nuclear factor-
kappaB (NF-kb) signalling and suppress macrophage TLR
expression suggests that vitamin D may also play a key role
as a feedback regulator of macrophage responses [24,25].
The only study looking at vitamin D levels in patients
with severe sepsis suggests that these patients have a lower
serum vitamin D level than healthy control patients. This
was associated with lower plasma levels of LL-37,
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suggesting that this deficiency is of functional importance
in vivo [26]. IL-1 and TNF production induced by TLR3 ag-
onists from monocyte derived macrophages are inhibited to
the same extent by 25(OH)D3 and 1,25(OH)2D3 after 24 -
hours suggesting that the vitamin D metabolites may have
a rapid anti-inflammatory action and that local intracrine
activation of 25(OH)D3 can be anti-inflammatory [27].
Recent data have further implicated vitamin D in adap-
tive immunity because of its influence upon the differenti-
ation of T cells between the regulatory T cell (Treg) and the
pro-inflammatory T helper 17 (Th17) subsets [28-30]. Th17
cells are known to stimulate tissue inflammation and neu-
trophil chemotaxis, both of which are seen in ALI, pre-
dominantly by IL-17 production. It also appears that
expression of markers of Treg cells (Foxp3) or Th17 cells
(IL-17) by T cells may not be stable and that there is a
greater degree of plasticity in their differentiation than pre-
viously appreciated [29]. Recent evidence has further sug-
gested Treg cells are important in the resolution of
experimental ALI. This suggests that local lung regulation
of the balance between Treg and Th17 cells may be a de-
terminant of resolution/persistence of neutrophilic inflam-
mation which is known to be associated with a poor
prognosis in human ALI.
Although the above suggest a potentially beneficial effect
of vitamin D, we must exercise some caution as some
studies have shown potentially adverse effects of vitamin
D. In low dose nasal LPS challenge, cellular inflammation
is actually lower in vitamin D receptor deficient (VDR
KO) mice due to toll-receptor hyporesponsiveness. In
addition the chemotactic effects of LL-37 could in theory
increase neutrophil recruitment to the lung; albeit in ALI,
CXCL-8 and ENA-78 are the main chemokines driving
neutrophil recruitment. More recently it has been shown
that the plasma LL-37 concentration was decreased in
vitamin D supplemented patients with tuberculosis, pos-
sibly representing a global suppressive effect of vitamin D
supplementation on markers of acute phase response or
an indirect response to enhanced microbial killing [14].
Despite these reservations, the predominant biological ef-
fects of vitamin D led us to hypothesise that vitamin D de-
ficiency may be a risk factor for ALI, causing elevated
inflammation which results in exaggerated epithelial dam-
age in at risk, vitamin D deficient individuals.
The VINDALOO trial is a three centre randomised
double blind, placebo-controlled trial aiming to define
the safety and effectiveness of a single high dose of vita-
min D in preventing ALI in a group of patients at high
risk of developing the condition.
Methods/Design
Trial approvals and conduct
The trial is approved by South Birmingham Research
Ethics Committee (REC 12/WM/0092). The trial is
registered on the International Standard Randomised
Controlled Trial Registry (ISRCTN27673620). The spon-
sor organisation for the trial is the University of Birming-
ham. The trial is funded by the Medical Research Council
UK (MRC reference G1100196). The trial will be carried
out in accordance with the Medical Research Council
(MRC) Good Clinical Practice Guidelines, applicable UK
legislation and Standard Operating Procedures of the Peri-
operative and Critical Care Trials Group at the University
of Birmingham. The trial will be reported in line with the
Consolidated Standards of Reporting Trials (CONSORT)
2010 guidelines [31].
Outcome measures
Primary outcome
The primary outcome will be the extravascular lung water
index (EVLWI) measured by PiCCO thermodilution cath-
eter at the end of the oesophagectomy (measured within
one hour post-operatively). In ALI the changes in lung
compliance that are a cardinal feature of this disease occur
due to the accumulation of extravascular lung water
(EVLW). The PiCCO EVLWI has been shown to be an in-
dependent risk factor for mortality in ALI and has been
used as the primary outcome in several clinical trials
in ALI (BALTI-1, HARP) [32,33] as well as post-
thoracotomy [34]. In BALTI-1 we demonstrated that the
transpulmonary thermodilution technique (PiCCO) is able
to detect a significant change in lung water with a treat-
ment that might be expected to achieve this objective. We
have tested the CV coefficient of variance of EVLWI mea-
surements previously and found it to be 6.8% over six se-
quential assessments over two hours. Further, we have
studied the perioperative changes in lung water following
oesophagectomy and demonstrated that preoperative vita-
min D status influences the level of accumulation of
EVLW.
Secondary outcomes
The trial secondary outcomes are clinical markers indicative
of lung injury: PaO2:FiO2 ratio, oxygenation index, develop-
ment of lung injury/ARDS during the first 28 days, venti-
lator and organ failure free days, survival (28 and 90 day)
and safety and tolerability of vitamin D supplementation.
Lung injury will be defined by the American European
Consensus Conference definition [35] as the acute onset
of: (1) bilateral infiltrates on the chest x-ray; (2) hypox-
aemia with a PaO2:FiO2 ratio of <40 kPa; and (3) ab-
sence of clinical evidence of left atrial hypertension.
Ventilator free days are defined in accordance with the
ARDSnet criteria as the number of calendar days after
initiating unassisted breathing to day 28 after random-
isation, assuming a patient survives for at least 48 con-
secutive hours after initiating unassisted breathing [36].
Un-assisted breathing is defined as one of at least 48
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consecutive hours of: (1) being extubated with face mask,
nasal prong oxygen, or room air; (2) T-tube breathing; and
(3) tracheostomy mask breathing, CPAP = 5 cm H20 with-
out pressure support of intermittent mandatory ventila-
tion assistance.
Organ failure free days are defined in a similar manner
to ventilator free days with an organ failure free day being
a day without evidence of non-respiratory organ failure.
Organ failure will be defined as a sequential organ failure
assessment (SOFA) score of greater than three [37].
Plasma indices of endothelial and alveolar epithelial
function/injury, plasma inflammatory response will be
measured by ELISA. Plasma vitamin D status (25(OH)
D3, 1,25(OH)2D3, VDBP) and calcium will be assessed
peri-operatively (pre-drug dose, pre-operative, post-
operative, day 1 and day 3) as well as EVLWI day 1
post-operatively (measured at 9 am on day 1).
Eligibility criteria
Patients will be eligible for the trial if they fulfill the fol-
lowing criteria:
 Planned transthoracic oesophagectomy for
oesophageal carcinoma at a participating centre.
 Men over 18 years old on the day of first dose of the
investigational medicinal product (IMP).
 Women over the age of 55 or more than 2 years
since menopause.
 Women of potential child bearing age (under 55 and
less than two years since menopause) may be
recruited provided they agree to use contraception
during the pre-post-operative period (eight weeks).
 Ability to give written informed consent to
participate in the study.
Patients fulfilling any of the criteria below will be
excluded:
 Known intolerance of vitamin D.
 Known sarcoidosis, hyperparathyroidism, or
nephrolithiasis.
 Known serum corrected calcium >2.65 mmol/L.
 Undergoing haemodialysis.
 Pregnant or breastfeeding.
 Patients with tuberculosis or lymphoma.
 Diagnosis of chronic obstructive pulmonary disease
(COPD) with a forced expiratory volume in one
second (FEV1) less than 50% predicted or resting
oxygen saturations of less 92%.
Power and sample size estimate
There are no direct data to predict the effect size of vita-
min D replacement upon EVLWI. In our preliminary
work with 50 patients, the patients with 25(OH)D3
concentrations less than 15 nmol/L had the greatest in-
creases in EVLWI (+3.2 ml/kg, +27%) compared to those
patients with less severe deficiency pre–postoperatively
(+1.0 ml/kg, +10% P = 0.013) suggesting that severe vita-
min D deficiency influences EVLWI. As a group, after
undergoing oesophagectomy our patients have a mean
post-operative EVLWI of 10.1 ml/kg and standard devi-
ation of 2.9 ml/kg. For the study to be able to detect a
change of 20% in EVLWI with a power of 80% we will re-
quire approximately 34 patients in each arm to reach the
primary endpoint (P = 0.05). An additional six patients will
be needed to allow for dropouts, such as open/close cases,
unexpected deaths and other difficulties with data collec-
tion. Thus, we intend to recruit 40 patients to each arm of
the study.
With 34 patients completing each arm of the study,
based upon preliminary unpublished data from 50
oesophagectomy cases, this study would detect a treatment
effect of vitamin D upon the PO2:FiO2 ratio postoperative
(PO) of ± 8.16 (± 20%), PO plasma soluble intercellular ad-
hesion molecule-1 (sICAM-1) of ± 16 ng/ml (± 32%),
plasma C-reactive protein (CRP) ± 53 ng/ml (± 33%), PO
plasma von Willebrand factor (vWF) ± 55% relative to con-
trol plasma (± 24.7% change), PO plasma high-mobility
group box 1 (HMGB-1) 5.42 ng/ml (± 54%), PO plasma
myeloperoxidase (MPO) 105 pg/ml (± 57%), PO plasma
MMP-9 51 ng/ml (± 57%), and PO plasma surfactant
protein-D (SP-D) 691 ng/ml (± 61%). All calculations as-
sume 80% power at a two-tailed significance level of 0.05.
Trial conduct
Approach to patients and obtaining informed consent
Patients will be identified through upper gastrointestinal
cancer teams. Eligible patients will be invited to partici-
pate by their treating clinician, specialist clinical nurse or
research nurse. If agreeable, written informed consent
will be obtained, following a face to face discussion about
the study.
Randomisation and drug / placebo supply
The trial drug manufacturer will produce the randomisa-
tion sequence using a block size of 10 with equal alloca-
tion between active and placebo groups. Drug (oral
cholecalciferol oily solution Vigantol, 300,000 IU (7.5 mg))
and matching placebo (Miglyol 812 oil, the vehicle for
vitamin D3 in Vigantol) will be supplied and packaged
according to the randomisation sequence into numbered
treatment boxes by Novalabs (Leicester, UK). Drug boxes
will be supplied to centres in blocks of 10 thus ensuring
an equal allocation between active and placebo groups to
balance any differences in case mix, pre-operative, opera-
tive and post-operative care between centres. Patients will
be randomised sequentially by allocating them to the next
numbered treatment pack held at the centre.
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Drug administration
Subjects will receive either 300,000 IU (7.5 mg) of vitamin
D or placebo seven days prior to planned oesophagectomy.
The drug will be administered by qualified medical or
nursing staff.
Concomitant medications
Patients taking the following medications are not eligible
for inclusion in the study:
 Taking more than 1,000 IU/day (25 mcg/day)
vitamin D supplementation by month preceding
enrolment.
 Taking cardiac glycoside, carbamazepine,
phenobarbital, phenytoin, primidone or long-term
immunosuppressant therapy.
 Patients taking benzothiadiazine derivatives at doses
higher than that which is recommended in the
British National Formulary (BNF).
 Patients taking a benzothiadiazine derivative in
combination with a calcium supplement.
Post randomisation withdrawals and exclusions
Subjects may withdraw from the trial or the trial treat-
ment at any time without prejudice. If a subject with-
draws from the trial treatment, then they will be
followed-up wherever possible and data collected as per
protocol until the end of the trial. The only exception to
this is where the subject also explicitly withdraws con-
sent for follow-up.
Blinding/un-blinding
Patients, clinical and research / trial staff will be unaware
of the arm of the study to which a patient is allocated. Ac-
tive and placebo treatment packs and their contents will
be identical in appearance. The protocol allows for emer-
gency un-blinding in the event of significant concerns
about patient safety. In the unlikely event that un-blinding
is required the local investigator will discuss this with the
Chief Investigator. All events will be logged.
Monitoring and reporting adverse events
VINDALOO is recruiting a population who are prone to
recognized medical and surgical complications. It is
expected that many of the patients will experience an
event that might be seen as a serious adverse event but
is a recognized complication following oesophagectomy.
Adverse and serious adverse events which are recognised
complications of surgery, for example, medical (pneumo-
nia, sepsis) and surgical (chyle leak, anastamosis leak)
will be recorded in the case report form.
Death and other serious adverse events thought to be
related to the study drug or serious unexpected serious
adverse reactions will be reported to the trial co-
ordinating centre and Chief Investigator within 24 hours
of becoming aware of their occurrence. The Chief Investi-
gator will inform the sponsor and regulatory authorities.
Data collection
Data up until hospital discharge will be recorded in each
subject's Case Report Form (CRF) by a member of the
trials team. Most of the data collected will be obtained
from the patient’s hospital notes. In the unlikely event
that a subject is transferred to another hospital, the
study team will ensure that data collection is completed
by the receiving hospital.
If the subject remains in hospital at 28 or 90 days, sur-
vival at these time points will be recorded by hospital
staff. Mortality after hospital discharge will be obtained
from the National Health Service (NHS) Statistical Tra-
cing Service (NSTS).
Statistical analysis plan
Data will be analysed with the help of the trial statistician.
Data will be analysed using SPSS for Windows 17.0. A de-
tailed analysis plan will be developed during the trial prior
to commencement of analysis. In brief, for continuously
distributed data, differences between groups will be tested
using independent samples t-tests with transformations of
variables to Normality if appropriate, or non-parametric
equivalents. Chi-squared tests (or Fisher’s Exact tests) will
be used for categorical variables. A P value of 0.05 will be
considered as significant. We will test for significant corre-
lations between changes in the biological markers using
standard methods. The treatment effect will be analysed
on an intention-to-treat basis. For further examinations of
relationships between a binary variable and known ex-
planatory variables, the following tests will be applied as
appropriate. Logistic regression will be used to provide the
estimated risk ratios for the treatment effect with associ-
ated 95% confidence interval (CI). Time to event out-
comes, such as duration of ventilation or duration of
hospital stay, will be analysed by survival methods and
reported as hazard ratios and 95% CI. A single final ana-
lysis is planned at the end of the trial.
Trial organisation/oversight
Trial oversight will be provided by a Trial Steering Com-
mittee (TSC) comprising investigators, clinicians and
trialists. An independent data monitoring committee will
monitor the safety of participants enrolled in the trial
through regular review of adverse event reports. An in-
terim analysis of efficacy is not planned.
Discussion
The preliminary data that this study is based upon sug-
gests a significant role for vitamin D deficiency as a risk
factor for the development of acute lung injury. This
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trial will look at biomarkers of alveolar epithelial damage
and inflammation to determine the proof of concept that
vitamin d replacement may have efficacy as a preventa-
tive agent for the development of acute lung injury.
Trial status
Patient recruitment commenced in September 2012 and
is expected to run for two years (last patient recruited in
August 2014).
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